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Abstract 
The tyrosine kinase inhibitor imatinib mesylate (IM) has proved a major advance in 
the management of patients with chronic myeloid leukaemia (CML) but about 15% of 
patients do not achieve complete cytogenetic responses (CCyR) (primary resistance) 
and a further 15-20% of those who do achieve CCyR eventually lose their response 
(secondary resistance). The best characterised mechanism of resistance is the 
expansion of a Ph-positive clone bearing an amino-acid substitution in the BCR-
ABL1 kinase domain (KD). We screened over 300 CML patients for KD mutations 
and demonstrated that detection of a mutation after achieving CCyR is an 
independent prognostic factor for the loss of response and disease progression 
regardless of the level of mutant clone. In contrast this study found no difference in 
the level of IM-induced reduction of phospho-Crkl in diagnostic CD34+ cells from 
patients who achieved CCyR compared with those who failed to achieve such 
response. However, I also studied levels of human organic cation transporter 1 
(hOCT1), a membrane protein responsible for facilitating entry of IM into cells. I 
showed that the level of hOCT1 at diagnosis predicted for 3 or more log reduction in 
BCR-ABL1 transcript level in the patients who achieved CCyR. I investigated the 
incidence of polymorphisms in the TP53 and MDM2 genes and showed an 
association between the TP53 P72R SNP and earlier age of onset of CML and an 
association between the MDM2 309 SNP and Sokal score in CML patients. Finally, I 
used array comparative genomic hybridisation to compare patterns in blood 
specimens obtained from 20 CML patients before treatment with patterns obtained 
from the same patients after induction of CCyR with IM; I showed aberrant patterns 
in several specific genes, most commonly NAMPT/PBEF1  on chromosome 7. I 
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concluded that the results of these studies provided strong evidence that CML at 
diagnosis was a heterogeneous disease and that methods could be further refined to 
develop a model that would predict response to a given dose of IM.  
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Background 
Review of associated literature 
Chronic myeloid leukaemia (CML) is a cancer of blood cells characterised by 
replacement of the bone marrow with malignant, leukaemic cells. It is generally 
believed that CML develops when a single, pluripotent haematopoietic stem cell 
acquires a Philadelphia chromosome carrying the BCR-ABL1 fusion gene. This gene 
confers a proliferative advantage on its progeny over normal haematopoietic elements 
and thus allows the Ph-positive clone gradually to displace the residual normal 
haematopoiesis(1;2). Many of these leukaemic cells can be found circulating in the 
blood and cause enlargement of the spleen, liver, and other organs. The diagnosis of 
CML is usually confirmed by finding the Philadelphia (Ph) chromosome, named after 
the city where it was first discovered. The Ph chromosome is the result of a reciprocal 
translocation—or exchange of genetic material—between the long arms of 
chromosomes 9 and 22. This exchange brings together parts of two genes: the BCR 
(breakpoint cluster region) gene on chromosome 22 and the proto-oncogene ABL1 
(human homologue of the Abelson murine virus) on chromosome 9. In the 
translocation that forms the fusion gene, a break occurs in ABL1 somewhere up-
stream of exon a2, and simultaneously a break occurs in the major breakpoint region 
of the BCR gene. As a result, a 5‘ portion of BCR and a 3‘ portion of ABL1 are 
juxtaposed on a shortened chromosome 22. The mRNA molecule transcribed from 
this hybrid gene usually contains one or other of two BCR-ABL1 junctions 
designated b2a2 (or e13a2) and b3a2 (or e14a2) respectively. Both BCR-ABL1 
mRNA molecules are translated into a 210 kD oncoprotein (p210
BCR-ABL1
). Other 
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variant breakpoints and fusions can give rise to full-length functionally oncogenic 
BCR-ABL1 proteins like p190
BCR-ABL1
, associated with the e1a2 mRNA, but they are 
rather rare in classical CML(1). 
The resulting hybrid gene, BCR-ABL1 codes for a fusion protein with greatly 
enhanced tyrosine kinase activity: This activates signal transduction pathways leading 
to uncontrolled cell growth. The leukaemogenic potential of p210
BCR-ABL
 results from 
the fact that the normal tyrosine kinase activity of the ABL1 protein is constitutively 
activated by the juxtaposition of BCR sequences. BCR acts by promoting 
dimerisation of the oncoprotein, such that the two adjacent BCR-ABL1 molecules 
phosphorylate each other on tyrosine residues. The uncontrolled kinase activity of 
BCR-ABL1 then overwhelms the physiologic functions of the normal ABL1 enzyme 
by interacting with a variety of effector proteins. The key pathways implicated are 
those involving RAS, mitogen-activated protein (MAP) kinases, signal transducers 
and activators of transcription (STAT), phosphatidylinositol 3-kinase (PI3K) and 
MYC. Most of the interactions are mediated by tyrosine phosphorylation and require 
the binding of BCR-ABL1 to adapter proteins such as growth factor receptor-bound 
protein 2 (GRB2), DOK, CRK, CRK-like proteins, SHC and casitas B lineage 
lymphoma protein(1). The net result is deregulated cellular proliferation, decreased 
adherence of leukaemia cells to the bone marrow stroma and a reduced apoptotic 
response to mutagenic stimuli(3). 
The p210 form of BCR-ABL1 is the most common product observed in patients with 
CML. The structure of the BCR-ABL1 protein and the biochemical pathways in 
which it is involved have been extensively studied(1;4). The tyrosine kinase encoded 
by the SRC-homology 1 (SH1) domain of the ABL1 component is undoubtedly the 
most crucial for oncogenic transformation. Other important motifs in the ABL1 
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portion are the protein interaction SRC-homology 2 (SH2) and the C-terminal actin-
binding and DNA binding domains. On the BCR moiety, the coiled-coil motif 
encoded by the first BCR exon is responsible for the dimerisation of the oncoprotein; 
a tyrosine at position 177 is crucial for the binding of adaptor proteins such as growth 
factor receptor bound protein 2; the N-terminal phosphoserine and phosphothreonine 
residues are required for interaction with SH2 containing proteins, including ABL1 
itself. 
The ABL1 protein is found in both the nucleus and the cytoplasm and can shuttle 
between these two compartments under the influence of nuclear localisation nuclear 
export signals, whereas BCR-ABL1 is exclusively cytoplasmic. Nuclear ABL1 is 
essentially a proapoptotic protein, playing a key part in the cellular response to 
genotoxic stress. BCR-ABL1 in contrast is largely antiapoptotic and although it 
retains the ABL1-derived nuclear export and nuclear localisation sequences, it seems 
unable to enter the nucleus. The main reason why the BCR-ABL1 protein is retained 
in the cytoplasm is its constitutively active tyrosine kinase(1;5).
 
Incidence, epidemiology and aetiology 
CML accounts for approximately 15% of all leukaemias in adults although the 
proportion is higher in the East Asia and Japan where chronic lymphocytic leukaemia 
is very rare. It has an incidence of 1.6 to 2.0 cases per 100,000 persons per year.  The 
median age of patients at presentation is 45 to 55 years. From 12 to 30% of patients 
are 60 years of age or older(6). The aetiology of CML is unknown in the majority of 
patients. However, the risk of developing CML is higher following exposure to 
radiation. This is evident from studies of survivors of the atom bomb explosions in 
Japan in 1945 and from the follow-up of patients treated with radiation for ankylosing 
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spondylitis and cervical cancer(7;8). There is no known association of CML with any 
infectious agent or chemical exposures. No familial predisposition has been 
implicated in CML but there are isolated reports of CML occurring in first degree 
relatives of affected individuals. Relapse of CML originating in donor cells following 
a related donor allogeneic stem cell transplant (SCT) has been recorded(9). 
Individuals expressing HLA-B8, HLA-A3 and HLA-DR4 have been reported to have 
reduced risk of developing CML(10;11). CML is a triphasic disease, and when left 
untreated progresses through defined phases of initial chronic phase (CP) to an 
intermediate accelerated phase (AP) followed by a terminal blast phase (BP). Before 
the advent of tyrosine kinase inhibitors the entire continuum from CP to BP lasted on 
average 3 to 5 years, but the range was wide. A patient can present in any of these 
three stages(12). 
History of chronic myeloid leukaemia 
Chronic myeloid leukaemia was the first type of leukaemia to be recognised. In 1841 
David Craigie in Glasgow saw a patient with fever, splenomegaly and leukocytosis; 
he saw a second similar patient three years later and this led his colleague John 
Hughes Bennett, a physician and pathologist, to perform an autopsy and to describe 
his findings in 1845 in the Edinburgh Medical and Surgical Journal(13). 
Simultaneously Rudolph Virchow saw a similar patient at the Berlin Charitē Hospital.  
The patient died 4 months later and Virchow noted at autopsy enlargement of the 
spleen. His report was published in German five weeks after Bennett's paper(14).  
Bennett and Virchow differed in the interpretation of their respective findings: 
Bennett concluded that his patient had died from 'the presence of purulent matter in 
the blood', implying some occult infection as the cause. Virchow was less inclined to 
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attribute the excess of colourless corpuscles to 'pyemia' and coined the descriptive 
term 'Weisses Blut' or 'white blood'; this was based on the Greek (s and ỉ) 
and became in German 'Leukaemie'. Virchow took the view that the cause of the 
disease was a primary alteration in haematopoiesis(15). Bennett meanwhile produced 
the term 'Leucocythaemia' or 'White Cell Blood' which also became the title of the 
book where he reported 37 cases(16).  The claim of priority between the two authors 
was debated subsequently and arguments over ―correct‖ nomenclature continued 
acrimoniously for some years. The sequence of events is recounted in some detail in 
an excellent review by Geary(17). Management of leukaemia in the 19
th
 century was 
no success story(18). Lissauer is credited with the first published report of the use of 
arsenicals(19)  though full details of his work are lacking. It is interesting to note that 
Arthur Conan Doyle, more famous for documenting the antics of Sherlock Holmes, 
reported in the Lancet the use of arsenic to treat a patient with  leukaemia in 
1882(20), so its use at that time cannot have been routine. Virchow had perceived that 
the disease could be neoplastic(15) but virtually nothing was known about its 
aetiology until chronic myeloid leukaemia was associated with the exposure to 
radiation after the explosion of the atomic bombs during the second world war. In 
1960 Nowell and Hungerford described a minute chromosome in cells cultivated 
from the blood of seven patients with chronic myeloid leukaemia(21). These findings 
were rapidly confirmed by others and the abnormal chromosome became known as 
the ―Philadelphia chromosome‖, abbreviated to Ph1 because the identification of 
further consistent cytogenetic abnormalities in other diseases was anticipated.  In the 
event the superscript (1) has been dropped in recent years. The Philadelphia 
chromosome was further characterised by Rowley(22) who showed that it was in fact 
the result of a translocation between chromosomes 9 and 22. In 1984 the breakpoint 
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cluster region (bcr) on chromosome 22 was discovered by the research group in 
Rotterdam (Groffen et al, 1984) and this was followed rapidly by the demonstration 
that BCR was fused with ABL (now termed ABL1) on the Ph chromosome(23). A 
crucial later observation was the capacity of the BCR-ABL1 gene to cause a disease 
simulating chronic myeloid leukaemia in experimental mice when introduced into 
murine haematopoietic stem cells by retroviral mediated gene transfer (Daley et al, 
1990). 
Radiotherapy entered clinical practice in the early years of the 20
th
 century and was 
arguably the first reliably effective palliation for CML. It remained standard therapy 
for more than fifty years. The rapid development of oral alkylating agents after the 
Second World War then led to introduction of busulphan, which had largely displaced 
radiotherapy by the 1960s(24). Curiously hydroxyurea was slow to gain popularity 
but eventually proved superior to busulphan, by which time the value of interferon-
alfa in inducing Philadelphia chromosome negativity in some patients had been 
clearly established(25). In the 1980s it became clear that allogeneic stem cell 
transplantation, though potentially hazardous or even fatal, could if successful induce 
long term remissions and probably cure for some patients. In the late 1990s evidence 
from France suggested that the best treatment for CML patients not destined for 
allografting was probably the combination of interferon plus cytarabine(26), though 
subsequent data from Italy cast some doubt on this conclusion(27). The last decade 
has been especially exciting in the story of treating chronic myeloid leukaemia. The 
pre-clinical development of imatinib mesylate (STI571) was spearheaded by Brian 
Druker(28) and the initial successful clinical use of this drug resulted in the 
introduction of imatinib as the front line therapy for newly diagnosed CML patients . 
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Clinical manifestations 
CML left untreated is fatal within a few years. The first plausible description of CML 
in 1845 suggests that the patient may have died from effects of 
hyperleukocytosis(13). Early in  the 20
th
 century, the average survival of untreated 
CML patients was 3.1 years compared to 3.5 years in those treated with 
radiotherapy(29). In the 1990s the median survival of CML with conventional therapy 
was around 5 years, though this figure promises to be much longer in the 21
st
 century. 
CML is a biphasic (or triphasic) disease. Typically CML is diagnosed while still in a 
readily defined chronic phase that was usually controlled with ease for 4-6 years 
(although in some exceptional patients, it lasted 15 or more years). Invariably the 
disease progressed eventually to a more advanced phase which was usually sub-
classified as either accelerated phase or blastic transformation; the latter phase is 
especially resistant to therapy, resembles an acute leukaemia and leads to death 
within 6 to 8 months(30). In 20-40% of patients in chronic phase, the disease 
transformed abruptly into blastic phase while in the other 60-80% of patients the 
transformation was more insidious and the disease gradually became more difficult to 
control with drugs (accelerated phase). Progression to blast phase occurred at a rate of 
approximately 5% for the first year, 12% for the second year and 20-25% for each 
subsequent year(31;32). The natural history of CML treated with tyrosine kinase 
inhibitors may differ substantially from that of disease treated with earlier agents.   
Chronic phase  
Ninety percent of CML patients present in chronic phase. The increasing health-
consciousness of today‘s population is reflected by widespread medical checks in 
asymptomatic individuals. Up to 30% of patients are diagnosed while still 
asymptomatic as a result of finding splenomegaly at routine physical examination or a 
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blood count with leukocytosis. Symptoms are generally related to these common 
findings in CML. The patient may suffer fatigue, fever, bone pain, weight loss and 
excessive sweating due to the effect of hyperdynamic haematopoiesis. Abdominal 
fullness and discomfort from the enlarged spleen are usual. Symptoms from 
hyperleukocytosis such as headaches and visual disturbances due to hyperviscosity 
occur rarely. About 2% of men present with priapism(33).  The commonest physical 
finding present in more than three-quarters of CML patients is splenomegaly. The 
spleen tip extends more than 10 cm below the left costal margin in half of these 
patients and it may occasionally be palpated even in the right iliac fossa. The 
magnitude of splenomegaly correlates well with the degree of leukocytosis. The 
larger the spleen, the more prone it is to infarction. Purpura and spontaneous bleeding 
are relatively uncommon and may be related to concomitant thrombocytosis. 
Lymphadenopathy is uncommon. In countries with advanced health care systems 
forty to fifty percent of patients have no physical signs at diagnosis; conversely in 
developing countries almost all patients will be symptomatic when first seen in the 
clinic.  
Advanced phase (accelerated and blastic phases)  
Patients may present in advanced phase where symptoms as described above develop 
over a relatively shorter period than that of chronic phase. In contrast to patients in 
chronic phase, patients in advanced phase are more likely to be symptomatic, with 
fever, bone pain and/or bleeding being more prominent. In the majority of patients, 
the progression to advanced phase from chronic phase is relatively insidious but 
distinct. The blood count and spleen size may escape the control of previously 
adequate treatment with hydroxyurea or interferon-.  There may be frequent 
episodes of infections and the patient feels in general less well. Areas of particular 
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bony tenderness may correlate with lytic lesions. Some patients may have symptoms 
suggestive of meningitis due to central nervous system infiltration, particularly in 
lymphoid blastic transformation. 
Progression of CML to myelofibrosis occurs in 5% of patients and is regarded as a 
feature of advanced disease. There is prominent splenomegaly which is usually 
greater than 10 cm below the costal margin. Features of marrow failure with 
increasing anaemia and thrombocytopenia intervene and there is usually 
extramedullary haematopoiesis with enlargement of the liver and occasionally of 
lymph nodes.  
Diagnosis 
The diagnosis of CML is commonly made by the typical appearances of the 
peripheral blood film and bone marrow biopsy. Cytogenetic analysis for the presence 
of the Ph is confirmatory. Molecular studies by polymerase chain reaction (PCR) 
assays for evidence of BCR-ABL1 transcripts provide additional confirmation of 
CML, and are especially valuable if cytogenetic studies are inconclusive.  
Peripheral blood  
The most obvious and diagnostic features of CML in the peripheral blood are 
neutrophil leukocytosis and basophilia. The leukocytosis ranges from 20 to 800 x 
10
9
/l and comprises cells at all the stages of differentiation from the myeloid lineage. 
These cells are morphologically unremarkable by light and electron microscopy(34). 
The predominant cells are neutrophils and myelocytes, the so-called ‗dual peak‘ in 
the haemogram. Primitive blast cells are rare (usually < 5%). Basophilia is an 
important diagnostic feature as its absence suggests other myeloproliferative 
disorders. Eosinophilia may be present but is of no diagnostic relevance. In the 
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majority of patients, there is thrombocytosis with platelet anisocytosis. Occasionally 
the platelet count may be more than 1000 x 10
9
/l. Most CML patients with 
splenomegaly have a mild normochromic normocytic anaemia which is also 
proportional to the degree of leukocytosis. Nucleated red cells are common 
accounting for the ‗leukoerythroblastic picture‘ of the blood film.  
Bone marrow 
The aspiration of the marrow for morphology and cytogenetic analysis is routinely 
performed in the diagnosis of CML. Examination of the marrow trephine biopsy in 
CML is helpful in staging the disease with regard to degree of marrow fibrosis and 
excluding occult blast transformation.  
The marrow in CML is markedly hypercellular with complete loss of normal fat 
spaces. There is a predominance of myeloid cells, particularly neutrophils and 
myelocytes but no features of abnormal maturation in the precursors. Myeloblasts are 
less than 5% of marrow elements. The basophilia seen in the peripheral blood is also 
present in the marrow. Megakaryocytes are usually increased in number, reduced in 
size and hypolobated. They may form clusters which are more apparent in the 
trephine biopsy. Occasional micromegakaryocytes may be present. Due to the 
increased myeloid to erythroid ratio, there is apparent erythroid hypoplasia. Erythroid 
precursors are otherwise unremarkable morphologically. Reticulin fibrosis is usually 
absent or mildly increased. Excessive reticulin fibrosis is associated with more 
advanced disease with massive splenomegaly and increased blast cell counts.  
Prognostic factors for non transplant therapy  
Various staging systems have been advocated in an effort to predict the prognosis of 
individual patients. The most accepted is that developed by Sokal in 1984(35); this 
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was revised recently by Hasford(36). In 1984 Sokal et al(35) devised a system to sub-
classify patients with CML in chronic phase into three prognostic groups for survival 
according to features assessed at diagnosis.  Data were analysed from 529 patients, 
mostly treated with busulphan, from six American and European series. The variables 
included in the analysis were those available in the vast majority of patients in the 
centres, such as age, sex and peripheral blood parameters. Variables that were 
missing in a significant number of cases, such as additional cytogenetic 
abnormalities, percentage of bone marrow blasts, etc, were not included. The final 
model arising from the multivariate analysis included weighted values for age, spleen 
size, peripheral blood blast cell percentage and platelet count. The Sokal score in an 
individual patient is no more than the relative risk (RR) for survival resulting from the 
Cox model when the particular platelet count, age, blast count and spleen size values 
of the given patient are entered in the Cox equation. Then patients were classified 
according to their RR into three distinct groups: patients with a relative risk lower 
than 0.8 are considered good risk,  patients with a relative risk higher than 1.2 are 
considered to be high risk and patients with a relative risk between 0.8 and 1.2 are 
classified as intermediate risk. This prognostic system has survived the passage of 
time and although some attempts have been made to improve it, it is still the most 
reproducible and widely accepted prognostic model for patients in chronic phase.  
Imatinib mesylate inhibits the BCR-ABL1 oncoprotein 
Imatinib mesylate (Glivec, Gleevec), is a 2-aminophenylpyridimine compound that 
can specifically inhibit the kinase activity of normal ABL1 and oncogenic BCR-
ABL1. It is now established as the first-line therapy for effectively all cases of newly 
diagnosed CML, regardless of disease phase. Prior to the introduction of IM, 
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therapeutic options were limited to Interferon alpha (IFN-alpha) therapy either alone 
or in combination with cytarabine, or allogeneic haematopoietic stem cell 
transplantation (SCT)(37). 
Mechanism of action: IM is effective in inhibiting ABL1, PDGFR, PDGFR, and 
KIT. All the fusion onco-proteins containing these activated kinases are potential 
targets for IM such as BCR-ABL1 in CML and Ph+ ALL, FIP1L1-PDGFR in 
eosinophilic leukaemia, ETV6-PDGFR in some variants of chronic myelomonocytic 
leukaemia and BCR-PDGFR in rare variants of CML(38). IM is sandwiched 
between the N-Lobe and C-Lobe of the ABL1 kinase domain and occupies the central 
region of the kinase. Part of the IM molecule occludes the region where the adenine 
ring of ATP normally binds. The rest of the compound penetrates further into the 
hydrophobic core of the kinase and wedges itself between the activation loop and 
helix-C, holding the kinase in an inactive conformation.  In total the compound 
makes 6 hydrogen bonds with the protein and the majority of contacts are mediated 
by van der Waals interactions(39).In the IM complex, the activation loop adopts a 
compact structure that moves Tyr253 over into close contact with IM(39).Tyr253 
makes only a weak van der Waals interaction with IM but forms water-mediated 
hydrogen bonds with the side chain of Asp-322 that folds the P-loop which is a 
glycine-rich and highly flexible structure and accommodates the groups of ATP, and 
increases surface complementarity with the drug through an induced-fit 
mechanism(40).The hydrophobic cage is completed by residues Leu-370 and Phe-
382. The piperazynyl ring lies along the hydrophobic pocket on the surface making 
van der Waals interaction with Val-289, Phe 359 and Asp-381 and hydrogen bonds 
with carbonyl oxygen atoms of Ile-360 and His-361. Thr-315 makes an important 
hydrogen bond with IM in the c-Abl1 complex.  Once IM is bound to ABL1, it jams 
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between the activation loop and  helix C preventing the activation loop from 
changing conformation(39). Thus IM functions as a competitive inhibitor of ATP 
binding. It binds to the inactive conformation of ABL, contacting 21 amino acid 
residues(41). Moreover IM forms a number of hydrogen bonds with the kinase 
domain. Methionine 318, Threonine 315, Methionine 290, Glutamine 286, Lysine 
270 and Asparagine 381 together with water molecules form a network of hydrogen 
bonds around the IM molecule(41). 
Clinical response and resistance 
 IM has very good oral absorption - its oral bioavailability is close to 100% and 
absorption is not impaired by food(42).  Its half-life after a single daily dose of 
400mg is 13 to 16 hours. The mean maximal concentration is 4.6 μM, reaching 1.46 
μM 24 hours after administration. This amount exceeds the concentration required for 
inhibition of cellular phosphorylation by BCR-ABL1(43) and is sufficient to cause 
the death of BCR-ABL1-positive cell lines in vitro(44). From pharmacokinetic 
studies, there is no evidence that the body mass of the patient has any impact on the 
plasma levels of IM(45). IM is metabolised predominantly in the liver by the 
CYP3A4/5 p450 enzyme system but does not induce activity of this enzyme and 
therefore drug plasma levels remain stable over time. For all patients treated with IM, 
the initial goal is the attainment of complete haematological response (CHR), defined 
as a normal peripheral-blood count in association with less than 5% of blasts in the 
bone marrow, ideally within 4 weeks of starting treatment and certainly by the 12th 
week of treatment. Response to treatment is then monitored by serial cytogenetic 
assessments of the bone marrow with the next level of response being the absence of 
the Ph chromosome, i.e. complete cytogenetic response (CCyR) as assessed by 
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conventional marrow metaphase analysis. Most patients treated with IM from 
diagnosis achieve complete cytogenetic response within 12 months. Further 
monitoring of BCR-ABL1 is then done either by fluorescence in-situ hybridisation, 
which has a sensitivity of up to 10
−3
 (and a false-positivity of 2–5%) or, preferably, 
by reverse-transcriptase polymerase chain reaction (RT-PCR), with a sensitivity of 
10
−5 
(46). Molecular monitoring of patients treated with IM from diagnosis shows that 
attainment of a three-log reduction in the concentration of BCR-ABL1 transcripts by 
RT-PCR from a laboratory standard value obtained for untreated patients is 
associated with a low risk of disease progression and, by extrapolation, with an 
increased duration of chronic phase. The three-log decrease has now become 
synonymous with a major molecular response (MMR). To date, about 5% of patients 
who achieve complete cytogenetic remission also become RT-PCR negative, but this 
number might increase with longer exposure to IM(47). 
Despite the excellent outcome achieved in the majority of patients in the IRIS study 
in which imatinib and the combination of interferon- plus cytarabine were compared 
in a prospective randomised trial for previously untreated patients with CML in 
chronic phase, it is apparent that a few patients do not succeed in obtaining a CHR 
and 20–25% do not achieve a CCyR. With relatively limited follow-up, less than 10% 
of patients had achieved complete molecular response (CMR) in the IRIS study. 
Failure to achieve the desired therapeutic milestones of CHR and CCyR is accepted 
as a primary resistance to IM therapy. Twenty to 25% of patients that reach CHR 
and/or CCyR will not maintain their response. This loss of response and progression 
of the leukaemic clone defines secondary (acquired) resistance to IM. Loss of CHR, 
loss of partial or CCyR, or an increase in 30% Philadelphia-positive marrow 
metaphases are criteria for secondary resistance(37). 
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Clinical resistance to IM is likely to be complex and may include extrinsic causes 
and/or intrinsic resistance of the leukaemic cells to the drug. Two distinct types of 
intrinsic resistance to IM can be postulated: (1) cases in which the leukaemic cells 
have become independent of BCR-ABL1 kinase activity for survival and 
proliferation, and (2) those that still require BCR-ABL1 but somehow have escaped 
the inhibitory effect of IM. Phosphorylation of the adaptor protein Crkl, which is a 
direct substrate of BCR-ABL1 in primary leukocytes from CML patients, has been 
used to distinguish these two mechanisms(40). 
Mechanisms of resistance to IM 
BCR-ABL Kinase Domain Mutations  
Mutations of the ABL kinase domain are detected in some of the patients with 
resistance to tyrosine kinase inhibitors (TKI) and might be the cause of resistance in 
some cases. The association between these mutations and resistance to TKI is 
discussed in chapter 1. 
BCR-ABL Gene Amplification  
Another common mechanism of resistance particularly in cell lines has been an 
increase in BCR-ABL1 mRNA and protein expression caused by gene amplification 
or increased transcription. Dose escalation of IM might restore responsiveness to IM 
in patients with increased expression of BCR-ABL1 as the mechanism of 
resistance(41). 
Efflux and influx of the drug 
The role of some cell membrane channels have been indicated as responsible for 
difference in IC50 of IM among different patients and as a cause of difference in level 
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of response.  The major group of influx proteins belong to the largest super-family of 
transporters, the solute carrier (SLC) super-family. In humans the SLC22 subfamily 
consists of 12 members encompassing the poly-specific organic cation transporters 
(OCTs). The OCT proteins are associated with the transport of endogenous and 
exogenous substrates, which exist as cations at physiological pH, across the plasma 
membranes in either direction(48). It was shown that IM is transported into cells via 
the OCT1 influx protein, a solute carrier which is involved only in influx and not 
efflux(49). The prognostic value of human OCT1 (hOCT1) in association with IM 
therapy is discussed in detail in chapter 3. There have been some debates about the 
role of ATP-binding cassette transporters in mediating IM resistance. IM may be an 
inhibitor or substrate of ABCG2 depending on its concentration(50-52). Jordanides et 
al showed that IM is an inhibitor of ABCG2 at concentrations above clinical trough 
plasma level in CD34+ cells. Thus aberrant expression of ABCG2 neither affects 
intracellular IM concentration nor mediates resistance in this population(53).
 
There 
are some reports which showed
 
IM was a substrate for MDR1 (ABCB1) in some cell 
lines(51;54), but Hatziieremia et al could not confirm these findings in primary CML 
cells(55). 
Alpha-1 acid glycoprotein (AGP) 
The plasma protein AGP was shown to bind IM in drug-treated mice and prevented 
IM from reaching its target and inhibiting BCR-ABL kinase activity(56).
 
A study 
investigating AGP levels in IM –treated CML patients found elevated AGP levels in 
over half of the patients, yet no correlation between elevated AGP levels and 
resistance to IM. Significantly, however, patients showing elevated levels of AGP 
were found to be slower to respond to IM. Total plasma concentration of IM is 
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comprised of AGP-bound IM, which is not distributed to the tissues, and free IM, 
which is potentially active(57). 
 
Clonal Cytogenetic Evolution  
There are also other cases where no mechanism of resistance can be identified. Not 
infrequently, there is clonal cytogenetic evolution in such patients i.e, the acquisition 
of cytogenetic abnormalities in addition to Ph chromosome(58).
 
However, the 
relationship between these abnormalities and IM-resistance has not been clearly 
defined, since clonal evolution is also observed in IM naïve patients. 
SRC Dependent Mechanisms 
SRC family kinases regulate multiple cellular events such as proliferation, 
differentiation, survival, cytoskeletal organisation, adhesion and migration as a 
consequence of their ability to couple with many diverse classes of cellular receptors 
and many distinct cellular targets(59). Multiple domains of BCR-ABL1 interact with 
and activate SRC kinases independently of BCR-ABL1 kinase activity(60;61). HCK 
and LYN are expressed and activated in the acute phase of CML patients, and their 
up-regulation correlates with disease progression and resistance in patients treated 
with IM(62;63). Dai et al showed the role of SRC kinase LYN in resistance to IM in a 
resistant cell line expressing low levels of BCR-ABL1 protein and mRNA. BCR-
ABL1 independent IM resistance was associated with marked activation of LYN and 
increased expression of BCL2 and reduced expression of p-Crkl. LYN is a potentially 
important downstream target of BCR-ABL1. Activation of Lyn is associated with a 
pronounced increase in the levels of the anti-apoptotic protein BCL2(64). Marked 
increase in mitochondrial associated BCL2 in these resistant cells may contribute to 
protection against IM mediated mitochondrial dysfunction(64). 
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Low activity of some tyrosine phosphatases 
Another mechanism of resistance, identified in cell lines and under investigation in 
patients is decrease in de-phosphorylation of STAT5.  STAT5 is reported to be an 
important molecule in BCR-ABL1 signalling and its constitutive phosphorylation is 
critical for proliferation of CML cells. In the IM resistant cell line KTR, T cell protein 
tyrosine phosphatase (TC-PTP) was markedly down-regulated and STAT5 
phosphorylation was high in spite of treatment with IM. The forced expression of TC-
PTP in KTR cells could restore sensitivity to IM. KTR cells have an abnormal  fusion 
isochromosome iso(18)(q10), which lacks 18p11.211.3, the location of the TC-PTP 
gene(65). Neviani et al reported that p210-BCR-ABL1 inactivates the tumour 
suppressor protein phosphatase 2A (PP2A) by enhancing the expression of the PP2A 
inhibitor SET and that PP2A loss-of-function accounts for increased and sustained 
BCR-ABL1 activity in CML-BC progenitors. In their study, reactivation of PP2A 
activity impaired BCR-ABL1 expression and function, leading to growth suppression, 
enhanced apoptosis, impaired clonogenicity, and decreased in vivo leukaemogenesis 
of both IM-sensitive and IM-resistant BCR-ABL1 lines and myeloid CML-BC 
patient cells(66). 
RUNX Dependent Mechanism of Resistance 
The RUNX gene influences the cellular response to IM(67). RUNX belongs to the 
core-binding factor gene family, representing a small group of heterodimeric 
transcription factors comprising RUNX1/AML1, RUNX2/AML3, RUNX3/AML2, 
and CBF-β. RUNX expression peaks in early haematopoietic stem cells (HSCs) and 
decreased levels of RUNX play a role in HSC homeostasis. In work by Miething et 
al,(67) over-expression of RUNX3 in a BCR-ABL1 transformed murine pre-B cell 
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line significantly protected the cells from IM–induced apoptosis, whereas a RUNX3 
mutant unable to bind DNA did not elicit this effect. They could also show by 
increasing RUNX1 expression that cells had reduced sensitivity to apoptosis.  This 
protective effect of increased RUNX1 expression seems to be specific for IM as they 
did not rescue BCR-ABL1 transformed Ba/F3 cells from apoptosis induced by 
cytarabine or etoposide.  They also showed that IM treatment also selected for cells 
with increased RUNX1 expression in patients with acute lymphoblastic leukaemia, 
further supporting a functional role for the gene in the IM response in humans(67).
 
JAK2/STAT5 Activation and Resistance to IM 
GM-CSF elicited IM  drug resistance via a BCR-ABL1-independent activation of the 
JAK-2/STAT5 signalling pathway in GM-CSF-receptor alpha receptor (CD116) 
expressing cells, including primary CD34+/CD116+ GM-progenitors (GMP)(68).
 
Elevated mRNA and protein levels of GM-CSF were detected in IM-resistant patient 
samples, suggesting a contribution of GM-CSF secretion for IM and nilotinib (NIL) 
resistance in vivo. Importantly, inhibition of JAK2 with AG490 abrogated GM-CSF-
mediated STAT5 phosphorylation and NIL resistance in vitro. Together, adaptive 
autocrine secretion of GM-CSF mediates BCR-ABL1-independent IM and NIL 
resistance via activation of the anti-apoptotic JAK2/STAT5 pathway(69). 
Primitive, Quiescent stem cells and Resistance to kinase inhibitors 
The number of quiescent CD34+cells in CML patients has been estimated to be 
around 5 x10
7
, based on the assumptions that the average patient has 10
12 
CML cells 
at diagnosis, of which 1% are CD34+ and only 0.5% of these are quiescent(70). 
In chronic phase of CML, excessive number of leukaemic precursor cells are 
produced and these generate variably increased numbers of morphologically and 
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functionally normal leukaemic progeny(71). CD34+38- cells represent the more 
primitive end of the CD34+ compartment (<5% of total CD34+ cells). Increased 
levels of BCR-ABL1 transcript, protein and kinase activity seen in the lin- (lineage-
negative) CD34+CD38- CML cells would be expected to contribute to a reduced 
sensitivity of these cells to BCR-ABL1-targeted therapeutics(72). One compartment 
of CD34+ is quiescent cells which are the most resistant cells of the stem cells to IM 
and dasatinib; these cells remain quiescent in cell culture in spite of a cocktail of 
growth factors (<1% of total CD34
+
 cells). The CML CD34+CD38- cell population is 
uniquely characterised by an elevated expression of BCR-ABL1 mRNA, protein and 
kinase activity, as well as an elevated expression of IL-3 and G-CSF, a highly 
suppressed expression OCT1 and an elevated expression of ABCB1 and 
ABCG2(72;73).  
There is mounting evidence that CML stem cells are not eliminated by IM in vivo, 
with patients in CCyR having easily detectable Ph+ CD34+ cells, colony-forming 
cells (CFCs), and long-term culture-initiating cells (LTC-ICs)(74). Copland et al 
showed that BCR-ABL1 transcripts could be detected by RT-PCR in all enriched 
populations of CD34+ and CD34+CD38- cells and in the same cells following 72 
hours exposure to IM. BCR-ABL1 transcript were significantly higher in total CD34+ 
and CD34+38- population of primary CML cells in comparison with more 
differentiated myeloid cells of the same patients. The inability of IM to reduce p-Crkl 
levels in CD34+CD38- cells suggests that these cells are inherently resistant to IM. 
Dasatinib inhibits phosphorylation of Crkl and reduces total numbers of 
CD34+CD38- cells at a clinically achievable concentration which is possibly due to 
significantly higher activity of dasatinib than IM(75).  
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According to Copland et al CD34+ cells can be divided in two groups, one group 
remaining quiescent and thereby highly resistant to IM and dasatinib and a second 
group represented by cells destined to proliferate. IM cannot inhibit these 
proliferating CD34+cells completely, probably due to significantly higher level of 
BCR-ABL1 transcripts. As dasatinib is 300 times more potent than IM, it could 
inhibit p-Crkl in CD34+CD38- better than IM. Although dasatinib was able to inhibit 
Crkl phosphorylation and kill those cells destined to move from G0 to G1, it was 
unable to affect those destined to remain quiescent in culture(75). 
Gene Expression studies 
There are several studies which investigated the pattern of gene expression in 
diagnostic samples and tried to find a correlation between the expression of some 
genes and prediction of resistance to IM, but there are very few genes common to 
these different studies which predict the response to IM; this disparity may be due to 
use of different cell types and also different panels(76-78). Radich et al reported that 
CML patients who relapsed after initially successful treatment with IM demonstrated 
a gene expression pattern closely related to advanced phase disease. Their studies 
point to specific gene pathways that could be exploited for both prognostic indicators 
as well as new targets for therapy(79). Investigators at the MD Anderson Cancer 
Center in Houston recently used a low density microarray analysis on pre-IM samples 
from newly diagnosed patients who had different levels of response to IM. They 
found PTGS1 was significantly differentially expressed in the IM-failure/resistant 
group. They also found higher levels of expression of RUNX3 and lower expression 
of PTPN22, CEBPA, TEC and ABL1 in secondary IM-resistance in comparison to 
optimal responders. According to their study patients with primary resistance had a 
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different pattern of gene expression in pre-IM samples in comparison to secondary 
resistant ones(80). 
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Aims 
The overall aims of this research project are to: 
Analyse kinase domain mutations in detail 
1. Investigate the frequency and role of KD mutations as the cause of 
resistance to IM and their effect on disease progression as a prognostic factor. 
2. Investigate the kinetics of the KD mutations in patients who receive 
dasatinib after showing resistance or intolerance to IM  
Investigate the utility of novel prognostic markers 
3. Investigate the prognostic value of in vitro inhibition of p-Crkl in CML 
CD34+ cells at diagnosis  
4. Investigate the prognostic value of hOCT1 transcript levels for achieving 
molecular response to IM  
5. Investigate the influence of TP53 polymorphisms at codon 72 and also 
MDM2 309 polymorphisms and their interaction on response to IM and 
survival in CML patients   
Detect chromosomal losses and gains associated with prognosis 
6. Use CGH array as a technique for investigating the heterogeneity of CML 
and the association between specific genomic patterns and clinical outcome  
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Chapter 1  
Frequency and role of KD mutations as the cause of 
resistance to tyrosine kinase inhibitors and their 
effect on disease progression as a prognostic factor 
 
Introduction 
The mechanism of resistance to IM has been ascribed to several possible factors (as 
described earlier) but perhaps the best understood and widely documented in clinical 
practice is the expansion of a Ph-positive clone bearing a BCR-ABL1 kinase domain 
mutation. Many of these mutations affect residues that form hydrogen bonds or 
hydrophobic interactions with IM. They lead to structural changes so that IM is no 
longer able to displace ATP, while still preserving the kinase activity. Amino acid 
changes can affect directly the contact position for IM, such as Y253, T315 and F317. 
Such mutations directly affecting IM binding typically lead to strong IM resistance. A 
second group of mutations shifts the equilibrium of the kinase toward an active state. 
Since IM can only bind to the inactive conformation of ABL,(81)
 
such exchanges 
obstruct IM access to the ATP-binding site(82). This group includes exchanges at 
positions located within the activation loop, such as H396 and M388, or mutations of 
the SH2-contact positions, such as S348 or M351. Alternatively IM resistant 
mutations can also be categorised according to their localization in different 
functional domains such as activation loop (A loop), ATP phosphate-binding loop (P 
loop), or C-helix. However this classification does not allow an estimate of the degree 
of resistance. For example, the class of P-loop mutations includes moderate (G250A, 
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Q252H, E255D) and strong IM resistance mutations (G250E, Y253H, 
E255V)(82;83).   
In vitro studies have shown that some mutations (T315I, E255K) have a one or two 
log increase of their IC50 values for IM compared with wild type BCR-ABL1. 
However, other mutants have less dramatic shifts of their IC50 value. Thus 
determining the precise mutation may be of major clinical relevance. For example in 
a patient with a mutation that confers a moderate increase in IC50, dose escalation of 
IM might be effective, whereas it would be useless for highly resistant mutant such as 
T315I(41). Some mutants, such as T315I and E255K, are insensitive to IM at 
clinically available doses, whereas others, such as M351T or Y253F, retain 
intermediate levels of sensitivity to IM. The probability of finding a mutation 
increases with disease duration and with advanced disease stage. Threonine 315 
makes a specific hydrogen bond with IM, but this cannot happen if the Threonine is 
mutated to Isoleucine. Tyr 253 makes a van der Waals contact with IM, and 
substitution of Phenylalanine at this position leads to a resistant form of the kinase.  
Amino acid 255 is located within the ATP-binding site of the kinase, and mutations 
that convert Glutamic acid to Lysine or Valine lead to enzymes that are insensitive to 
IM. Methionine 351 is not part of the ATP-binding loop nor is it within that 
activation loop; however it occurs at the base of the activation loop which may 
explain its ability to influence binding of IM leading to a resistant enzyme form(58). 
The T315 is called the ‗gatekeeper‘ residue. The hydroxyl group of the T315 makes a 
hydrogen bond with IM and T315 side chain controls the binding of inhibitor to the 
hydrophobic cage that is close to ATP-binding domain. Most of the inhibitors contain 
substitutes, which are accommodated by a hydrophobic cage, which is near the ATP 
binding domain of wild type kinase. Mutations of T315 disturb this hydrophobic cage 
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and prevent the drug from being accommodated in the hydrophobic area. Although 
T315 mutation disturbs the hydrophobic cage it does not affect the ATP binding 
region, so ATP can bind and the catalytic activity continues(84). 
Several groups have reported the presence of mutations even in untreated patients; 
therefore the selective pressure exerted by IM appears to favour the outgrowth of pre-
existing resistant clones. It is likely that more sensitive technology may detect 
mutations in even more patients before IM therapy and help to identify patients at risk 
of future IM resistance. The possibility that some of the mutations confer a growth 
advantage to the malignant clone even in the absence of IM has been suggested by the 
finding of increased kinase activity of a mutation involving Y253(41). Ex vivo studies 
by Griswold et al(85) have shown differences not only in resistance to IM but also in 
growth and proliferative abilities of different mutations in ABL kinase domain. 
Through ex vivo studies in BaF3 cell line the growth capacity of different clones was 
shown in this order: Y253F>E255K>WT>T315I>H396P>M351T(85). The BCR-
ABL1 Y253F mutant induces significantly more phosphotyrosine in vivo than wild 
type BCR-ABL1 when expressed at similar levels. This finding raises the interesting 
possibility that some BCR-ABL1 mutations that cause resistance to IM might also 
contribute to the progression of chronic-phase CML to accelerated phase or blast 
crisis, which may help to explain the rapid emergence of drug resistance in these 
patients(40). Y253F may disrupt the binding of a physiological ABL1 inhibitor, 
because this mutant of BCR-ABL1 exhibits increased kinase activity compared to 
wild type when expressed in cells, but not in in vitro kinase assays using purified 
ABL1(86). Branford et al reported a strong association of mutations located in the P-
loop with a poor prognosis in both accelerated phase and chronic phase patients(87). 
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In contrast, the data from Skaggs et al (88) on the oncogenicity of some mutations 
were different from that reported by Griswold. The Skaggs et al analysis of 
oncogenicity and kinase activity of the most common and clinically relevant 
mutations including T315I, E255K, Y253F, E255V, Y253H, M351T, F317L, T315A 
along with naive p210-BCR-ABL1 showed a spectrum that included potencies greater 
or less than native BCR-ABL1-p210. In most cases oncogenicity correlated with 
kinase activity. An important exception was BCR-ABL1 T315I, which displayed 
increased oncogenic potency but reduced kinase activity toward classical BCR-ABL1 
substrate(88). Phosphotyrosine profiling techniques that revealed several tyrosine 
phosphorylation peptides were uniquely and reproducibly elevated in cells expressing 
each of the kinase inhibitor resistant mutants, indicative of mutation-specific 
phosphotyrosine signatures. It means a single amino acid substitution in the kinase 
domain can exert specific effects on substrate recognition. T315I and E255K 
consistently showed a 10-20% increase in potency relative to native p210-BCR-
ABL1, demonstrating that they are indeed gain-of-fitness mutants as suggested by 
clinical evidence of pre-treatment detection.  Y253F and E255V displayed potencies 
similar to p210-BCR-ABL1. Y253H, M351T, F317L and T315A had substantially 
weaker transforming activity. E255K and Y253F had greater kinase activity than 
p210 whereas Y253H, T315I, E255V, F317L and M351T had reduced activity. T315I 
mutant was 20% more potent than p210 in bone marrow transformation despite a 
nearly 50% reduction in V max.  In the case of T315I, a mutation specific-
phosphorylation pattern in the phosphate binding loop of BCR-ABL1 explains the 
difference in oncogenicity relative to wild-type BCR-ABL1 and the closely related 
T315A mutation. T315I-expressing cells favour Y257 phosphorylation, whereas 
T315A-expressing cells favour Y253 phosphorylation. Y253 phosphorylation 
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suppresses oncogenicity, whereas Tyr257 plays a more complex role in promoting 
oncogenicity(88). 
 
The presence of kinase domain mutations has been studied mainly in patients in 
advanced phase and in CP patients when they become resistant to IM, but the 
prognostic implication of KD mutations for progression free survival (PFS) has not 
been established since there are no published studies in which resistant and non-
resistant patients have been monitored for mutations systematically. This is 
particularly important as KD mutations have been identified in patients with stable 
cytogenetic responses and in patients before starting IM therapy. Here I describe 319 
CP patients who were systematically screened for KD mutation to investigate any 
association between the detection of BCR-ABL1 KD mutations and PFS. We also 
investigate the kinetics of KD mutations after the change of therapy to dasatinib in 46 
patients who failed on IM. 
 
Materials and Methods 
Patients in the IM Study 
 Between January 2000 and August 2006, 380 adult patients with BCR-ABL1-
positive CML in CP were treated with IM at the Hammersmith Hospital in London. 
Of the 380 patients 356 were still in CP after 6 months of IM therapy and 319 of these 
had sequential samples for BCR-ABL1 kinase domain (KD) mutations analysis and 
were analysed further in this study. One hundred and forty eight of these 319 patients 
had been treated previously with IFN-α and 171 had received IM as first line therapy 
within 6 months of diagnosis. Bone marrow morphology and cytogenetics were 
assessed at diagnosis and then every 3 months until patients achieved CCyR. 
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Thereafter patients were monitored by real-time quantitative PCR and annual bone 
marrow examinations. CCyR was defined by the failure to detect any Ph 
chromosome-positive metaphases in two consecutive bone marrow examinations with 
a minimum of 30 metaphases examined and major cytogenetic response (MCyR) was 
defined by combining the number of complete and partial cytogenetic responses 
(≤35% Ph-positive metaphases). Cytogenetic relapse (loss of CCyR) was defined by 
the detection of one or more Ph-positive marrow metaphases, also confirmed by a 
subsequent study. Bone marrow examination was triggered by a rise in BCR-ABL1 
transcript numbers to a level consistent with cytogenetic relapse.  
Patients in the Dasatinib Study  
This study comprised 46 consecutive patients with Ph-positive and/or BCR-ABL1 
positive chronic myeloid leukaemia, judged to be resistant or intolerant to IM, who 
started treatment with dasatinib at the Hammersmith Hospital in London between 
April 2005 and July 2006. Two patients had stopped IM because of intolerance and 
44 had been judged to be resistant. Of the 46 patients, 26 were still in CP, 11 were in 
AP and nine were in BP at the time of starting dasatinib. Dasatinib was administered 
at a dose of 70 mg twice daily by mouth but dosage was reduced if necessary in the 
presence of myelosuppression or for other toxic effects. The study was approved by 
the Research Ethics Committee of the Hammersmith Hospital and all patients gave 
informed consent for their participation. 
RNA extraction, cDNA synthesis and sample analysis 
A cell pellet was prepared from 10 to 20 ml peripheral blood and/or from 2 to 3 ml of 
one marrow aspirate, both of which had been collected into EDTA or preservative-
free heparin and was lysed in guanidine isothiocyanate (GTC). Total RNA from 
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peripheral blood, bone marrow and cell harvests samples was extracted using the 
Qiagen RNeasy Kits. Prior to subjecting the samples to RNA extraction the cellular 
pellet was stored as GTC lysates. Nucleic acids are stable in GTC, which degrades 
proteins, including RNAse. RNA was extracted using an ion exchange column 
chromatography and centrifugal force. The step by step procedure is described below. 
1-GTC lysates were thawed (stored at -20C) for RNA extraction.  
2-350l of 70% Ethanol was transferred into appropriately labelled 1.5 ml micro-
centrifuge tubes using 1000 ml plugged tip. 
3-On thawing, GTC was vigorously vortexed one at a time  
4-350l of GTC lysate was transferred to appropriately labelled 1.5 ml micro-
centrifuge tubes. 
5-700l suspension was transferred to a appropriately labelled RNeasy spin column.  
6- In addition to the samples, we included blank ethanol control, i.e. add 700l of 
70% Ethanol to a separate spin column and proceed as per patient sample. 
7-The mixture was incubated at room temperature for 30 minutes. 
8-The columns were centrifuged for 15 seconds at 8000 x g.  
9-The flow-through was discarded from the collection tubes. 
10-650 l RW1 Buffer (Qiagen RNeasy Kit) was transferred to the spin columns and 
centrifuged for 15 seconds at 8000 x g and the flow-through was discarded. 
11- 500l RPE Wash Buffer (Qiagen RNeasy Kits) was transferred to the spin 
column and centrifuged for 15 seconds at 8000 x g and the flow-through was 
discarded and the columns placed into a new collection tube. 
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12-500l RPE Wash Buffer was added to the spin columns and centrifuged for 2 
minutes at 15000 x g. 
13-The flow-through and the collection tubes were discarded. 
14-The columns were placed upside down onto tissue paper in the hood, and the lids 
were kept closed for 2 minutes. This allowed any residual 70% ethanol at the bottom 
of the column to evaporate. 
15-The columns were transferred to new labelled, 1.5ml micro-centrifuge tubes. The 
lids of the spin columns were opened slightly, and were left for approximately 20 
minutes. This will allow any remaining 70% ethanol present within the spin columns 
to evaporate. 
16-25l of RNase-free water was applied to the centre of each column. 25l of water 
was also set aside into a 1.5mL micro-centrifuge tube which was used later as a 
control for subsequent cDNA synthesis. 
17-The RNA was eluted from the membrane by centrifuging for 2 minutes at 15000 x 
g.  
18- Each spin column was removed and discarded.  
19- Before discarding the pink Qiagen columns, a RNA sample for the reverse 
transcriptase (RT) negative control was extracted. RT negative sample is prepared by 
eluting with 25 l of RNase free water through one of the patients‘ Qiagen column, 
selected randomly, from which RNA had already been eluted once. This ‗RT 
Negative control‘ was then treated as per other RNA samples. However, cDNA mix 
added to this ‗sample‘ was void of RT enzyme. 
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In addition to the samples, cDNA synthesis should also include the following blank 
controls: 
 
(a) 70% Ethanol control from the RNA extraction protocol.  
(b) Sterile water control (25 l), an aliquot of sterile water set-aside from the 
RNA Extraction protocol. 
(c) GTC control saved from the sample processing. 
(d) RT Negative control 
21-The RNA was incubated at 65C for 10 minutes. This is to ensure the RNA is 
linear, i.e. to denature any secondary structures.  
22-The tubes were transferred to a micro-centrifuge and pulse spun to collect the 
contents to the bottom of the tube. Then the tubes were transferred to ice 
immediately, to avoid formation of RNA secondary structures. 
23-One cDNA mix (see appendix 1) was thawed per 10 samples (including the blank 
controls) at room temperature. For more than 10 samples, the aliquots of cDNA mix 
were thawed into a single 1.5ml micro-centrifuge tube. 
24-6 l RNAsin (Ribonuclease Inhibitor) (per 10 samples) was added to the cDNA 
mix and vortexed briefly. 
25-21l of cDNA mix was taken and added to the non-template control (NTC) only.   
26-12l Moloney Murine Leukaemia Virus Reverse Transcriptase (M-MLV) RT (per 
10 samples) was added to the remaining cDNA mix and vortexed briefly.  
27-21l of cDNA mix was transferred to each of the other samples/controls (ie. not 
NTC tube).   
28-Each tube was incubated at 37C for 2 hour.  
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29-The mixture was incubated at 65C for 10 minutes to inactivate the reverse 
transcriptase.  
30-The cDNA was stored at –70C. 
BCR-ABL1 transcript numbers were then analysed by real-time quantitative 
polymerase chain reaction as part of the routine monitoring of the patient‘s response 
to treatment
45
.  
Direct sequencing 
Using 5 μl  of cDNA, a first round amplification of the BCR-ABL1 gene from exon 
13 of the BCR gene to exon 10 of the ABL1 gene was carried out using primers B2A 
(600nM) and JAMR (600nM) (Table 1-1) to exclude the normal ABL1 from 
mutational analysis (see appendix 2) (Figure 1-1). 1 μl of the BCR-ABL1 amplicon 
from each sample in the study was subjected to nested primer PCR in a final volume 
of 100 μl using primers NTPB+ and NTPE- to generate an 863-bp fragment 
containing the entire Abl KD (see appendix 2; Figure 1-1). 8 μl of the PCR products 
was electrophoresed through a 2.0% agarose gel in TBE buffer; if a single amplicon 
was observed the 50 μl of PCR products was purified using ChargeSwitch PCR 
clean-up kit in accordance with the manufacturer‘s instructions (Invitrogen, Carlsbad, 
US). Otherwise, the PCR fragment containing the Abl KD was excised from the gel 
and purified using commercially available QIAquick Gel Extraction kit as 
recommended by the manufacturer (QIAGEN GmbH, Hilden). The purified 
amplicons were then subjected to Sanger‘s dideoxy-chain termination reaction using a 
Big-Dye ABI 310 sequencer (Applied Biosystems, Foster City, USA). This part of 
the experiment was carried out in the MRC Genomic Cores Laboratory, 
Hammersmith campus.  The reaction was primed with oligonucleotides NTPB+, 
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ABLKR, ABLKF and ITKE, listed in Table 1-1. In each case the sequence obtained 
was compared with the published ABL1 sequence, GenBank M14752, using BLAST 
2 software. All observed base substitutions were confirmed by sequencing the 
complementary strand. 
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Figure 1-1 Position of primers for amplification of different parts of BCR-ABL1 
kinase domain  
The blue and red blocks represent BCR and ABL1 exons respectively. Primers B2A 
and JAMR were used to amplify the kinase domain from BCR-ABL fusion gene and 
to exclude the normal ABL1 from mutational analysis. NTPB+ and NTPE- were used 
for amplification of the kinase domain in the second step of the nested PCR to 
produce an 863 bp fragment. To sequence the kinase domain ITKE-, ABLKF, 
ABLKR and NTPb+ primers were used. The primer pairs of P Loop, 315, 41, 9 and C 
were used for amplification various fragments of kinase domain in different second 
step of nested PCR reactions which were used for pyrosequencing. 
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Table 1-1  Sequence of the primers 
Primer Sequence 
B2A 5‘-TTCAGAAGCTTCTCCCTGACAT-3‘ 
JAMR 5‘-GTACTCACAGCCCCACGGA-3‘ 
NTPB+ 5‘-AAGCGCAACAAGCCCACTGTCTAT-3‘ 
NTPE- 5‘-CTTCGTCTGAGATACTGGATTCCTG--3‘ 
ABLKF 5‘-AACGCCGTGGTGCTGCTGTAC-3‘ 
ABLKR 5‘-CAGTTTCGGGCAGCAAGATC-3‘ 
ITKE 5‘-CTGGAACATTGTTTCAAAGGCTTGGT-3‘ 
P Loop-F1  5‘-TACGACAAGTGGGAGATGGA-3‘ 
P Loop-R1  5‘-GCCACCGTCAGGCTGTATTT-3‘ 
253+315-F 5‘-CGCAACAAGCCCACTGTC -3‘ 
41-F  5‘-GTTGTACAAGGCCACTCAGATCTCGT-3‘ (Biotinylated) 
41-R  5‘-TCTCGGTGCAGTCCATTT-3‘ 
315F  5‘-GCCGTGAAGACCTTGAAGGA-3‘ (Biotinylated) 
315R  5‘-CCAGGAGGTTCCCGTAGGTC-3‘ 
C-F  5‘-TTACCCGGGAATTGACCTGT-3‘ (Biotinylated) 
C-R  5‘-TGTTTCAAAGGCTTGGTGGA-3‘ 
F9  5‘-CTAGAGATCTTGCTGCCCGAAACT-3‘ (Biotinylated) 
R9  5‘-GACAGGTCAATTCCCGGGTAA-3‘ 
SNP-1-2 5‘-GAACGCACGGACATC -3‘ 
SNP-2-9 5‘-CACCCTGAAGCACAA-3‘ 
SNP-315 5‘-CCCCCGTTCTATATCA -3‘ 
SNP-276 5‘-TGAAGACCTTGAAGGAG -3‘ 
SNP-311 5‘-GAACTCAGTGATGATATAGA -3‘ 
SNP-351 5‘-CCAAGATCTCTGTGGATGA-3‘ 
SNP-359 5‘-CAAGATCTCTGTGGATGA -3‘ 
SNP-417 5‘-GACGTCGGACTTGATG -3‘ 
SNP-438 5‘-CCAATTCCCGGGTAAG-3‘ 
SNP-453 5‘-CCATGCGGTAGTCCT-3‘ 
SNP-459 5‘-CCTTCTGGGCGCT -3‘ 
SNP-486 5‘-CTTGGTGGATTTCAGC-3‘ 
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Pyrosequencing 
When a BCR-ABL1 mutation was detected by direct sequencing in a patient for 
whom we had three or more previous cDNA samples, these were subjected to 
pyrosequencing in accordance with the manufacturer‘s instructions (Pyrosequencing 
AB, Uppsala, Sweden). The BCR-ABL1 amplicon was used as a template for nested 
PCR using primers that flanked the region containing the putative mutation. One of 
the primers for each reaction was biotinylated (Figure 1-1, Table 1). Each cDNA was 
tested in duplicate. A single-stranded DNA template was isolated by combination of 
alkali denaturation and mixing biotinylated PCR products with streptavidin-coated 
sepharose beads (GE Healthcare, Amersham, UK).  
Purification of target complementary strand of PCR product was done as described 
briefly below 
1. 20µL PCR product was transferred to a 24-well micro titre plate to which 70 
µL Binding buffer had already been added. The plate was sealed with Micro 
Amp clear adhesive film (Applied Biosystem, USA). 
2. The microtitre plate was spun on the shaker @1200rpm/min for about half-an-
hour at RT. 
3. The adhesive film was removed and the microtitre plate was placed on to the 
template preparation platform for pyrosequencing. 
4. The vacuum pump connected to the hand held 24-pin grid was started. 
5. The grid was then transferred to the microtitre plate making sure that each pin 
went to the bottom of the well. It was kept in the same position till fluid 
sucked out of the wells. 
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6. The grid was then transferred to the trough containing the 70% ethanol for 
about 10-20 seconds to get rid of the tween (component of the binding buffer) 
from the beads. 
7. The grid was then quickly transferred to the trough containing 0.2M NaOH 
for about 5 seconds after the NaOH started coming out of the tube to denature 
the double stranded PCR product,  
8. The grid was transferred into the trough containing the wash buffer (Biotage) 
and after the entire buffer went though the grid the pump was switched off. 
9. The grid was transferred to the 96-well pyrosequencing plate containing the 
annealing buffer and primer mix (see appendix 4).The grid was shaken 
properly to drop all the beads from the tips into the respective wells.  
10. To anneal the sequencing primer to the single stranded template, the plate was 
heated in the PCR machine at 80
o
C for 2 min followed by slow cooling at RT. 
11. The plate was put in the slot of the pyrosequencing machine. 
12. The cartridge was loaded with the enzyme and substrate mix and the 4 dNTPs 
in the respective wells as per instructions. The cartridge was then placed in the 
slot in the pyrosequencing machine and the reaction started. 
13. The pyrosequencing results were analysed using PyroMark Q24 software 
(Biotage, Uppsala Sweden).   
The pyrophosphate released on incorporation of a complementary nucleotide to the 
sequencing primer was converted to adenosine 5‘ triphosphate (ATP) by sulfurylase. 
The ATP generated was utilised as a coenzyme for luciferase that oxidises luciferin to 
oxyluciferin and thereby emits light (Figure 1-2). The intensity of the light is 
proportional to the level of the single nucleotide polymorphism (Q-SNP) in a given 
sample. The percentages of mutant and non-mutated alleles were determined by the 
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Allele Quantitation Algorithm using the PSQtMA software (Pyrosequencing AB, 
Uppsala, Sweden).  
The linearity of Q-SNP by pyrosequencing was tested by subjecting cDNA generated 
from graded mixes of Ba/F3 cell lines transfected with BCR-ABL1 cDNAs 
containing either the wild-type ABL1 sequence (BaF3/BCR-ABL1) or the E255K 
mutation (BaF3/BCR-ABL1 E255K). The mixes ranged from 10 to 100% BCR-
ABL1 E255K (Figure 1-3). To ensure reproducibility, the cDNA synthesised from 
each mix was tested in triplicate by Q-SNP. A similar experiment with lower 
percentage of mutations -including 1, 2 and 5% mutation- was repeated using 
BaF3/BCR-ABL T315I cells diluted against non-mutant BaF3/BCR-ABL1 cells.  
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 Figure 1-2. The principles of pyrosequencing  
As explained in the method section (www.pyrosequencing.com). 
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Figure 1-3. Comparison between pyrosequencing and direct sequencing  
The mix column represents the percentage of the E255K BCR-ABL1 positive BaF3 
diluted against non mutant, which is shown as blue in the graph. The PCR column 
represents the level of the mutant BCR-ABL1 copies measured by pyrosequencing. It 
is shown as pink in the graph. 
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Restriction Fragment Length Polymorphism (RFLP) Analyses 
Where possible, the loss or gain of a restriction site as a consequence of base 
substitution was used to determine if the two mutations observed in an individual 
coexisted in the same subclone or were in two distinct subclones. For example the 
ACT to ATT substitution in codon 315 of the ABL1 moiety of the BCR-ABL1 gene 
eliminates the DdeI restriction recognition site. Similarly, a TAC to CAC substitution 
in codon 253 eliminates the RsaI recognition site. For the patient with T315I mutation 
co-existent with Y253H, we used RFLP methodology in addition to pyrosequencing 
to investigate if the both mutations were present in the same clone. Nested primers, 
253+315 and ABLKR were used to generate a 448 bp amplicon (Table 1-1, Figure 1-
4). Restriction enzymes DdeI and RsaI (both from Invitrogen) were used to digest. 
The Y253H and T315I mutations lead to the loss of Rsa I and DdeI recognition sites 
respectively, yielding 211, 108, 52, 22 and 11bp fragments, when a double digest was 
performed on an amplicon containing both mutations. For the experiment a non 
mutant control was also digested with the same enzymes as a control (Fig 1.4). For 
the patient with co-existent F311I and T315I the Sau3a and Dde I were used to digest 
the 448 bp fragment. TTC to ATC substitution in F311I creates a Sau3A restriction 
enzyme site. The co-existence of F311I and T315I leads to the creation of Sau 3a and 
loss of Dde1 respectively and produces 218, 55, 54, 49, 19 and 4 bp fragments after 
digestion (Fig 1.4). 
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Figure 1-4  RFLP Analysis  
(A) A schematic representation of the BCR-ABL1 gene is shown. The grey and white 
boxes represent the BCR and ABL1 exons, respectively. The positions of the B2A  
and JAMR primers used to amplify 1500 (e13a2) and 1400 (e14a2) bp PCR products 
are indicated. 
(B) Nested primers, 253+315 and ABLKR were used to generate a 450 bp amplicon.  
(C) Sau 3a and Dde I, thin black and dotted lines, respectively, restriction maps are 
illustrated. The M311I creates a Sau 3a recognition site. The fragment sizes generated 
by normal, N1, and mutant, P11, alleles when a double digest is performed are 
shown.  
(D) Rsa I and Dde I, bold black and dotted lines, respectively, restriction map for the 
Normal (N1) and mutant (P12) alleles are shown. The Y253H and T315I mutations 
lead to the loss of Rsa I and Dde 1 recognition sites respectively, yielding the 
indicated fragments, when a double digest is performed. 
(E) A 3.5 % ethidium bromide stained gel with digested PCR products from Patient 
11 (P11) and normal control (N1) are shown, along with a100 bp molecular marker 
(Promega) (M). The absence of 68 bp fragment in Lane P11 is consistent with the 
Patient 11 having both M311I and T315I mutations in the same Ph (+) clone. 
(F) Sanger sequencing read display of T315I and M311I mutations in Patient 11. 
(G) Ethidium bromide stained gel is illustrated, showing the fragments sizes observed 
when PCR products from Patient 12 were cut with Dde I and Rsa I enzymes. The 
fragment sizes observed are consistent with both Y253H and T315I mutations being 
present in the same Ph (+) clone. The normal control (N2) is indicated along with a 
100 bp molecular marker (Promega) (M). 
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Cloning of BCR-ABL1 KD 
For two cases of dasatinib treated patients who developed a second mutation in 
addition to the primary one, the 863 bp fragment generated by nested PCR, as 
described above in Figure 1, was cloned using TOPO TA Cloning kit (Invitrogen, 
Glasgow, UK) in accordance with recommendations from the manufacturer. A 
suspension of transformed competent cells was plated onto ampicillin resistant plates 
and incubated at 37°C overnight. Subsequently, five 2 ml aliquots of ampicillin 
resistant medium, each inoculated with a bacterial colony were incubated in a shaker 
overnight at 37°C. DNA was extracted from the overnight cell cultures using SV 
Minipreps kit (Promega, Southampton, UK) according to procedures recommended 
by the manufacturer. The isolated DNA plasmid was then subjected to dideoxy chain 
termination reaction as described previously to sequence the BCR-ABL1 KD. 
Scorpion Primers for detection of T315I Mutation 
Scorpion PCR – The principle of the T315I Scorpion-based real time PCR assay is 
outlined in Figure 1-5. Briefly, the pre-designed assay comprises 2 elements: (1) the 
Scorpion primer, carrying a 5‘ probe section attached to a quenched fluorescent 
molecule and primer sequences specific for a region upstream of BCR-ABL1 KD 
residue 315; and (2) an unlabelled amplification refractory mutation system (ARMS) 
discrimination primer specific for the T315I mutation on the reverse DNA strand 
(DxS Ltd., Manchester, UK). In the presence of a T315I mutation, the ARMS primer 
binds to the T315I site and extends in a 3‘ direction, producing a binding site for the 
Scorpion primer. Subsequent extension of the Scorpion primer produces a target site 
for the probe. Following denaturation, the 5‘ end of the Scorpion primer changes 
conformation allowing the probe to anneal to the newly synthesised target site thus 
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releasing the fluorophore from the dark quencher resulting in fluorescence emission. 
The FAM-labelled T315I mutation assay was applied to all patient and cell line 
cDNA samples, in parallel with a second FAM-labelled Scorpion assay specific for 
an alternative sequence within the ABL gene which acted as a control. Briefly, PCR 
amplification of 5µl of cDNA solution was performed using 0.5µM of Scorpion 
primer and 0.5µM of ARMS reverse primer in a total reaction volume of 25µl. 
Reactions were performed using an ABI 7900HT Real Time PCR machine (Applied 
Biosystems Ltd) and run for 40 cycles under the following cycling parameters: 30 
seconds at 95°C followed by 1 minute at 60°C. The reaction mixture conditions were 
standardised using Scorpion PCR Mastermix (DxS Ltd.) as previously described(46). 
When analysing output data, a ∆Ct threshold of 11 (obtained by running multiple 
samples of negative genomic DNA) was used to classify a positive result. 
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Figure 1-5  Mode of action of the T315I Scorpion PCR assay (DxS Diagnostics) 
i.) If the T315I-specific reverse primer finds a binding site and amplification 
proceeds, a Scorpion primer binding site is produced. (ii.) Binding and (iii.) Extension 
of the Scorpion primer produces a binding site for the probe .iv.) Following a second 
round of denaturation, the conformation of the Scorpion changes to allow annealing 
of the probe to the newly synthesised binding site releasing the fluorescent molecule 
(F) from the dark quencher (Q) resulting in the emission of fluorescence. A PCR 
blocker (B) prevents read-through of the looped tail in a subsequent round. 
.  
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Statistical Analysis 
Probabilities of progression free survival (PFS) were calculated using the Kaplan-
Meier method. PFS was defined as survival without evidence of accelerated or blastic 
phase disease. The probabilities of cytogenetic response and cytogenetic relapse were 
calculated using the cumulative incidence procedure, where cytogenetic response or 
relapse were the events of interest and death and disease progression were the 
competitors. For PFS analysis, patients were censored at the time of stem cell 
transplant; for cytogenetic responses and emergence of KD mutation patients were 
censored at IM discontinuation. In the analysis performed to identify prognostic 
factors for PFS, mutations were considered only when detected for the first time 
before the loss of CHR. Univariate analyses to identify prognostic factors for PFS, 
cytogenetic relapse and emergence of KD mutations were carried out using the log-
rank test. Variables found to be significant at the p<0.25 level were entered into a 
proportional hazards regression analysis; a forward stepping procedure was employed 
to find the best model. The influence of KD mutations on the different outcomes was 
studied in a time- dependent Cox model. The proportional hazards assumption was 
confirmed by adding a time-dependent covariate for each covariate.  P-values were 2-
sided and 95% confidence intervals (CI) computed.  
Results 
Results of comparing the sensitivity of different conventional 
methods for BCR-ABL1 kinase domain mutation detection  
cDNA from serial dilution of T315I BCR-ABL1 positive cells against non-mutant 
BCR-ABL1 positive BaF3 cells was amplified for kinase domain of ABL1 in a nested 
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PCR. The final product was used for detection of T315I by direct sequencing, RFLP, 
Q-SNP pyrosequencing. The lowest level of mutation that could be picked up by 
these methods was 30, 10 and 5% for direct sequencing, RFLP and Q-SNP 
pyrosequencing, respectively. When pyrosequencing was used for just sequencing, 
the lowest level of detection was 20%. At the same dilution, a small peak for 
mutation in T315I could be seen in direct sequencing which was present under the 
wild type peak, but it could be easily missed in the presence of a background signal. 
Thus the level of sensitivity for direct sequencing was considered to be approximately 
30% which would be the correct level of sensitivity if the test were to be carried out 
without prior knowledge of the mutation status in a specific sample. The comparison 
between direct sequencing and pyrosequencing using E255K BCR-ABL positive 
BaF3 cells diluted in non-mutant cells is illustrated in Figure 1-3.   
Results of scorpion primers for detection of T315I  
In order to validate the T315I Scorpions assay as a tool for routine use, it was applied 
to 61 CML patient cDNA samples with known T315 mutation status. The assay 
correctly identified the mutation in all 34 patient samples in which T315I was 
previously identified by direct sequencing or pyrosequencing (Table 1-2). No sample 
shown to be T315I-negative by one of the latter two methods was classified as 
positive using the Scorpion assay, indicating an absence of false-positive results. The 
T315I-negative cohort contained 3 patients known to carry alternative KD mutations, 
including 2 different samples from a patient with the T315A mutation, which 
involves the same base pair residue as T315I. Importantly, all three patients were 
designated T315I-negative using the Scorpion approach, thus establishing the high-
specificity of this assay.  
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To explore the sensitivity of the Scorpion assay in comparison to direct sequencing 
we prepared limiting dilution experiments by mixing known quantities of two strains 
of BCR-ABL1 positive BAF3 cells, one with, and one without the T315I mutation 
(Table 1-2). Direct sequencing identified the T315I down to a dilution of 30% 
mutation-positive cells, but, contrary to several recent reports, failed to identify the 
mutation in the subsequent dilution (20%). In contrast, the Scorpion assay correctly 
detected the presence of a mutant clone to a dilution of 1%, failing to detect the 
mutation only in the cDNA sample extracted from 0.1% mutation-positive cells. 
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Table 1-2  Summary of samples and experiments used to validate the T315I 
scorpion Assay 
Patient material 
Patients - no.  
Total samples – no. 
 
25 
61 
T315I status assessed by sequencing/pyrosequencing 
T315I-positive – no. (%) 
T315I-negative – no. (%) 
 
34 (56) 
27 (44) 
T315I status assessed by Scorpions assay 
T315I-positive – no. (%) 
       T315I-negative – no. (%) 
Concordance with direct sequencing/pyrosequencing, % 
 
34 (56) 
27 (44) 
100 
Limiting dilution cell line experiments 
 100%, 60%, and 40% T315I-positive population 
  direct sequencing 
  scorpions 
 20% T315I-positive population 
  direct sequencing 
  scorpion 
 5% and 1% T315I-positive population 
  direct sequencing 
  scorpion 
 0.1% T315I-positive population 
  direct sequencing 
  scorpion 
 
 
detected 
detected 
 
not detected 
detected 
 
not detected 
detected 
 
not detected 
not detected 
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Results of Mutation Analysis in Patients Treated with IM 
KD Mutation Development  
During the time of follow up, 37 (11.6%) patients developed KD mutations. The 
median time from the start of the IM therapy to first detection of a specific mutation 
was 489 days (range 29-1566 days). Ten patients developed a mutation before 
achieving or while in CCyR (406 days, range 29-722), an additional 21 developed 
mutations while in CHR (424 days, range 151-1533) and 6 more before progression 
to advanced stage (1005 days, range 370-1566). Table 1-3 summarises the mutations 
identified and patients‘ characteristics.  The 5 year cumulative incidence of KD 
mutations was 13.9%. KD mutations were less frequent in patients who achieved 
CCyR. The 5 year cumulative incidence of KD mutations in patients on CCyR was 
5.5% vs 29.1%  for patients who had failed to achieve complete cytogenetic response 
(p<0.0001). KD mutations were also less frequent in newly diagnosed than late CP as 
the 5 years cumulative incidence of  mutations detected while the patients were in 
CHR was respectively 6.6% and 17% (p=0.01).  
However, late chronic phase patients who had achieved CCyR had a similar incidence 
of KD mutations to the newly diagnosed patients in CCyR, namely 5.3 vs. 5.6, 
(p=0.89). Univariate and multivariate analyses carried out to identify pre-therapy 
predictors for the development of KD mutations (Table 1-4) showed that the patients 
older than 47 years, late CP patients, patients with high risk Sokal scores, patients 
with additional cytogenetic abnormalities at the onset of IM therapy and patients with 
two coexisting transcript types (e14a2 and e13a2) had significantly higher 
probabilities of developing KD mutations. On the multivariate analysis late CP and 
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high Sokal risk score were independent predictors for the development of KD 
mutations (RR=2.7; p= 0.005 and RR=2.5, p=0.03). 
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Table 1-3  KD Mutations and Patients’ Characteristics (Time in Months) 
Status at 
onset of 
imatinib 
Transcript 
type 
Sokal 
risk 
group 
CE at 
onset of 
imatinib 
Best response Outcome 
AA 
substitution 
Time from 
IM therapy 
to  detection 
of the 
mutation 
Time from 
first detection 
of mutation 
to loss of 
CCyR or last 
follow up 
Time from the 
first detection 
of mutation to 
loss of CHR or 
last follow 
up** 
Time from the 
first detection 
of mutation to 
progression or 
last follow up 
Maximal 
dose of 
IM 
received 
Maximal 
percentage 
mutated vs wild 
type achieved 
during the 
follow up 
Percentage 
mutated/wild 
type at last 
follow up or at 
progression 
New D e13a2 High No Pri Hem Res UCP F359V (inter) 12   25 600 95 95 
LCP e13a2 Inter No Pri Hem Res UCP M351T (Low) 28   57 800 89 73 
LCP e13a2 Inter Yes Pri Cy Res BP Y253F(High) 26  4 4 600 54 50 
LCP e13a2 High No Pri Cy Res UCP F486S (inter) 10  41 45 400 91 89 
LCP e14a2 Low Yes Pri Cy Res BP M244V (inter) 60  -19 13 600 100 100 
LCP both High No Pri Cy Res AP G250E (inter) 12  10 51 600 88 83 
LCP e14a2 High Yes Pri Cy Res UCP F486S (inter) 31  2 48 800 88 88 
LCP e14a2 High No Pri Cy Res BP L248V (Low) 8  17 17 600 48 45 
LCP both High No Pri Cy Res BP F359V (inter) 49  -2 4 600 10 8 
LCP e13a2 Low Yes Pri Cy Res AP E453K (NK) 14  9 48 800 100 <5 
LCP e14a2 Inter No Pri Cy Res BP E255V(High) 14  16 16 800 30 25 
New D e13a2 High No Pri Cy Res UCP M244V (inter) 5  4 25 800 100 56 
LCP e14a2 Inter No Pri Cy Res AP F359V (inter) 82  -29 16 600 88 88 
LCP both Inter Yes Pri Cy Res UCP M244V (inter) 22  24 55 800 93 89 
New D e13a2 Inter No MinCyR CHR E453V (NK) 29  32 32 800 90 90 
LCP both High No MinCyR AP Y253H(High) 5  8 8 600 10 <5 
LCP both Inter No MinCyR UCP F486S (inter) 
70  0 34 800 45 <5 
7
1
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Continued (Table 1-3) 
 
Status at 
onset of 
imatinib 
Transcript 
type 
Sokal 
risk 
group 
CE at 
onset of 
imatinib 
Best response Outcome 
AA 
substitution 
Time from 
IM therapy 
to  detection 
of the 
mutation 
Time from 
first detection 
of mutation 
to loss of 
CCyR or last 
follow up 
Time from the 
first detection 
of mutation to 
loss of CHR or 
last follow 
up** 
Time from the 
first detection 
of mutation to 
progression or 
last follow up 
Maximal 
dose of 
IM 
received 
Maximal 
percentage 
mutated vs wild 
type achieved 
during the 
follow up 
Percentage 
mutated/wild 
type at last 
follow up or at 
progression 
LCP e14a2 Low No MCyR CHR E453K (NK) 51  18 18 800 80 80 
LCP e13a2 Low No MCyR AP G250E (inter) 6  46 46 800 10 <5 
LCP e14a2 Inter No MCyR UCP M244V (inter) 8  20 44 800 88 <5 
LCP e13a2 Inter No MCyR AP G250R(High) 13  22 36 800 100 100 
LCP e14a2 Inter Yes MCyR BP H396R (inter) 23  2 2 800 50 50 
LCP e13a2 Inter No MCyR AP T315I(High) 12  24 29 600 100 100 
LCP both Inter No MCyR CHR M244V (inter) 35  43 43 800 90 64 
New D both High Yes MCyR BP F311I (NK) 16  22 36 600 80 62 
LCP e14a2 Low No MCyR UCP H396R (inter) 19  21 37 600 45 35 
LCP e13a2 High No MCyR AP L384M (inter) 28  11 11 400 25 <5 
New D e13a2 High No CCyR AP E459K (NK) 13 3 3 3 400 80 80 
New D both Inter No CCyR CHR M351T (inter) 9 38 52 52 600 94 18 
New D e14a2 High No CCyR MCyR T315I (High) 8 21 35 35 600 100 25 
LCP e14a2 High No CCyR* CCyR M244V (inter) 14 56 56 56 600 100 <5 
New D e14a2 Inter No CCyR MCyR L387M (Low) 24 20 21 21 800 100 100 
New D e13a2 Low No CCyR MCyR S417F (NK) 24 12 29 29 800 100 <5 
LCP e14a2 High No CCyR BP E459K (NK) 23 49 49 51 600 80 71 
LCP e13a2 Inter No CCyR* CCyR M244V (inter) 
19 70 70 70 800 97 <5 
7
2
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Continued (Table 1-3)  
 
Status at 
onset of 
imatinib 
Transcript 
type 
Sokal 
risk 
group 
CE at 
onset of 
imatinib 
Best response Outcome 
AA 
substitution 
Time from 
IM therapy 
to  detection 
of the 
mutation 
Time from 
first detection 
of mutation 
to loss of 
CCyR or last 
follow up 
Time from the 
first detection 
of mutation to 
loss of CHR or 
last follow 
up** 
Time from the 
first detection 
of mutation to 
progression or 
last follow up 
Maximal 
dose of 
IM 
received 
Maximal 
percentage 
mutated vs wild 
type achieved 
during the 
follow up 
Percentage 
mutated/wild 
type at last 
follow up or at 
progression 
LCP e14a2 Inter No MMR* MMR 
F317L, 
H396R (inter) 
1 42 42 42 800 100 78 
New D e14a2 High No CMR* CMR S438C (NK) 8 67 67 67 600 100 <5 
 
 
 
Abbreviations, New D: Newly diagnosed, LCP: Late chronic phase, Inter: Intermediate, Pri Hem res: Primary haematological resistance, 
Pri Cy Res: Primary cytogenetic resistance, MinCyR: Minor cytogenetic response (36-95% Ph-positive), UCP: Uncontrolled CP, AP: Accelerated 
phase, BP: Blastic Phase 
* Mutation detected before CCyR 
** Negative values indicate that mutation was detected after the loss of CHR 
 
7
3
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Table 1-4  Five year cumulative incidence of development of KD mutations, loss 
of CCyR and probability of PFS 
Variable  KD mutation 
Loss of 
CCyR 
PFS 
    
Age 
>47 years 
47 years 
p=0.04 
16.9% 
10.2% 
p=0.1 
14.3% 
25.4% 
p=0.4 
79.0% 
78.3% 
    
Sex, 
Male  
Female 
p=0.8 
11.8% 
14.1% 
p=0.3 
15.8% 
23.4% 
p=0.9 
79.0% 
79.0% 
    
Sokal risk group, 
Low 
High + Intermediate 
p=0.01 
6.2% 
15.3% 
p=0.08 
11.5% 
23.5% 
p=0.009 
89.1% 
75.0% 
    
Interval since diagnosis to onset of imatinib, 
 1 year 
> 1 year 
p=0.01 
8.7% 
19.6% 
p=0.6 
21.4% 
17.1% 
p=0.4 
79.5% 
77.0% 
    
Status at the onset of imatinib therapy.  
Newly diagnosed CP patients  
Late CP  
p=0.005 
6.6% 
19.5% 
p=0.6 
16.5% 
21.6% 
p=0.06 
83.8% 
75.2% 
    
Additional cytogenetic abnormalities. 
Yes 
No 
p=0.002 
36% 
11.7% 
p=0.3 
0 
20.8% 
p=0.01 
81.3% 
55.9% 
    
Transcript type. 
One 
More than one 
p=0.02 
11.6% 
28.5% 
p=0.02 
3.6% 
16.7% 
p=0.5 
78.9% 
80.9% 
    
Dose intensity of imatinib during the first 6 
months of therapy. 
400 mg/day 
<400 mg day 
 
p=0.36 
9.3% 
14.2% 
 
p=0.7 
20.7% 
15.6% 
 
p=0.7 
79.6% 
78.3% 
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The development of KD mutations predicts for the loss of CCyR  
Of the 214 patients who achieved CCyR a KD mutation was detected in 10 patients 
(4.7%), of whom 4 had a mutation detected before they achieved CCyR (M244V in 2 
patients, F317L and S438C each in one patient); the median time between the 
detection of a mutation and the achievement of CCyR was 318.5 days (range 84-628). 
In these four patients the transcript level continued to decrease though the mutation 
was still detectable and the CCyR was sustained on IM (median follow up after CCyR 
1830.5 days, range 1114-2214). In the remaining 6 patients the mutation (T315I, 
L387M, S417F, E459K (n=2) and M351T co-existing with H396R) was detected 
after the achievement of CCyR (median time from the time of CCyR 190 days, range 
28-606). The 6 patients lost their CCyR and 2 eventually progressed to advanced 
phase. At the time of detection in our cohort of patients the median log reduction in 
BCR-ABL1 transcript levels was 2.4 (range 1.9-2.7). The median time from the 
detection of the KD mutation to loss of CCyR was 623 days (range 84-1473).  The 
median time between the detection of the KD mutation and a rise by two-fold in the 
transcript level was 361 days (range 84-692).  
Thirty (14%) of the 214 patients who achieved CCyR lost their response during 
follow up. The univariate and multivariate analysis carried out to identify prognostic 
factors for loss of CCyR showed that the development of tyrosine KD mutations was 
highly predictive for loss of CCyR (RR=3.8, p=0.005).  We further classified the KD 
mutation as belonging to the P-loop (n=0), as M244V (n=2) or as non P-loop (n=8). 
The RR for loss of CCyR in the patients who did not harbour the M244V was 7.1 
(p<0.0001), while the M244V mutation did not show any adverse effect. The rest of 
the variables analysed in the univariate analysis are shown in table 1-4. The 
development of a KD mutation was the only independent predictor for loss of CCyR 
in the multivariate analysis. 
 76 
The development of KD mutations predicts for progression to 
advanced phase 
Of 49 (15%) patients who progressed to advanced phase during follow up, a KD 
mutation was detected in 17 patients before progression (median time between the 
detection of mutation and progression was 488 d, (range 71-1540); in 14 of them the 
mutation was detected before the loss of CHR. The median time between the 
detection of mutation and the loss of CHR was 410 days (range 71-1473). KD 
mutation was detected in 20 patients who did not progress (19 while in CHR), the 
median follow up after the detection of progression was 1821 days (893-2662). 
Univariate and multivariate analyses were used to evaluate the impact of different 
prognostic factors on PFS (including the emergence of KD mutations in patients in 
CHR). High Sokal risk and the presence of additional cytogenetic abnormalities at 
onset of IM therapy were found to have a significant effect on the PFS. Patients 
developing KD mutations had a higher risk of progression (RR=3.7, p<0.0001). The 
other major predictor for PFS was the achievement of CCyR (RR=0.13, p<0.0001). In 
the multivariate analysis the only independent predictors for PFS were the 
achievement of CCyR (RR= 0.15, p<0.0001) and the development of KD mutations 
(RR= 2.3, p=0.01). 
When the 33 KD mutations detected in patients before loss of CHR were sub-
classified according to the level of resistance, it was found that the 6 patients 
harbouring KD mutations with high level of resistance had a significantly worse PFS 
than the 27 patients with low, intermediate and unknown levels (RR 8.6, p=0.001) 
when the three latter groups were pooled together for analysis. Similarly, when the 
patients were classified in accordance with the position of the KD mutation, the 7 
patients harbouring a p-loop mutation had significantly worse prognosis than the 
patients with other mutations (RR=5.4, p=0.001), while patients with the mutation 
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M244V (n=6) had similar outcome to patients without any mutation (RR<0.0001, 
p=0.97). 
At 2 years, 250 patients were still in CHR and 23 had developed KD mutations (while 
still in CHR). Patients who had developed a mutation by 2 years had a significantly 
worse 5 years PFS (64.6% vs. 85.8, p=0.0001).  In the multivariate analysis only the 
presence of mutation and the cytogenetic response were independent predictors for 
PFS (RR=3.0, p=0.004 and RR=0.18, p=0.0001, respectively). Figure 1-6 illustrates 
the PFS analysed according to the presence or absence of KD mutations, the degree 
of IM resistance and the location of the amino acid substitution. 
KD mutations do not need to become the predominant clone in 
order to have adverse effect on PFS.  
Patients could be classified into three subgroups on grounds of the presence of a 
mutated or wild type kinase domain pattern.  In 16 patients (group A) the proportion 
between wild type and mutated BCR-ABL1 increased progressively until the mutated 
clone became the predominant clone (more than 50%). In 14 out of 16 patients the 
dose of IM was increased above 400 mg. Two patients in this group had the M224V 
mutation and 2 others had mutations in the P-loop. Two patients had a mutation 
which is associated with a high in vitro level of resistance. Seven of these 16 patients 
progressed to advanced phase. 
In 11 patients (group B) the proportion of mutated cells increased above 50% (median 
level 100%, range 80-100%) and then decreased below this threshold (median value 
at last follow up 21%, range >5-50%). In all these 11 patients the dose of IM was 
increased above 400 mg. The majority of the patients in this group had the mutation 
M244V (n=5). One patient had a mutation with a high in-vitro level of resistance, 6 
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with intermediate and 4 with an unknown level of resistance. Only 2 patients in this 
group progressed to advanced phase. 
In 10 patients (group C) the proportion of the mutated cells remained at or below 50% 
during the follow up (maximal values median level 37.5%, range 10-50%). In 9 of 10 
patients the dose of IM was increased above 400 mg. None of the patients had the 
mutation M244V and 5 had a P-loop mutation. Three patients had a mutation with a 
high in vitro level of resistance, 6 with intermediate and 1 with a low level of 
resistance. Eight out of the 10 patients in this group progressed to advanced phase. 
The adverse effects of tyrosine KD mutations on PFS are restricted 
to patients with secondary cytogenetic resistance to IM.  
Two hundred and sixty-six patients achieved at least some degree of cytogenetic 
response (MCyR in 244 cases) of whom 23 (8.6%) developed a KD mutation whereas 
of the 53 patients with primary cytogenetic resistance, 14 (26.4%) developed a KD 
mutation (p=0.001). There was no significant difference in the characteristics of the 
KD mutations between both groups since the median time to the first detection of 
mutation was 547 days for the cytogenetic refractory group and 489 days in the 
responding group (p=0.4). A M244V mutation occurred in 3 (21%) patients with 
primary cytogenetic resistant and in 4 (17%) responders (p=0.8). 
We found that the adverse effect of KD mutations described above was limited to 
patients with secondary resistance to IM. In patients with primary cytogenetic 
resistance and mutations, the adjusted RR for progression was 0.54 (p=0.35), while in 
patients with secondary cytogenetic resistance and mutation, the adjusted RR for 
progression was 6.0 (p<0.0001). 
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Figure 1-6  The effect of KD mutations on PFS  
Panel A shows 5 years cumulative incidence of KD mutations (5CIKM). Panel B 
shows 5CIKM comparing the patients whose best response was CCyR and those who 
failed to achieve CCyR.  Panel C shows 5CIKM comparing the newly diagnosed 
patients and late CP patients. Panel D shows the cumulative incidence of KD 
mutations comparing newly diagnosed and late CP but in the patients whose best 
response was CCyR. The Y and X axes represent the cumulative incidence of KD 
mutations and months from start of IM therapy respectively. 
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Varying response to escalating the dose of IM in patients with CML 
who “acquire” a BCR-ABL1 M244V mutant allele.  
Monitoring of BCR-ABL1 transcript levels in 6 patients with CML treated with IM 
who were found to have the same BCR-ABL1 M244V mutant allele showed different 
kinetics for the M244V mutant clone in different patients. In vitro data suggest that 
this mutation is moderately resistant to IM, with an inhibitory concentration at 50% 
(IC50) of 4.1 M(89), and that resistance may be overcome by dose escalation. In 
practice, the response to increasing the doses of IM varied in the 6 patients (Figure 1-
7), an observation that can be interpreted in 1 of 3 ways: (1) the degree to which the 
mutation confers resistance to IM is very variable in different patients; (2) the 
presence of a M244V mutant may not always be the direct cause of the resistance; or 
(3) differential responses are due to very different pharmacokinetics of IM in the 
different patients. The levels of wild-type and mutant BCR-ABL1 transcripts were 
quantified by RQ-PCR and Q-SNP pyrosequencing, in all available samples (median 
number, 15 per patient; range, 5-27 per patient). After an initial reduction in 
leukaemia cell load while on 400 mg/day of IM, increasing the dose in 3 of the 6 
patients resulted in a further decrease in BCR-ABL1 transcript levels. Two of these 
patients achieved CCyR at IM doses of 500 and 600 mg/day, respectively, and in both 
cases the mutant allele eventually became undetectable by pyrosequencing (Figure 1-
7 D-E). The third patient (Figure 1-7A) also achieved CCyR, with total BCR-ABL1 
transcript levels stabilised at less than 1.0%, but almost all transcripts still showed the 
mutant allele, implying that the mutation was the cause of the observed resistance. 
For the other 3 patients the IM dose was increased to 1000 mg/day in 2 cases (Figure 
1-7 B-C) and to 700 mg/day in the third (Figure 1-7 F), but BCR-ABL1 transcript 
levels were largely unchanged and consisted almost entirely of the mutant allele. 
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Furthermore, in these 3 ―resistant‖ patients no other mutation was found by direct 
sequencing. The data reported here show clearly that the degree to which the same 
mutant BCR-ABL1 clone is inhibited by IM differs in different patients. If these 
differences are not attributable to major inter-patient variation in IM 
pharmacokinetics, then they imply that whereas the M244V mutation may be the 
direct cause of the IM resistance in some cases, its presence in other cases may be 
quite incidental, and other previously identified or unidentified mechanisms must be 
the principal cause of the resistance. 
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Figure 1-7  Different kinetics of M244V BCR-ABL1 kinase domain mutation 
This figure shows BCR-ABL1 transcript levels as measured by RQ-PCR and the 
relative size of the mutant clone while the patients were being treated with IM as 
single agent. The Y axis on the left and right represent Log BCR-ABL1/ABL1 ratio 
and the percentage of mutation respectively. X axis represent the time (months) from 
the start of IM therapy. Black and red lines represent BCR-ABL1/ABL1 and M244V 
mutant BCR-ABL1 kinase kinetics respectively. 
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Results of Mutation Analysis in Patients Treated with 
Dasatinib  
We detected KD mutations by direct sequencing at the time of starting dasatinib in 12 
(Table 1-5) of the 46 patients.  In the remaining 34 patients no mutations were found 
at the time of starting dasatinib or thereafter within one year of follow up.  Of the 12 
patients with mutations 8 were still taking dasatinib at the time of this analysis for a 
median period of 11+ months (range 6+ to 25+). The drug had been discontinued in 4 
patients. In these 12 patients we identified four patterns of evolution after starting 
dasatinib:    
1) In four patients (nos. 1 to 4) the mutant clone identified before starting dasatinib 
became undetectable and remained so during the duration of follow-up. This was 
associated with a clinical response and a >2 log reduction in BCR-ABL1 transcripts 
compared with the pre-dasatinib transcript level.   
2) In three patients (nos. 5 to 7) the mutant clone identified before the start of 
dasatinib persisted during treatment or became transiently undetectable and then 
recurred. The occurrence of a mutation did not always precede clinical relapse.  
3) In three patients (nos. 8 to 10) the original mutated clone disappeared but a new 
mutant clone was acquired, which was F317L in each case. (Figure 1-8) 
4) In two patients (nos. 11 and 12) a new mutation (T315I) appeared in addition to the 
original mutation in the same clone. (Figure 1-9 (a) & (b)). 
In the two patients of Group 4 one mutation was identified in the earliest available 
sample but the second mutation, T315I, was identified after an initial response to 
dasatinib. The fact that in both cases the level of the second mutation paralleled 
closely the level of the first mutation provided strong evidence that the second 
mutation actually occurred in the subclone that carried the original mutation.  This 
was confirmed by RFLP data, which yielded fragment sizes consistent with 
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sequencing data showing that in each case the two mutations were present in the same 
allele (Figure 1-4). In contrast, Q-SNP kinetic data for two mutations in patient no.10, 
whilst on IM, strongly suggested the presence of two distinct sub-clones. 
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Table 1-5  Clinical summaries of 12 patients with kinase domain mutations 
P
a
ti
en
t 
n
o
. 
 
A
g
e 
(y
r)
 
S
ex
 
Imatinib                                                     Dasatinib  Current status 
Duration 
of IM   
treat-
ment 
(months) 
Best 
response 
on IM 
 
KD Mutation 
 pre-DB 
 
Clinical 
phase 
at the 
start of 
DB 
Cytogenetic 
analysis 
prior to DB 
 (Ph+ %) 
Best 
resp-
onse  
on DB 
Duration 
of 
treatment 
(months) 
KD mutation  
post-DB 
 
1 51 M 43 
 
PCyR H396R CP 100 MMR 13+ none MMR 
2 28 M 35 
 
CHR E453V CP 91 MMR 23+ none MMR 
3 58 F 24 
 
CCyR F359V CP N/A CCyR   7+ none CCyR 
4 43 F 24 
 
CHR H396R BC 100 MMR 14+ none MMR 
5 
 
53 M 39 CHR L248V AP 89 PCyR 
 
25 L248V CHR 
6 37 M 35 
 
PCyR G250R AP 100 CCyR 24+ G250R CCyR 
7 
 
55 M 48 PCyR M244V CP 100 CCyR 22+ M244V PCyR 
8 50 F 48 
 
CCyR M244V CP 100 PCyR 23 F317L CHR 
9 
 
40 M 58 CHR M351T AP 100 CHR 24+ F317L CHR 
8
8
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Continued (Table 1-5) 
P
a
ti
en
t 
n
o
. 
 
A
g
e 
(y
r)
 
S
ex
 
Imatinib                                                     Dasatinib  Current status 
Duratio
n of IM   
treatme
nt 
(month
s) 
Best 
response 
on IM 
 
KD Mutation 
 pre-DB 
 
Clinical 
phase 
at the 
start of 
DB 
Cytogenetic 
analysis 
prior to DB 
 (Ph+ %) 
Best 
respons
e on 
DB 
Duration 
of 
treatment 
(months) 
KD mutation  
post-DB 
 
10 56 F 36 
 
CCyR H396R 
  (M351T) 
CP 43 CCyR  7+ F317L PCyR 
 
11 
 
52 F 48 PCyR F311I BC 100 CCyR 8+ F311I 
 T315I  
Dead 
(BC) 
12 24 F 7 PCyR Y253H BC 100 CCyR 6+ Y253H 
T315I 
Dead 
(BC) 
 
The M351T mutation became undetectable during IM therapy, and was not present prior to DB therapy. 
Abbreviations:  CCyR: Complete cytogenetic response; PCyR: Partial cytogenetic response; MMR: Major molecular response; Ph+: Philadelphia 
chromosome positive; IM: Imatinib Mesylate; DB: dasatinib; NA: Not available; CP: Chronic phase; AP: Accelerated phase; BC: blast crisis 
8
9
 
 
 90 
Figure 1-8  Emergence of F317L BCR-ABL1 kinase domain mutation following 
Dasatinib therapy 
The kinetics of the BCR-ABL1 transcripts measured by RQ-PCR is represented by 
the bold black line. Red, green and blue lines represent the kinetics of the M351T, 
H396R and F317L BCR-ABL1 percentage respectively. A 56-year old female 
(Patient no.10) with CML in chronic phase was started on 400 mg daily IM. After 30 
months from start of IM the M351T mutant clone had decreased from 80% to 50%, 
but an additional mutation, H396R, was identified. Subsequently, the 2 mutations 
evolved discordantly consistent with 2 distinct subclones. After starting dasatinib 
only H396R mutation was detectable. One month from start of dasatinib therapy, 
H396R became undetectable, a third mutant subclone, F317L, was detected by Q-
SNP. The Y axis on the left and right represent Log BCR-ABL1/ABL1 ratio and the 
percentage of mutation respectively. X axis represents the time (months) from the 
start of IM and dasatinib therapy.  
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Figure 1-9  Compound mutations 
The Y axis on the left and right represent Log BCR-ABL1/ABL1 ratio and the 
percentage of mutation respectively. X axis represents the time (months) from the 
start of dasatinib therapy. Black, green, blue and purple lines represent the kinetics of 
BCR-ABL1/ABL1 ratio, F311I, T315I and Y253H percentage respectively. The Q-
SNP data implied both mutations were in the same allele for both A and B. 
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Clones with KD mutations are selected by the pressure of kinase 
inhibitors rather than proliferative advantage  
To understand if the mutations in BCR-ABL1 KD have proliferative advantage over 
non-mutant clone we looked at the kinetics of the mutant clone in patients who were 
off kinase inhibitors. We had 3 patients who were treated with semi-synthetic 
homoharringtonine (HHT, omacetaxine) or recombinant interferon-α (IFN-α) after 
showing resistance to kinase inhibitors. The kinetics of the BCR-ABL1 mutant clone 
during non-kinase inhibitor therapy can provide some information about the 
proliferative advantage or disadvantage that a mutation might give to the clone over 
the non-mutant one.  We followed the kinetics of the mutation in at least 3 patients 
who were off kinase inhibitors for at least 12 months. Two patients (Patients A&B) 
had T315I at the time of stopping dasatinib. One patient (Patient C) had F486S 
mutation in the C-terminal part of the KD and IM was suspended due to resistance.  
Patient A had achieved CCyR after 4 months therapy with IM but later BCR-ABL1 
transcripts started to increase progressively and a T315I mutation was identified, so 
IM stopped and the patient started IFN-α. CCyR was achieved on IFN-α. 
Interestingly, on rIFN the percentage of mutant transcripts measured by Q-SNP 
pyrosequencing decreased from 100% to undetectable level.  
Patient B was a CML patient who received IFN-α initially and was then switched to 
IM at a later stage. The patient showed resistance to kinase inhibitor therapy and 
T315I mutation was identified. The patient started on HHT while she was in 
accelerated phase but achieved a CHR 5 months later. The marrow showed a minor 
cytogenetic response, and at 10 months the percentage of the T315I mutant clone had 
decreased from 100% to undetectable level. However, a second mutant clone, G250E 
which is a P-loop mutation emerged and started to evolve to dominate the BCR-
 93 
ABL1 positive cell population (Fig 1.10); it constituted more than 80 % of the BCR-
ABL1 positive cells in the last follow up. 
Patient C developed F486S mutation which is an intermediate resistant mutation, so 
IM was stopped for her and IFN-α was started. She was off kinase inhibitors for 24 
months. F486S decreased within this period and finally became undetectable but then 
a new clone dominated which was positive for E462K. This mutation had not been 
described before and there are no data on the proliferative characteristics that it gives 
to the BCR-ABL1 positive cell or its kinase activity.  
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Figure 1-10  The kinetics of BCR-ABL1 kinase domain mutations following 
stopping TKI 
The kinetics of the BCR-ABL1 transcripts measured by RQ-PCR are represented by 
the bold black line. Red and blue lines represent the kinetics of the T315I and G250E 
BCR-ABL1 percentage respectively. At 14 months since the stop of dasatinib and 
starting HHT, the percentage of the T315I mutant clone decreased from 100% to 
undetectable level. However, a second mutant clone, G250E emerged and started to 
evolve to dominate the BCR-ABL1 positive cell population and constituted more than 
80 % of the BCR-ABL1 positive cells in the last follow up. 
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Discussion 
In this study we have investigated the association between some specific factors at the 
time of diagnosis and the patients‘ response to IM therapy. We also looked at the 
incidence and importance of kinase domain mutations in emergence of resistance to 
IM and prognosis.  
We screened CML patients samples who had been treated at Hammersmith Hospital 
either as newly diagnosed patients or as recipients of IM after failure of IFN-α or 
hydroxyurea. The emergence of mutations in the KD of BCR-ABL1 is the most 
common mechanism of resistance to IM identified in clinical samples(90). T315I is 
the most resistant mutation to all the known tyrosine kinase inhibitors, to date. At 
present patients who fail IM therapy, or are intolerant, are candidates for dasatinib 
therapy. As T315I is the mutation with highest resistance to all the known kinase 
inhibitors including dasatinib, it is important to exclude the patients who have this 
mutation before starting dasatinib therapy. Direct sequencing which is the standard 
technique for mutation screening has a sensitivity of about 30%.  Thus there is a need 
for a method to detect T315I with a greater sensitivity. We decided to develop a 
method for detecting T315I especially to apply to the patients who may be selected 
for dasatinib therapy. Thus we developed and tested a new method for rapid, specific 
and sensitive detection of the T315I KD mutation in CML using allele specific PCR 
with a self-probing fluorescent primer. This real-time PCR-based ―closed tube‖ 
method obviates the need for post-PCR manipulation and demonstrated the requisite 
reproducibility of a diagnostic test, identifying the correct mutation status in 61 
patient cDNA samples. Its specificity was notable by the absence of false positive or 
negative results. Kinase domain mutations other than T315I were correctly classified 
as T315I-negative. Furthermore, in limiting dilution experiments the assay 
demonstrated a significantly higher sensitivity than direct sequencing, readily 
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detecting a population of mutated cells when present at a level of 1% or above. Used 
as described this real time PCR assay was sufficiently quantitative to identify 
differing levels of mutated BCR-ABL1 transcripts. More precise quantification, 
although outside the scope of current diagnostic recommendations, may be achieved 
via the production of a standard curve. Testing serial dilutions of T315I BCR-ABL1 
positive BaF3 with a non-mutant cell line showed the sensitivity of detection for 
T315I to be 20% for pyrosequencing, 10% for RFLP and 5-10% for Q-SNP 
pyrosequencing.  Q-SNP pyrosequencing had a better sensitivity for detection than 
the other two methods and also it was quantitative but still needed two step PCR, 
preparation step and pyrosequencing and required advance knowledge of the mutation 
to be tested. 
The clinical significance of very low levels of mutated T315I BCR-ABL1 positive 
cells has not been adequately addressed. Using an allele specific oligonucleotide 
PCR, Willis et al(91) reported the presence of T315I-positive BCR-ABL transcripts at 
a level undetectable by direct sequencing in a CML patient prior to administration of 
IM therapy. The patient subsequently achieved a major molecular response on IM. 
The authors postulated that the mutation may have occurred in a cell with limited 
potential for self-renewal, thus explaining its failure to expand in this patient. 
Conversely, all T315I mutations present at levels that are detectable by direct 
sequencing have been associated with clinical resistance(92). It is logical to speculate 
that there exists a finite level of mutated BCR-ABL1 cells predictive of loss of 
response that remains beyond the resolution of conventional techniques. Accurate 
definition of the threshold for clinical significance via Scorpion-based quantification 
of low-level T315I-bearing clones can be the subject of future work. 
We did investigate the effect of KD mutations even at the time of optimal response 
because the majority of studies on KD mutations have been done in patients with 
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resistance to IM or in patients after progression to advanced phase, therefore the 
prognostic implication of KD mutations in CP patients with a continuous 
haematological or cytogenetic response to IM has not yet been established. Our 
analysis showed the presence of KD mutations and the achievement of CCyR were 
the only two independent predictors for PFS. 
For the patients who had achieved CCyR, KD mutations were the only significant 
predictor for loss of CCyR and were detected before any detectable change in the 
transcript level (median time 12 months). It is unclear what the most efficient method 
for monitoring mutations in patients in CCyR might be. In our study mutations could 
be detected long before a rise in the transcript level which indicates their 
identification with intervention could have some merit(93).
 
However, to 
systematically screen patients in CCyR for the presence of a relative rare 
phenomenon such KD mutations would represent a considerable financial burden, 
which would benefit only a minority of patients.  A reasonable compromise could be 
to screen twice a year patients with incomplete cytogenetic responses and patients in 
CCyR with only a relative modest reduction in the transcript level (<2.5 log), in 
particular if they have a high Sokal risk score. 
Branford et al(94) described that P-loop mutations were associated with poor 
prognosis. Jabbour et al(95) were unable to confirm this finding. One possible 
explanation for this discrepancy could relate to the incidence and effect of the M244V 
mutation. This mutation was predominant in the Jabbour study while was 
comparatively rare in the Branford study.  
In our study we classified the mutations in three sub-categories: 1. M244V positive 
patients (our most frequent mutation; 7/37 cases), 2. mutations occupying the residues 
245-255 (P-loop); 3. other mutations. The mutation M244V did not have any adverse 
effect in PFS, while the remaining mutations were associated with a worse prognosis. 
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Patients with P-loop mutations (excluding M224V) had a significantly worse 
prognosis than the patients with other mutations. The reasons why patients with a P-
loop mutations do worse remain unclear.  
KD mutations conferred a bad prognosis independently of their kinetic pattern 
(except for pattern B, which consisted mainly of patients with the mutation M244V). 
The fact that mutations do not necessarily need to become the predominant clone in 
order to produce an adverse effect on PFS suggests that at least in some cases they are 
not the actual cause of the progression but are instead merely an epiphenomenon 
associated with the unidentified mechanism responsible for generating the resistance. 
Patients with primary cytogenetic resistance to IM were more likely to develop KD 
mutations after the resistance had already been identified, indicating that the 
mechanism of resistance was in operation since the beginning of therapy, which in 
turn suggests that the emergence of mutations merely reflects a higher level of 
‗genomic instability‘. Moreover the fact that mutations were more frequent in patients 
in the high Sokal risk group supports the hypothesis that the probability of developing 
a mutation is related to the basic biology of the disease rather than being merely a 
random event.  
A mutation in a patient who had shown resistance to IM can not be always considered 
as the cause of resistance. The study of six patients with detectable M244V and 
difference in the response of these patients to IM dose increase support this 
hypothesis. If these differences are not attributable to major inter-patient variation in 
IM pharmacokinetics, then they imply that whereas the M244V mutation may be the 
direct cause of the IM resistance in some cases, its presence in other cases may be 
quite incidental, and other previously identified or unidentified mechanisms must be 
the principal cause of the resistance. These observations suggest that KD mutations in 
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some resistant cases are just a surrogate marker or a sign of genomic instability in the 
cells which in itself is not the cause of resistance. 
Our data also suggest that the KD mutations are selected by the kinase inhibitor 
therapy and if the selective pressure of kinase inhibitors is removed then the level of 
the mutant clone will drop unless the mutation gives some proliferative advantage to 
the clone. The kinetics data from the patients who developed a mutation shows the 
increase in the level of mutation from undetectable to different levels on IM and it 
clearly shows the selective effect of kinase inhibitors. In vitro studies by Griswold et 
al(85) showed that highly resistant mutations such as T315I result in an even less 
proliferative quality than non-mutant BCR-ABL1 in the BaF3 cell line, while a study 
by Skaggs et al(88) on the oncogenicity of T315I showed the opposite finding. This 
discrepancy might be due to different methodology as Skaggs measured oncogenicity 
mainly based on the produced pattern of phosphorylated protein signature in BaF3 
and proliferation in primary mouse bone marrow cells transformed with mutant BCR-
ABL1 retrovirus. Skaggs et al showed that kinase activity decreased in T315I but it 
caused higher oncogenicity in the transfected mouse bone marrow cell.  
We investigated the proliferative phenotype of T315I mutant clone in patients. In our 
study the dominance of the mutant clone in the patients seemed to be due to a 
selective effect of IM or dasatinib rather than to their proliferative advantage over the 
non-mutant BCR-ABL1 cells. We followed the change in the kinetics of the mutation 
in at least 3 patients (T315I in 2 cases and F486S) who were off kinase inhibitors and 
treated with HHT and rIFN which are not specific inhibitors of BCR-ABL1 kinase. A 
fall in the level of T315I, (the most resistant mutation to all known kinase inhibitors), 
was observed in patients who were treated with non-kinase inhibitors. However, in 
one of these two patients the reduction in T315I level was accompanied by an 
increase in the level of a clone with G250E mutation, which finally dominated the 
 100 
leukaemic population. There are no data about the proliferative qualities of G250E 
but as it is part of the P-loop and in vitro studies have shown that Y253F and E255K 
(both in P-loop) have higher proliferative advantage over non-mutant BCR-ABL1 
positive BaF3 cells(85), it can be hypothesised that G250E might also have higher 
proliferative qualities and it did not dominate on IM therapy because T315I had a 
higher level of resistance to IM.  As soon as the selective pressure of kinase inhibitor 
was removed, the cells carrying G250E started to proliferate and became the 
dominant clone. It also proposes that G250E has proliferative advantage over the non-
mutant BCR-ABL1 clone though we have yet to assess the proliferative advantage of 
the G250E mutation. Data from another CML patient with dominant P-Loop mutation 
(Y253H) clone, even post transplant, would suggest that some P-loop mutations 
provide a proliferative advantage over the non-mutant/wild type clone.  
The disappearance of the T315I and emergence of non-mutant BCR-ABL1 clone in 
the second patient who received IFN-α confirms the data from Griswold et al that 
T315I has a lower proliferative activity than the non-mutant BCR-ABL1 positive 
cells and that the expansion of this clone is dependent on IM selection only. The 
mechanism of action of IFN-α for suppression of BCR-ABL1 positive cells in CML 
is not well known, but specific interaction between IFN- receptor–generated 
signalling and the cell cycle phase has been identified. It has been shown that IFN- 
may impose a number of proliferative restrictions via cell cycle controlling genes 
such as inhibition of cyclin-dependent kinases, down-regulation of c-Myc, and 
reduction of DNA binding activity of E2F(96;97). These modes of action seem to 
inhibit the consequence of BCR-ABL1 kinase activity rather than BCR-ABL1 kinase 
itself so IFN- does not seem to have selective inhibitory effect on T315I BCR-
ABL1 positive cells. Thus a decrease in the percentage of the T315I clone can be 
explained by the removal of the kinase inhibitor from the environment of the 
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leukaemic cells and a lower proliferative activity of the T315I clone than the non-
mutant BCR-ABL1 positive cells. 
The level of the F486S clone also fell and became undetectable on non-kinase 
inhibitor therapy in the third patient but instead a new clone with E462K which had 
not been reported before dominated the BCR-ABL1 positive cells. E462K is a new 
mutation and there are no data about its proliferative advantage.  
The kinetics of the mutation are specific for each kinase inhibitor. Our findings are 
consistent with the notion that dasatinib, being appreciably smaller than IM, may 
have a greater affinity for the active kinase conformation and may therefore be able to 
inhibit a significant number of IM resistant mutant clones(98). Furthermore the data 
support the conclusion that contact site mutants, notably T315I and F317L, may both 
be especially resistant to dasatinib(91). These observations imply that in patients nos. 
6 and 7 in the dasatinib study with the mutant subclones G250R and M244V 
respectively, the dasatinib resistance was not directly attributable to the mutant 
subclone but rather to other undefined mechanism(s).  In this series no patient who 
lacked a mutation when starting dasatinib subsequently acquired one, suggesting that 
a specific subgroup of CML patients may have a particular predisposition to acquire 
new BCR-ABL1 KD mutations. These findings raise the issue of when precisely the 
T315I subclone originated in the leukaemia cell population in patient nos.11 and 12 
(in the dasatinib study). The fact that the dasatinib resistant clone appeared to develop 
abruptly in both patients implies either that the T315I mutation developed de novo 
after start of dasatinib or that it pre-existed the dasatinib treatment but was held in 
check by another unidentified clonal population that was in turn then suppressed by 
dasatinib. Whichever the case, the two mutations may act in synergy to confer a 
major proliferative advantage over the non mutated leukaemia cell population.  
 102 
The precise mechanism that links a TKI-resistant KD mutation and subsequent events 
is unclear. First, what is the basis of the proliferative advantage of that subclone over 
the non-mutated clone, and second what is the basis for the possible progression to 
advanced phase disease? To address these questions one may speculate that a given 
mutant clone is permitted to expand ‗selectively‘ when the choice, dose and duration 
of TKI therapy are all ‗suboptimal‘. This expansion would presumably allow an 
increase in the size of a population of leukaemia cells especially susceptible to 
acquisition of additional genetic changes, either in the BCR-ABL1 gene or equally 
credibly in other genes, and this in turn would expedite progression to a more 
aggressive phenotype for the leukaemia. This hypothesis highlights the need for early 
detection of an emerging resistant clone with the aim of eradicating it before it 
becomes refractory to further treatment.  
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Chapter 2  
P-Crkl as a predictive factor of response to imatinib 
 
Introduction 
IM induces CCyR in approximately 80% of newly diagnosed chronic phase CML 
patients(99). However, 20% of patients do not achieve CCyR (primary resistance) 
and up to 20% of patients who achieve CCyR may subsequently lose it (secondary 
resistance)(99). Mutations in the BCR-ABL1 kinase domain are found in 
approximately 30% of the patients in chronic phase who lose their response to IM. 
Mutations are the best described mechanism associated with secondary resistance but 
play only a limited, if any, role in primary resistance(47). 
As CML is a stem cell disorder, the response to IM may be more appropriately 
evaluated in the ―stem cell‖ compartment and therefore CML CD34+ stem cells 
collected at time of diagnosis have been used in various studies to predict patient 
response(100-102). Insufficient suppression of the Ph-positive CD34+ stem cell 
population by therapeutic levels of IM at diagnosis can be used as the surrogate 
marker for ―poor‖ IM responders. This can be achieved by measuring the reduction in 
phosphorylation of BCR-ABL1 and its downstream targets as a measurement of the 
oncoprotein kinase activity(45;103;104). However, because the BCR-ABL1 
oncoprotein is degraded upon lysis of primary CML cells, the measurement of the 
BCR-ABL1 kinase activity by western blot is technically challenging(105;106). 
Therefore, the activity of BCR-ABL1 in primary cells is often evaluated by 
measuring a surrogate target for phosphorylation, such as p-Crkl(107-109). 
The Crkl gene is located centromeric to the BCR gene on chromosome 22 and 
encodes an adaptor protein of 38kD molecular weight,(110) consisting of an SH2 
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domain and two tandem SH3 domains in the absence of any catalytic domain(111). 
ABL1 and BCR-ABL1 are capable of phosphorylating Crkl, and Crkl forms specific 
complexes with both proteins in COS-1 cells transfected with these proteins. Tyrosine 
phosphorylation (Tyr 207) of Crkl occurs in primary CML patients as a direct 
consequence of BCR-ABL1 protein. Importantly P-Crkl is not detectable in BCR-
ABL1 negative cells. Patients responding to IM have significantly lower Crkl 
phosphorylation during therapy while resistant patients exhibit high cellular Crkl 
phosphorylation at the time of relapse. Crkl complexes with BCR-ABL1 in primary 
CD34+ cells (as demonstrated by co-immunoprecipitation studies and confocal 
microscopy) and is phosphorylated by BCR-ABL1 kinase(105;106). Tyrosine 
phosphorylation (Tyr 207) of Crkl occurs in primary CML cells as a direct 
consequence of BCR-ABL1 protein expression(112;113). Importantly, as p-Crkl is 
not detectable in BCR-ABL1 negative cells it represents a leukaemia-specific target 
to measure BCR-ABL1 activity(107). 
A study by White and colleague(114) measured p-Crkl in mononuclear cells from 
peripheral blood collected after 2 or 3 weeks of IM treatment and showed a direct 
correlation between reduction of p-Crkl and achievement of CCyR. They also 
measured p-Crkl to determine the IC50
imatinib
 in pre-treatment mononuclear cells from 
CML patients and showed that the in vitro sensitivity to IM-induced inhibition of 
ABL1 kinase activity predicted major molecular response at 12 months of starting 
IM(115). More recently, Hamilton et al(102) developed a flow cytometry based 
method of measuring p-Crkl inhibition in CML CD34+ stem cells to evaluate the 
response to IM. This study was limited to observation made in eight patients, and 
although the methodology was feasible and reproducible, a larger cohort of patients 
was needed to corroborate their preliminary findings.  
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We identified 36 chronic phase CML patients from whom CD34+ stem cells were 
available from time of diagnosis and who received IM as first line therapy. The 
methodology by Hamilton and colleagues was applied to investigate the value of p-
Crkl as a prognostic marker for IM response in CML patients in this study.  
Materials and Methods 
Patients 
Leucapheresis samples from patients newly diagnosed with CML and prior to the 
start of IM therapy were frozen and stored in the Cellular Therapy Centre at Imperial 
College NHS Healthcare Trust at the Hammersmith Hospital, London, UK. Formal 
consent was obtained from all patients for the use of their samples for research 
purposes. For p-Crkl analysis, samples from 36 patients were analysed in this study. 
Twenty four of these patients had achieved CCyR on standard dose of IM (400mg 
per day). Of the 12 patients who failed to achieve CCyR on 400mg IM daily, 8 
patients failed to achieve even a partial cytogenetic response (PCyR, ≤35% Ph-
positive metaphases). In three of these 12 patients the dose of IM was increased to 
600 and for one to 800 mg, but the level of cytogenetic response did not improve in 
any of these four patients.  
 
CD34+ Cell Separation  
Frozen pre-IM total WBCs were thawed according to the following steps (protocol 
kindly provided by Prof. Junia Melo):  
1. 5x thawing solution (consisting of 50 ml RF10 [= RPMI 1640 + 10% FCS + 
2% glutamine + 2% pen./strep.]+ 50,000 U DNase I (Calbiochem) + 500 U 
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preservative free heparin (Monoparin, CP Pharmaceuticals Ltd) was prepared for 
processing of every 5 samples. 
2. 10 mL-aliquot of 5x thawing solution was warmed in a 37°C water bath. 
3. Each cryovial was thawed in a water bath at 37°C and the cells were transferred 
to a 20 mL polycarbonate (―Universal‖) tube. 
4. 10 mL of Pre-warmed 5x thawing solution was added to the cells. 
5. The cells were spun at 1,500 rpm for 5 min at room temperature, and then the 
supernatant was discarded 
6. 200000 U of DNase I was added directly to the pellet and the tube was 
vortexed gently to disrupt the pellet and was tapped against the bench to prevent 
the formation of clumps for at least two minutes. 
7. 10 mL of RF-10 was added to the DNaseI-soaked pellet and was centrifuged as 
before. 
8. The supernatant was discarded and DNase I was added to the pellet (as above, 
ie, leave it for 2-3 minutes) and 10 mL RF-10 again. 
9. The cells were spun and the supernatant was discarded then the cells were re-
suspended in 15 mL of RF-10. 
10. If small clumps were still visible when re-suspending after the 2
nd
 lot of 
DNase I, a further 3
rd
 batch of 200L DNase I was added and left at 37C (water 
bath) for (a maximum of) 30 min before re-suspending and spinning. Very 
stubborn clumps were removed after re-suspension in RF10 by passing through a 
cell strainer as excessive DNase I results in poor cell viability.  
The next step was to separate MNC from total WBC as MNC is the template for 
CD34 positive cells separation. The thawed cells were resuspended in 15 ml of RF-10 
and transferred to a 50 ml Falcon tube containing 20 ml Ficoll-HyPaque 
TM
 Plus (GE 
Healthcare, Uppsala)  and centrifuged for 30 minutes at 1800 rpm in a bench 
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centrifuge. MNCs were transferred from the inter-phase of Ficoll and Plasma to a new 
tube and counted by haemocytometer. CD34 positive cells were separated from MNC 
using CD34 positive collection kit (StemCell technologies). 10
4
 to 10
5
 cells were used 
for checking the purity using flow cytometry as follows. The cells were washed with 
PBS (1% FBS) and then re-suspended in PBS (1% FBS) with monoclonal antibodies 
to the human CD34 antigen and also with mouse IgG1 Isotype Control Antibody 
(both from CALTAG Laboratories) separately. The antibodies were FITC conjugated. 
5 μl of the antibodies were used per 106 cells according to manufacturer‘s 
instructions. The cells were incubated with antibodies on ice for 20 minutes or at 4
o
C 
for 30 minutes. The cells were washed after incubation with PBS (1% FBS) and re-
suspended in 350 μl of PBS and were read by FACS. 
Culture of CD34 + Cell   
The media for CD34 culture was a serum free media (Iscove‘s modified Dulbecco‘s 
medium, Sigma), 1% glutamine (100mM), 1% penicillin-streptomycin (100mM), 0.1 
μM 2-mercaptoethanol (Sigma) supplemented with a serum substitute (BIT; StemCell 
technologies). SFM was further supplemented with a 5 growth factor cocktail 
comprising 100 ng/ml Flt3-ligand and 100ng/ml stem cell factor and 20 ng/ml each of 
interleukin (IL)-3, IL-6 (all from StemCell Technologies) and granulocyte colony-
stimulating factor (Chugai Pharma Europe Ltd, London, UK). One ml of media with 
suspended CD34+ cells were transferred to a 24 well plate (BD). At least 5x10
5 
CD34+ cells were treated with 5 M IM in each well for 16 hours along with 
untreated ones for each sample.  
Fluorescence In Situ Hybridisation (FISH) 
The percentage of Ph positive cells in the separated CD34+ cells was measured by 
fluorescence in situ hybridization. Up to 5x10
4 
CD34+ cells were fixed using a 3:1 
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solution of methanol: acetic acid and applied drop-wise to a glass microscope slide. 
The BCR-ABL1 DC DF FISH probe (Abbott Molecular, Berks, UK) was applied 
according to manufacturers‘ instructions. A Smart-Capture 2 imaging system 
(Digital Scientific, Cambridge, UK) was used for analysis. This analysis was carried 
out by members of the Cytogenetic laboratory at the Hammersmith Hospital, in 
London.  
Measurement of Intracellular Phospho-Crkl Using Flowcytometry 
At least 5x10
5 
CD34+ cells were treated with 5 M IM in each well for 16 hours. 
After 16 h of exposure to the drug, 5x10
5 
CD34+ cells from treated and untreated 
protocol were transferred to 1.5 ml microcentrifuge tubes and washed with 
PBS/1%BSA/0.1%Azide by spinning them in a microcentrifuge for 3 minutes at 5000 
rpm. The cell pellet of CD34+cells was then re-suspended in 100l Reagent A (fix 
medium), from ‗Fix and Perm‘ kit (CALTAG Laboratories) and were incubated at RT 
for 15 minutes. The cells were washed with 1ml PBS/BSA/Azide and centrifuged 
(5000 rpm for 3min). The supernatant was discarded and 25l Reagent B 
(permeabilising medium) from ‗Fix and Perm‘ kit (CALTAG Laboratories) was 
added to the cell pellets; and it was then vortexed briefly. 2.5l (225 ng Phospho-Crkl 
(Tyr207) Antibody, New England Biolabs) was added directly to each tube except for 
one labelled as control for background fluorescence and then vortexed. The cells were 
incubated at RT for 30-60min, and then washed with 1ml PBS/BSA/Azide and 
centrifuged (5000rpm for 3min). Cells were re-suspended in 100l PBS/BSA/Azide 
and 2l of antibody-anti rabbit FITC (2l) (Sigma) was added to each cell suspension 
including the control for background fluorescence and they were incubated at RT for 
30 minutes in dark room. 
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The cells were washed with 1 ml PBS/BSA/Azide and centrifuged (5000rpm for 
3min).  The wash step was repeated. The supernatant was poured off and the cells 
were re-suspended in 500 l of PBS/BSA/Azide and analysed by FACS. The effect of 
IM on inhibition of p-Crkl was expressed according to the following formula: 
(Geometric Mean (GM) of p-Crkl in treated CD34 positive cells - GM of the CD34 
positive cells stained with just the secondary antibody) / (GM of p-Crkl in untreated 
CD34 positive cells - GM of the CD34 positive cells stained with just the secondary 
antibody). 
Western blotting 
Western blotting was performed using standard techniques with the same specific 
anti-p-Crkl primary antibody (1:1000)(New England Biolabs) as used in 
flowcytometry and an anti-rabbit IgG, HRP-linked secondary antibody (1 in 
2000)(New England Biolabs). The membranes were then stripped in 1x ‗Re-Blot Plus 
Strong Antibody stripping Solution‘ (Chemicon, Hampshire, UK) for 5 minutes at 
room temperature and re-probed with anti-Crkl antibody (1:250) (Santa Cruz 
BioTech) for control. Specific bands were visualised using the enhanced 
chemiluminescence system (ECL, Amersham).    
Mutational analysis of the BCR-ABL1 kinase domain 
Samples from the patients in this study were analysed for the presence of a BCR-
ABL1 kinase domain mutation within 12 months of starting therapy. 
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Results 
IM causes inhibition of p-Crkl in K562 and CD34+ cells and it is 
dose dependent 
We applied a flow cytometry based method for measurement of p-Crkl as described 
by Hamilton et al for studying in vitro inhibition of BCR-ABL1 kinase by IM in IM 
naïve CD34+ cells from newly diagnosed CML patients. To set up the technique for 
measurement of intracellular p-Crkl in CD34+ cells from patients we used K562 as 
Philadelphia positive and HL60 as Philadelphia negative cells. K562 and HL60 cells 
were treated with and without IM and then the intracellular level of p-Crkl was 
measured. The effect of different IM dosage on the level of p-Crkl in K562 cells was 
examined and the sensitivity of the technique in detecting varying levels of p-Crkl in 
relation to IM dosage (Figure 2-1.A) was investigated. Maximum inhibition of p-Crkl 
in K562 cells was achieved using between 5 and 10 μM IM. From each experiment, 
K562 cells were lysed in parallel and p-Crkl was measured by western blot (Fig 2-
1.B). Western blot data was in agreement with data from flow cytometry. The result 
of the cell line study demonstrated the sensitivity of this technique for detecting the 
differences in the levels of p-Crkl according to the level of inhibition by varying 
doses of IM.  
 To confirm that the reduction of p-Crkl by IM in CML CD34+ cells is dose 
dependent, CD34+ cells from a newly diagnosed patient were treated with 1, 5 and 
10 μM IM for 2 hours and then p-Crkl examined by flow cytometry. This analysis 
confirmed the dose dependent-inhibition of p-Crkl by IM in CML CD34+ cells. The 
maximal reduction of p-Crkl also occurred between 5 to 10 μM of IM (Fig 2-2). To 
investigate the time of IM exposure when maximal reduction of p-Crkl occurs, 
CD34+ cells from a newly diagnosed patient were treated with 5 μM IM for 2, 4, 8, 
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12 and 16 hours and p-Crkl measured at each time point. The maximal level of 
reduction was observed after 2 hours of drug exposure, beyond which only a minor 
change was observed before its level stabilised for the next 14 hours (Fig 2-3). In 
two cases CD34 separation was performed in duplicate at different time points from 
the same leucapheresis, with less than 10% difference in the paired results.  
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Figure 2-1  Dose dependent inhibition of p-Crkl in K562 cells  
A) Dose dependent reduction of p-Crkl in K562 cells measured by flow cytometry. 
The Y axis represents the Geometric Mean Fluorescence Intensity (GMFI) and the X 
axis represents the dose of IM. B) Western blot analysis, on cell lysate from the same 
cell population used for flow cytometry. P-Crkl band was reduced in intensity as the 
dose of drug increased. Crkl protein was used as loading control. 
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Figure 2-2  Dose dependent reduction of p-Crkl in CML CD34+ cells 
P-Crkl is reduced in CML CD34+ cells as the dose of IM increases. The Y axis 
represents the percentage of the p-Crkl ratio (see Methods). The X axis represents 
the dose of IM.  The time of exposure to drug in this experiment was 2 hours.  
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Figure 2-3  Reduction of p-Crkl at different time points by IM in CML CD34+ 
cells 
A) P-Crkl decreases significantly after 2 hours of drug exposure and remains 
relatively stable for the next 14 hours. The Y axis represents the percentage of p-Crkl 
ratio (see Methods). The X axis represents the time of exposure to IM. B) Histogram 
representing p-Crkl in the untreated (green) and also treated cells at 2 (blue) and 16 
(orange) hours respectively. The purple peak shows cells stained with secondary 
antibody alone and is used as a control for background fluorescence. 
A 
B  
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P-Crkl phosphorylation tests in responding and non-responding 
patients 
CD34+ cells from 36 newly diagnosed CML patients were then isolated as described 
above. FISH analysis confirmed that at least 95% of the separated CD34+ cells were 
Ph positive.  No BCR-ABL1 kinase domain mutation was detected within 12 months 
of therapy. The p-Crkl ratio in IM treated CD34+ cells was analysed in patients 
grouped according to either cytogenetic or molecular response.  
 The p-Crkl ratio obtained in 12 patients who failed to achieve CCyR ranged from 25 
to 68% (median 40%) compared to 28 to 64% (median 50%) in 24 patients who 
achieved CCyR (Figure 2-4.A). The median p-Crkl ratio in treated CD34+ cells from 
the 8 patients who failed to achieve PCyR was 41% (25-68%).  
With respect to molecular responses, patients ranged from those who achieved a 4 
log reduction in BCR-ABL1/ABL1 ratio (group 5 in Figure 2-4.B) to those who 
failed to achieve any detectable molecular response (group 1; Figure 2-4.B). There 
was no significant difference in p-Crkl activity among any of these groups (Figure 2-
4.B). 
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Figure 2-4  Inhibition of p-Crkl in different sub-groups of patients based on 
their best clinical response to IM 
A) The p-Crkl ratio was not statistically different between the patients who achieved 
CCyR on IM therapy and those who did not (p=0.44). B) P-Crkl ratio in the different 
IM response subgroups. a) Haematological response without achieving PCyR; b) 
PCyR; c) CCyR but no major molecular response (MMR is defined as 3 or more log 
reduction in BCR-ABL1 transcripts from the laboratory standard value obtained for 
untreated patients in Hammersmith Hospital); d) MMR with less than 4 log reduction 
in BCR-ABL1 transcripts; e) MMR with 4 log or higher reduction in BCR-ABL1 
transcripts.  
A 
 
B 
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Discussion 
About 20-25% of CML patients treated with IM as first line therapy fail to achieve 
CCyR. Resistance in the presence of effective inhibition of the BCR-ABL1 kinase 
could indicate that the leukaemic cells are independent of BCR-ABL1 kinase activity 
and rely on other pathways for survival and proliferation. This is commonly 
described in the more advanced phases of the disease(116). Identifying those patients 
who will fail to achieve an optimal response to treatment prior to initiation of therapy 
is of clinical importance, particularly now that more potent agents are available.  As 
CML is a stem cell disorder, we considered that the in vitro response to IM in 
CD34+ cells (as measured by inhibition of Crkl phosphorylation) might predict 
therapeutic response. The results of some experiments performed by Liat Greener 
from the department of Haematology in Imperial College London, Hammersmith 
Hospital showed that CD34+ cells had the highest detectable p-Crkl level in 
comparison to PMN and MNC. Her data also showed the greatest degree of 
inhibition in CD34+ cells following treatment with IM, thus supporting the use of 
CD34+ cells rather than mononuclear cells for analysis. 
In CD34+ cells obtained at diagnosis p-Crkl was inhibited to a similar degree by 5 
µM of IM in patients who achieved CCyR and in those who failed to gain CCyR. My 
data suggest that the in vitro inhibition of BCR-ABL1 in CD34+ cells does not 
predict for clinical response to IM. The IM concentration of 5µM is similar to the 
2.95 µg/ml plasma concentration which is achieved clinically in the patients who 
take 400 mg IM daily(117). Indeed, in four patients who failed to achieve CCyR on 
400 mg of IM, the dose of the drug was increased to 600 mg (in 3 patients) and 800 
mg (in 1 patient) with no effect on cytogenetic response, thereby excluding any 
confounding effect of the use of a higher in vitro dose of IM in our study. As the IM 
responders and non-responders had a similar inhibition of BCR-ABL1 in vitro, this 
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could suggest the presence of in vivo factors, which either prevent the inhibition of 
BCR-ABL1 kinase by IM or permit the leukaemia cells to proliferate and survive 
regardless of BCR-ABL1 inhibition.  
In vitro inhibition of p-Crkl was used to measure the IC50 
imatinib
 in MNC from newly 
diagnosed CML patients by White et al(115). They showed higher dose of IM for 
inhibition of p-Crkl in MNC was associated with suboptimal response. The 
predictive value of in vitro inhibition of p-Crkl in their study and its failure in our 
study may reflect the various effects of IM on different cell population (MNC versus 
CD34+ cells). 
The smaller cohort of patients (7 responders and 1 non-responder) in the Hamilton et 
al study compared to the substantially larger cohort in our study (24 responders and 
12 non responders, of which 4 failed even to achieve a PCytR) may explain the 
discrepant results. Indeed, in their conclusions they suggested that the preliminary 
data needed to be confirmed on the larger set.  
An alternative explanation for the lack of a measurable difference between the two 
groups of patients could be the activation of BCR-ABL1 independent signalling 
pathways. In recent years several studies have reported on the relevance of these 
pathways when considering response to therapy. Wang et al have shown 
autosecretion of GM-CSF mediated BCR-ABL1-independent IM resistance via 
activation of the antiapoptotic JAK2/STAT5 pathway(69). Jilani et al showed that 
patients with resistance to IM therapy had significantly lower levels of BCR-ABL1, 
Crkl and AKT phosphorylation than previously untreated patients(118). Their 
observation emphasises that IM resistance is not necessarily dependent on BCR-
ABL1 kinase activity only but is likely to be due to the activation of other pathways 
such as STAT5. To investigate the role of other pathways which might predict 
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response, measuring the activity of other markers such as total phosphotyrosine 
might be useful as suggested by Schultz et al(100).  
Insufficient inhibition of BCR-ABL1 by IM, or activation of alternative pathways that 
maintain the cells in a leukaemic phenotype despite BCR-ABL1 kinase inhibition, 
may be responsible for the lack of optimal response to IM therapy in a number of 
patients. The mechanism of Crkl phosphorylation in CML may be more complex and 
further investigation is required to clarify the underlying mechanisms.  
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Chapter 3  
Prognostic value of hOCT1 transcript level for the 
achievement of molecular response in CML 
 
Introduction 
Drug transporters play a key role in drug absorbance, distribution, and elimination in 
vivo at the cellular level, in the transport of drugs across cell membranes and, hence, 
in determining intracellular concentrations. The variation in the capacity of leukaemic 
cells to permit enough IM to accumulate inside the cells might be an influencing 
factor for achievement of optimal response.  Thomas et al showed that the transport 
of IM into the cells is an active rather than a passive process and seems to be 
mediated by hOCT1 protein, an ATP-dependant membrane protein channel(49). The 
human OCT1 (hOCT1, SLC22A1) contains 554 amino acids. It is predicted to have 
12 transmembrane domains and contains one large, extracellular hydrophobic 
loop(119); it is expressed in many human tissues, especially in the liver(120). 
Together with other members of the solute carrier family, it mediates the transport of 
a variety of molecules(121).  
hOCT1 belongs to a small family of electrogenic facilitated drug transporters 
(hOCT1, 2 and 3) that transport a wide variety of organic cations, including drugs, 
toxins, neurotransmitters and many other compounds across the cell membrane(122). 
hOCT1 is primarily found in the sinusoidal (basolateral) membrane of hepatocytes 
and, to a lesser extent, in intestinal epithelial cells but it is not expressed in the 
kidney, and hOCT1 deficiency is therefore unlikely to affect renal excretion in 
humans(123;124). Based on its properties and tissue distribution, hOCT1 is expected 
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to play a role in the uptake of substrates from the blood into the liver and intestinal 
epithelium(124). Investigators from a Liverpool team reported that baseline level of 
hOCT1 expression measured in total WBC at diagnosis in CML patients  predicts 
cytogenetic response, progression free survival and overall survival(125). Crossman 
et al also reported that the baseline expression of hOCT1 mRNA level in bone 
marrow MNC from pre-IM CML samples was variable and not significantly different 
from healthy bone marrow donors. However, the mean pre-IM expression level in 
non-responders was significantly lower than the responders (response was defined as 
achievement of CCyR within the first year of therapy)(126). Both studies did not find 
any association between the transcript levels of ABC transporters (ABCA2, ABCG2 
and ABCB1) and response in the same cohort of patients. A recent study from the 
MD Anderson Cancer Centre on the expression of selected genes using low density 
microarray (including hOCT1/SLC22A1) did not find strong correlations between 
hOCT1 transcript levels and response to IM. They used total WBC collected from 
newly diagnosed CML patients with varying degree of IM response.  However, they  
observed decreased hOCT1 transcript levels in blast phase disease(80).   
Functional studies by White et al showed that most CML patients with suboptimal 
response to IM had low hOCT1 activity(127). Recent data from the Adelaide group 
indicates that CML CD34+ cells had a significantly lower intracellular uptake and 
retention of IM (IUR
 imatinib
) than that of CML CD34 negative cells. This was due to 
variation in the functional activity of the hOCT1 protein and lower expression of 
hOCT1 in CML CD34+. These findings were restricted to leukaemic cells and the 
level of hOCT1 transcript was reduced further in the more primitive 
CD34+cells(128).  
It is well established that polymorphic genetic variations in some drug-metabolising 
enzymes can dramatically affect the handling of certain drugs in the body, sometimes 
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with significant consequences for therapeutic efficacy(129). The detected 
polymorphisms most severely affecting hOCT1 functions, Cys88Arg and Gly401Ser, 
result in a reduction of 87% to 98% of transport of various classical but structurally 
diverse OCT substrates(130). The same group also showed the maximal transport 
activities of the Arg61Cys polymorphism in hOCT1 was largely reduced(130). 
hOCT1 is responsible for the uptake of the anti-hyperglycemic drug, metformin, in 
the hepatocytes. Some studies provide evidence that the pharmacokinetics properties 
of metformin were significantly different between the individuals who carried one of 
the reduced function alleles, R61C, G401S or G465R(131). Becker et al reported that 
the genetic variation at rs622342 in the hOCT1 was associated with glucose lowering 
effect of metformin in patients with diabetes mellitus(132). Takeuchi A et al 
evaluated the functional consequences of Pro283Leu, Arg287Gly and Pro341Leu 
variations in hOCT1 and found Pro283Leu and Arg287Gly had completely 
diminished transport activity. They also found Pro341Leu had a significantly, but not 
completely diminished transport activity(133). 
Although there are many potential ways in which hOCT1 polymorphisms might 
affect the response to drugs and toxins, it is uncertain whether these processes will 
have any marked practical impact(124). 
The in vitro studies by Hu et al indicate that IM is a weak substrate for hOCT1, and 
that this transporter by itself is unlikely to contribute substantially to the deposition 
and activity of profile of IM but expression of hOCT1 might provide a composite 
surrogate for the expression of several transporters that are relevant to the 
intracellular uptake and retention of IM(134). 
To confirm the clinical importance of the hOCT1 in association with molecular 
response to IM in CML patients in an independent study we decided to investigate: 
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1-  the level of hOCT1 transcripts in peripheral leukocyte subpopulations (MNC, 
PMN) in normal individuals; 
2- the effect of BCR-ABL1 oncogene on the expression of hOCT1 and possible 
variation while on IM therapy; 
3- the prognostic value of hOCT1 transcript level in the IM treated CML 
patients; and 
4- the association between known SNPs in hOCT1 and clinical response of CML 
patients who were treated with IM as first line therapy in CP 
 
 
Materials and Methods 
Patients and Normal controls 
Blood was taken from 21 normal consenting volunteers. 133 patients were 
investigated; 89 had achieved CCyR and 44 failed to achieve major cytogenetic 
response (MCyR). 60 archived WBC cDNA from diagnostic and their matched 
cytogenetic remission samples from 89 CML patients treated with 400 mg IM for 2 
years or longer (as first-line treatment) and had achieved CCyR were used for 
transcript measurement in this study. The characteristics of the 60 patients are shown 
in Table 3-1. Formal consent was obtained from all patients for the use of their 
samples for research purposes. 
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Table 3-1  Characteristics of the 60 patients  
 n=60 
Age at diagnosis (years) 
median (range) 
 
46 (21-86.4) 
Sex 
proportion of males (%) 
 
63.3 
BCR-ABL1/ABL1 ratio at diagnosis 
median (range) 
72.1 (21.3-334.2) 
Time from diagnosis to IM therapy (months) 
median (range) 
2.3 (0-4.8) 
Patients with MMR 
Percentage (6 years cumulative incidence) 
60 (66.1) 
Time to MMR (months) 
median (range) 
 
20.0 (5-53) 
Patients with a 4-log reduction 
Percentage (6 years cumulative incidence) 
38.3 (47.6) 
Time to 4-log reduction (months) 
median (range) 
 
33.0 (9-66) 
Patients with CMR 
Percentage (6 years cumulative incidence) 
20 (26.4) 
Time to CMR (months) 
median (range) 
 
42.8 (11.9-60) 
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Cell Separation 
Polymorphonuclear cells (PMN) and mononuclear cells (MNC) were separated using 
Ficoll-HyPaque
TM
 Plus (GE Healthcare, Uppsala) and lysed in cell lysis buffer RLT 
(Qiagen) supplemented with β-mercaptoethanol (Sigma-Aldrich) (10 µL β-
mercaptoethanol per 1 ml RLT). CD34 positive cells were separated from MNC 
using CD34 positive collection kit (StemCell technologies) as described in chapter 2. 
RNA isolation and cDNA synthesis 
RNA was isolated from the lysed cells using RNA easy kit. Total RNA was extracted 
using a commercially available kit (Qiagen, Crawley, UK) and reverse transcribed to 
cDNA using MMLV reverse transcriptase as described in chapter 2.  
Measurement of h-OCT1 transcripts 
The hOCT1 (SLC22A1) cDNA sequence was obtained from Ensemble Genome 
Browser. Primers and probes for quantification of hOCT1 were designed using ABI 
Gene Express 1.5 software (Table 3-2). These primers were used in a conventional 
PCR (see appendix 3) for amplification of the fragment which was then cloned into 
BSCRIPT plasmid. The amplification included an area with no known SNP and its 
length was 78bp extending from exon 7 to exon 8. This amplicon was inserted into a 
plasmid (pCR®2.1-TOPO® Vector) using the TOPO TA Cloning Kit as 
recommended by the manufacturer (Invitrogen). After growing the transformed Ecoli 
(One Shot® Chemically Competent TOP10 E. coli) in a 1.5% solid LB agarose 
(Bacteriological Agar, Sigma-Aldrich) gel (Ampicilin 100µg/ml), 10 colonies were 
selected and grown up in 2 ml liquid LB in a shaker incubator overnight at 37°C. The 
plasmid was extracted from this liquid using Qiagen miniprep kit (QIAGEN). The 
purified plasmid was sequenced using M13 Forward and Reverse Primers, provided 
 126 
with the cloning kit and recognising sequences flanking the TOPO TA cloning site. 
The colony with appropriate insert was grown in 100 ml LB overnight and plasmid 
was extracted using QIAgen Maxiprep kit (QIAGEN, Germany). The purified 
plasmid was measured using NanoDrop ND-1000 Spectrophotometer and the copy 
number of plasmids with inserted hOCT1 was calculated (see the appendix 5). Then 
plasmid was diluted in tRNA buffer (see appendix 6) in 10-fold dilutions.  These 
plasmid dilutions were used to generate a standard curve for real time PCR 
measurement using the ABI 7500 platform. The -gluronidase (GUS) gene was used 
as a housekeeper control for normalisation to ensure PCR efficiency equivalence 
(Primer sequence in Table 3-2). The real time PCR reaction for hOCT1 was done in 
a Taqman system with primer concentration of 300 nM and probe concentration of 
200 nM. To reduce the variation and optimise the condition for comparable results 
from different plates run, hOCT1 and GUS were measured in the same plate. In 
addition the diagnostic and remission samples for those who had achieved CCyR 
were tested in the same plate. For the normal and remission samples with cDNA 
from their PMN, MNC and total WBC, all the reactions were also tested in the same 
plate. To produce a standard curve for GUS, RNA was extracted from K562 cell line 
and converted to cDNA. Serial dilutions of K562 cDNA in tRNA buffer were 
prepared and used for all the experiments in this study. Thus the template source of 
GUS for standard curve was the same for all the tests in this project to avoid 
variations. The hOCT1/GUS ratio was calculated by dividing the average quantity of 
hOCT1 to GUS for each sample. 
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Table 3-2  The Sequence of the Primers 
Primers Sequence 
hOCT1 Forward 5‘-GGGCAGCCTGCTCGT-3‘ 
hOCT1 Reverse 5‘-CGGCCAACACACTGATTATG-3‘ 
hOCT1 Probe 5‘FAM-
ATGATTTTTATCTCACCTGACCTGCACTGGTTAA-
TAMRA 3‘ 
GUS Forward 5' - GAAAATATGTGGTTGGAGAGCTCATT - 3' 
GUS Reverse 5' - CCGAGTGAAGATCCCCTTTTTA - 3' 
GUS Probe 5' FAM- CCAGCACTCTCGTCGGTGACTGTTCA -
TAMRA 3' 
P283L  Forward 5‘-CCTGCTCTACTACTGGTGTGTGC-3‘ (Biotinylated) 
P283L  Reverse 5‘-CCATTCTTTTGAGCGATGTGG-3‘  
P283L  Sequencing 5‘-CTCTACTACTGGTGTGTGC-3‘ 
P341L  Forward 5‘-ATGCTTTCCCTCGAAGAGGAT-3‘ 
P341L  Reverse 5‘-ATGAAGGTGCGCTTCCTCAG-3‘(Biotinylated) 
P341L  Sequencing 5‘-ACCTGTTCCGCACGC-3‘ 
R61C  Forward 5‘-GGTTTCACACCTGACCACCACTG-3‘ (Biotinylated) 
R61C  Reverse 5‘-TATAGTTCAGCTCCTCCGCAGGG-3‘ 
R61C  Sequencing 5‘-AGGGCTCCAGCCACA-3‘ 
C88R  Forward 5‘- AGGAGCTGAACTATACAGTGCC-3‘ 
C88R  Reverse 5‘- TGGTTCCAGTCCACTTCATAGC-3‘ (Biotinylated) 
C88R  Sequencing 5‘- GCGGGCGAGGCCTTC-3‘ 
G401S  Forward 5‘-TACTCCGCTCTGGTCGAAAT-3‘ 
G401S  Reverse 5‘-CAGTGCAGGTCAGGTGAGATAAA-3‘(Biotinylated) 
G401S  
Sequencing 
5‘-ATCACCATTGACCGC-3‘  
rs622342  Forward 5‘-TCAGTGAGCTGTGATACAATTCAA-3‘(Biotinylated) 
rs622342  Reverse 5‘-TGCCTTTCTTGATGTTTTTTTGTG-3‘ 
rs622342  
Sequencing 
5‘-TGAGATTGTTAGATCTATGT-3‘ 
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Determining single nucleotide polymorphisms  in hOCT1 
Polymorphisms in positions R61C (rs12208357), C88R (rs55918055), P283L 
(rs4646277), R287G (rs4646278), P341L (rs2282143), G401S (rs34130495) and 
rs622342 were determined using pyrosequencing. Primers for amplification and 
sequencing the SNPs were designed using PSQ Assay Design software (Biotage, 
Uppsala Sweden) (Table 3-2). Primer concentration was 500nM. 2 µL of DNA 
template was used in a total PCR reaction of 30 µL.  PCR amplification was done in 
the thermocycler (ABI GeneAmp PCR System 2700) using Nick 60 program 
(Appendix 3). 6 μl of the PCR products was electrophoresed through 2.0% agarose 
gel; if a single amplicon was observed then 20 μl of PCR products were used for 
genotyping by pyrosequencing as described in chapter 2.  
 
Results 
The accuracy of hOCT1 detection and consistency of the results 
To confirm the consistency of the data produced by real time PCR, both the Ct and 
ΔCt values for each dilution of the standards (0.1, 0.01, 0.001 and 0.0001) were 
compared. The inter-run coefficient of variance (CV) for the ΔCts of all the standards 
was 9.96%, with a 95% confidence interval of 0.06 (Figure 3-1), which was 
considered an acceptable level for aggregating data from consecutive runs.  
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Figure 3-1 The inter-run variation 
This figure shows the inter-run variations for the 4 serial dilutions of the standards 
plasmid. The X and Y axis represent the number of runs and ΔCt of the runs; 
respectively.1SD and 2SD stand for the first and second standard deviation.  
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hOCT1 is expressed differently in polymorphonuclear and 
mononuclear cells 
One aim of this project was to investigate the association between BCR-ABL1 
oncoprotein and the expression of hOCT1 in CML patients. To answer this question 
we measured hOCT1 at diagnosis when nearly all the peripheral blood cells were 
Philadelphia positive and compared its level with the hOCT1 levels in total PB 
samples collected at the time of complete cytogenetic response. As the main 
population at diagnosis is granulocyte cells of the granulocyte series whereas 
granulocytes decrease to about 70% of the total WBC at time of remission, we 
needed to know if there is a significant difference in the level of hOCT1 in PMN and 
MNC as the latter population would have been contributing to the hOCT1 
measurement in the remission samples in our study. We measured hOCT1 in PMC, 
MNC and also total WBC from peripheral blood of 21 healthy individuals.  As 
shown in Figure 3-2 the level of hOCT1 (p<0.0001) is significantly higher in PMN 
than in MNC (median 6.52, range: 0.9-20.15 vs. median 0.09, 0.02-1.34 respectively, 
p<0.0001).  The hOCT1 transcript measurement showed up to one log difference in 
transcript level in the WBC of the normal volunteers. This indicates high variability 
in the hOCT1 transcript level and suggests a possible heterogeneity in the patients‘ 
response to IM. Measuring hOCT1 transcript in CD34+ cells from 8 diagnostic CML 
samples showed a wide variation in the expression (range: 0.0004-0.03, median: 
0.0033) but the median value was significantly lower than the median level for PMN 
(Range: 0.01-0.058, Median: 0.038) for 10 newly diagnosed CML patients 
(p=0.0003). 
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Increased hOCT1 Transcript Level in Remission Compared to 
Diagnosis  
We measured hOCT1 in paired diagnostic and remission (CCyR) samples of 60 
CML patients who had been treated with IM as front-line therapy. As can be seen in 
Figure 3-3, hOCT1 levels increased in all but two CCyR samples. The hOCT1 
transcript level was significantly higher (p<0.0001) in the remission (range: 0.15-
8.88, median: 2.2) compared to diagnostic (range: 0.02-3.511, median: 0.14) 
samples. As shown in Figure 3-4, the level of hOCT1 transcript in total WBC 
remission samples (n=60) on IM was not significantly different (p=0.1566) from the 
level of hOCT1 in total WBC from normal individuals (n=21) which suggests an 
inhibitory effect of BCR-ABL1 on the expression of hOCT1 in diagnostic samples 
rather than an upregulation due to IM treatment. 
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Figure 3-2  hOCT1 transcripts in normal and CML leukocyte subpopulations  
Figure A shows the significant difference between mononuclear cells (MNC) and 
polymorph nuclear cells for the expression of hOCT1 in normal individuals. hOCT1 
is expressed significantly (p<0.0001) higher in PMN than MNC. Figure B shows the 
transcript level of hOCT1 is significantly lower in CML CD34+ cells than hOCT1 
transcript level in PMN at diagnosis (p=0.0003). 
A 
 
B 
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Figure 3-3  Comparison of hOCT1 transcripts in matched diagnostic and 
remission samples 
This figure shows the hOCT1 level has increased significantly (p<0.0001) in 
remission samples compared to their matched diagnostic samples.  
 
 
Figure 3-4  hOCT1 transcript level in remission and normal samples 
The hOCT1 transcript level was not significantly different (p=0.156) between WBC 
from 21 normal healthy volunteers and WBC from the time of complete cytogenetic 
remission from 60 CML patients.  
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The predictive value of hOCT1 transcript  
To investigate the prognostic role of hOCT1, pre-IM samples from newly diagnosed 
patients were selected to obtain a homogenous group of patients (with regards to 
their treatment). Of 133 patients we have pre-imatinib samples for 66, of whom 60 
had achieved CCyR. Unfortunately (for this study) the number of patients who did 
not achieve CCyR was small, which made any statistical comparisons difficult. 
Therefore, to maximise our power of investigation we decided to concentrate on 
studying level of hOCT1 and its correlation with: 
 i) Major molecular response (MMR: 3 log reduction in BCR-ABL1 transcript level 
from the laboratory standard value obtained for untreated patients in Hammersmith 
Hospital),  
ii) 4 log reduction in BCR-ABL1 transcript level from the laboratory standard value 
obtained for untreated patients in Hammersmith Hospital 
iii) Complete molecular response (CMR: undetectable BCR-ABL1 transcript using 
real time PCR).  
The range of hOCT1 transcript level expressed as the percentage of hOCT1/GUSB 
ratio is shown in Table 3-3. The median value 0.16, was used as threshold for 
investigating the association between the three groups of patients defined above. 
Higher levels of hOCT1 transcripts at diagnosis significantly predicted for the 
achievement of MMR (p=0.0003), 4 log reduction (p=0.001) and CMR (p=002) 
(Figure 3-5.A, B, C). The 31 patients with a transcript level lower than the median 
value (0.16) had lower probabilities of achieving MMR, 4 log reduction and CMR at 
6 years than the 29 patients with higher levels than the median (Table 3-3). 
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Table 3-3  hOCT1 transcript level among the patients with different levels of 
molecular response 
hOCT-1 transcript level n MMR (%) 4log (%) CMR (%) 
 
median (range): 0.16 (0.021-3.51) 
 
≤0.16 
>0.16 
 
 
 
31 
29 
 
 
p=0.0003 
55.2 
81.4 
 
 
p=0.01 
42.0 
64.8 
 
 
p=0.02 
16.6 
45.3 
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Figure 3-5  Prognostic value of hOCT1 transcript levels 
hOCT1/GUSB ratio (%) > 0.16 group in red and hOCT1/GUSB ratio (%) <0.16 in 
blue. 
A: Correlation between hOCT1 transcript level and achievement of MMR.  
B: Correlation between hOCT1 transcript level and achievement of 4 log reductions 
in BCR-ABL1 transcript levels 
C: Correlation between hOCT1 transcript levels and achievement of CMR 
 
 
A 
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B 
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hOCT1 and single nucleotide polymorphisms 
We investigated the association between 7 SNPs in the hOCT1 gene and patients‘ 
response to IM. SNP P283L, R287G and C88R were not analysed for this association 
as the variation of SNP was too small to be used for any comparison (Table 3-4). 
Therefore, we investigated the association between the transcript level of hOCT1 and 
the remaining 4 screened SNPs. The frequency of the screened SNPs in this study 
was very similar to the frequency reported among Caucasians. We found no 
association between the hOCT1 transcript level and any of the individual SNPs. 
However, SNP G401S (rs34130495) was associated with IM response (Table 3-3). 
Patients with 401(G/A) genotype (n=6) had a higher chance of achieving a 3 log 
reduction in BCR-ABL1 transcripts (p=0.015). However, the number of patients 
with the 401(G/A) polymorphism was very small and larger number of patients with 
this SNP would be needed to confirm the association. 
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Table 3-4  The frequency of single nucleotide polymorphisms in hOCT1 in the 
CML patients in this study and their association with MMR 
 
 
SNP Frequency of SNPs 3 log reduction in BCR-
ABL1 transcript (MMR) 
R61C G/G  
n=107 
(0.829) 
G/A  
n=21 
0.162) 
A/A  
n=1 
0.007 
p=0.979 
C88R  T/T  
n=130 
0.978 
T/C  
n=3 
0.022 
 * 
P283L C/C  
n=130 
0.985 
T/C  
n=2 
0.015 
 * 
R287G C/C  
n=132 
1 
  * 
P341L  C/C  
n=121 
0.917 
C/T  
n=11 
0.083 
 p=0.909 
G401S G/G  
n=126 
0.955 
G/A  
n=6 
0.045 
   p=0.0155 
rs622342 G/G  
n=21 
0.165 
G/T  
n=56 
0.437 
T/T  
n=51 
0.398 
p=0.674 
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Discussion 
We investigated the differential expression of the hOCT1 transcripts in PMN, MNC 
and the total WBC from 21 normal individuals and found that hOCT1 was expressed 
at a significantly higher level in the PMN population. In a diagnostic CML sample 
the main population is cells of the granulocyte series (mainly PMN). The hOCT1 
transcript levels in WBC at diagnosis in CML patients were significantly lower than 
levels measured in remission. While PMN constitute about 70% of the WBC at 
remission and the hOCT1 level is significantly higher in normal PMN, the increased 
level of hOCT1 at remission must be either due to the effect of IM on the expression 
of hOCT1 or to an inhibitory effect of the BCR-ABL1 oncoprotein in diagnostic 
cells. When we compared the hOCT1 transcript level measured in total WBC in 
remission samples of 60 CML patients and 21 normal individuals we found no 
significant difference between these two groups. Therefore, we concluded that IM 
did not induce hOCT1 expression and the low level of hOCT1 at diagnosis and its 
high level at remission are likely to be due to the inhibitory effect of BCR-ABL1 on 
the leukaemic cells.  
We investigated the predictive value of hOCT1 among the patients in our study. 
Zhang et al did not find a strong correlation of hOCT1 transcript level with IM 
resistance(80), whereas Wang et al found hOCT1 to be an important clinical 
determinant of the response to IM(125). In the present study involving 60 patients 
who had been treated with IM as first line of therapy and had achieved CCyR, 
hOCT1 transcript level was identified as a predictor of MMR, 4 log reductions in 
BCR-ABL1 transcript and CMR. Our previous data did not show that the mechanism 
of primary failure to achieve major cytogenetic responses was dependent on the level 
of BCR-ABL1 kinase inhibition (chapter 2), which might undermine the importance 
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of hOCT1 as a predictor of MCyR. The achievement of CCyR is the major objective 
of therapy since it is associated with prolonged survival(99;135;136). 
In patients who achieve CCyR, BCR-ABL1 transcript levels may be monitored to 
assess the quantity of residual leukemia and results are often expressed as the log10 
reduction from a standardised value for untreated patients. For patients investigated 
at the Hammersmith Hospital, it is generally accepted that CCyR corresponds to an 
approximately 2-log reduction in transcript levels(137). By 5 years, approximately 
50% of patients will have achieved a 3 log reduction in transcript levels (defined as a 
major molecular response or MMR)(99); this confers further clinical benefit(138) 
and is often considered an important therapeutic target(139). With continued 
treatment, perhaps 20-30% of patients will eventually achieve a 4-log reduction and 
in 10% of patients the transcripts will become undetectable (complete molecular 
response or CMR)(99). In some cases CMR may be the equivalent of ―cure‖ as it is 
possible to discontinue the IM in some of these patients without subsequent 
relapse(140;141). The reasons underlying the different responses in different patients 
are unclear but they may reflect the intrinsic heterogeneity of CML(35;142). Thus 
variations between patients in hOCT1 transcript levels might explain the varying 
levels of molecular responses that they do achieve. Therefore, we investigated the 
association between hOCT1 transcript levels and achievement of 3 or 4 log 
reductions in BCR-ABL1 transcript in the patients who had achieved major or 
complete cytogenetic response on IM and found a significant association between 
hOCT1 transcript level in diagnostic samples and the achievement of MMR. 
Similarly functional studies of hOCT1 in CML patients showed a significant 
association between hOCT1 activity in diagnostic samples and the achievement of 
MMR.  
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The investigation of hOCT1 SNPs in this population of CML patients did not 
produce significant prognostic value for response to IM for markers such as C88R, 
P283L and R287G with the wild type allele being the most frequently detected. 
R61C, P341L and rs622342 showed no association with major molecular response. 
G401S was the only SNP which showed a significant prognostic value for achieving 
MMR. However, this specific SNP would induce reduced hOCT1 function, and 
therefore this finding is at present unexpected and partly unexplained. Therefore, the 
result should be interpreted with caution and a larger cohort is needed to validate this 
finding. 
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Chapter 4  
 
The impact of TP53 and MDM2 polymorphisms on 
response to imatinib and survival 
 
Introduction 
TP53 tumour suppressor gene 
After genotoxic stress, hypoxia, oncogene activation or other toxic stimuli, the TP53 
tumour suppressor protein is post-translationally stabilised and induces either growth 
arrest or apoptosis. The growth arrest arm of the TP53 pathway has been shown to 
rely heavily on the ability of TP53 to function as a transcription factor and to 
transactivates the cyclin-dependent kinase inhibitor p21(143). There is also evidence 
for a transcription-independent function of TP53 in this process. In response to 
hypoxia, TP53-dependent apoptosis occurs in the absence of transactivation of TP53-
target genes. Deletion of the proline-rich domain of TP53 impairs its ability to induce 
apoptosis, yet it maintains the ability to transactivate pro-apoptotic genes such as 
BAX. These data have led to the hypothesis that TP53 has pro-apoptotic activity 
independent of transactivation and that this activity probably maps to the proline-rich 
domain of TP53(144). 
TP53 plays a major role in chronic myeloid leukaemia. In particular, isochromosome 
17, resulting from the loss of chromosome 17 short arm where TP53 maps, is one of 
the most frequent alterations detected during disease progression from chronic phase 
to the blast crisis(145-147). 
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K562 cells express the BCR-ABL1 fusion gene, but lack the TP53 protein as a result 
of the loss of one copy of the TP53 gene on one allele and a point mutation in exon 5 
of the same gene on the other allele leading to an early translational stop at codon 
148(148). In a study by Brusa G et al, K562 apoptotic response to IM-induced 
inhibition of p210 BCR-ABL1 tyrosine kinase was significantly delayed compared to 
other cell lines or purified haematopoietic progenitors(149). The authors 
demonstrated that, while the majority of the clonal BCR-ABL1-transduced CD34+ 
myeloid progenitors die within 24h of their in vitro exposure to IM, 72 hour exposure 
is required to significantly increase the apoptotic fraction of the IM treated K562. In 
contrast, the apoptotic rate of wild-type TP53 over-expressing K562 was increased 
more than twice compared to the parental cell line. The higher rate of apoptosis in 
TP53-positive K562 may occur as a result of an up-regulation of apoptotic signals 
(BAX, p21 and gadd45)(149). Bursa et al found a TP53 consensus region for the 
p210 tyrosine kinase domain spanning a region between 218 and 221 amino acids 
possibly involved in TP53 cytoplasmic compartmentalisation(149). It is therefore 
possible that, following IM-induced inhibition of the p210 bcr-abl tyrosine kinase 
activity, TP53 might be released from its interaction with BCR-ABL1 protein and left 
free to shuttle into the nucleus.  
It has also been established that BCR-ABL1 itself results in the degradation of TP53. 
BCR-ABL1 activates the PI3K/AKT pathway, which in turn leads to phosphorylation 
of MDM2. Phosphorylated MDM2 ubiquitinates TP53, which results in its rapid 
degradation by the 26S proteosome(150). 
TP53 is accumulated in BCR-ABL1-expressing cells in response to DNA damage and 
is usually dependent on N-terminal phosphorylation of TP53 including Ser15, Thr18 
and Ser20. ATR, and also to a lesser extent ATM, seem to play a role in the robust 
phosphorylation of TP53-Ser15 in p210 BCR-ABL1 cells in response to DNA 
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damage. Phosphorylation of Ser15, Thr18, and Ser20 in human TP53 is essential for 
prevention of MDM2-TP53 interaction leading to degradation of TP53, but still 
MDM2 has an important role to keep the balance of TP53 in BCR-ABL1 cells. The 
final outcome of TP53-mediated effects after DNA damage depends on the fine 
balance between phosphorylation-dependent stabilisation and MDM2-mediated 
degradation(143;151). 
Accumulation of TP53 after genotoxic treatment may generate a strong pro-apoptotic 
signal. The pro-apoptotic activities of TP53 may be inhibited by BCR-ABL1-
dependent stimulation of expression of BCL-X1, phosphorylation of BAD and 
prevention of BAX and BAD translocation to the mitochondria(151). 
Conventional chemotherapeutic agents can exploit the same signalling networks 
influenced by TP53 for their optimal antitumour effects, so TP53 mutations acquired 
during tumourigenesis can promote drug resistance as a by-product of tumour 
evolution. Based on this assumption, Wendel et al inhibited TP53 using RNAi in 
BCR-ABL1 positive BaF3 cells and showed that it caused resistance to IM-induced 
apoptosis without preventing the inhibition of the p210-BCR-ABL1(152). In their 
analysis of 50 heterogeneous CML patients who had started with IM in late disease 
stage and had developed haematological resistance to the drug, 20% had evidence of 
cytogenetic alterations on chromosome 17. Of resistant patients with chromosome 17 
abnormalities (and no ABL kinase mutations) 3 of 5 patients showed TP53 mutations 
that were not present in pre-IM samples(152).  
Single nucleotide polymorphisms (SNPs) are distributed throughout the genome and 
contribute to many of the individual traits that define us as unique. These SNPs also 
influence predisposition to diseases, response to drugs or therapies. Like most genes, 
TP53 has a number of established SNPs, many of which have been the focus of recent 
investigation(153). 
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One common sequence polymorphism of the TP53 gene involves a guanine/cytosine 
exchange at the second position of codon 72 on exon 4 which leads to either arginine 
(TP53-R72) or proline (TP53-P72) protein variants with altered primary structures 
and different chemical functions(144). Both polymorphisms have been implicated in 
cancer(153). Thomas et al reported that TP53-R72 variant was a better suppressor of 
cellular transformation, an activity believed to rely on the pro-apoptotic function of 
TP53(154). Dumont et al showed that TP53-R72 variant is more efficient than TP53-
P72 variant at inducing apoptosis and demonstrated that at least one mechanism 
underlying this greater efficiency is enhanced localisation of the TP53-R72 variant to 
mitochondria. Mitochondrial localisation of TP53 is known to contribute to apoptosis. 
Enhanced mitochondrial localisation of the TP53-R72 is due at least in part to its 
greater binding and ubiquitination by E3 ubiquitin ligase MDM2, which leads to 
enhanced interaction with the nuclear export protein CRM1, resulting in nuclear 
export of TP53-R72 variant(144).   
Bergamaschi et al investigated the difference in response to IM between CML 
patients with proline (TP53-P72) or arginine (TP53-R72) at position 72. In their study 
they looked at three groups: 44 CML patients in CP who had been treated with IM, 52 
randomly selected archived CML samples and 174 control samples taken from 
umbilical cord blood. TP53-P72 was more common in the CML patients than in the 
controls and this was mainly due to a higher portion of homozygosity in the patients‘ 
cohort. Among the CML patients, TP53-P72 was present in 55% of non-responders 
but only 23% of the responders. Importantly, the patients with higher Sokal scores 
had a higher portion of TP53-P72, thus identifying the TP53-P72 allele as an adverse 
prognostic factor(155).  
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MDM2 
MDM2 is an important negative regulator of the TP53 tumour suppressor. It is the 
name of a gene as well as the protein encoded by that gene. The level of MDM2 
protein in cells has a significant effect upon the TP53 response and oncogenesis. 
MDM2 is over-expressed in approximately 10% of cancers. Constitutive over-
expression of MDM2 in a mouse model results in increased susceptibility to cancer 
development. In humans, MDM2 is amplified in 30% of osteosarcomas and soft 
tissue sarcomas. There is ample evidence in both mice and human that a small 
increase in MDM2 protein can reduce the activity of TP53 resulting in tumour 
formation(156).  
There are two promoter-enhancer regions in the MDM2 gene that regulate the levels 
of MDM2 mRNA. The first promoter is upstream of the first exon and regulates the 
basal level of MDM2. The second is in the first intron and contains both SP1 binding 
site and a TP53-responsive DNA sequence that increases the expression of MDM2 
after TP53 response. There are two SNPs in this 524 bp intron, one at 309 (T > G) 
and another at 344 (T>A). SNP309 (G/G) creates an improved SP1 site that regulates 
the basal levels of MDM2 transcription.  The SNP309 T allele is the ancestral allele 
but the high frequency of the G allele in many populations indicates that selective 
pressure is in support of G variants, despite this variant being a potential risk allele 
for cancer. Transcription factor SP1 and the oestrogen receptor bind more efficiently 
to the 309G variant(156). Hu et al showed that in oestrogen-responsive cells, 
oestrogen preferentially induced the transcription of MDM2 from the SNP309G 
promoter and resulted in a higher level of MDM2 in SNP309G/G cells than 
SNP309G/T or SNP309T/T cells. This increase in MDM2 would lead to TP53 
suppression and might lead to hormone-related cancers. Altered expression of MDM2 
can mask the modifications in TP53(157). The cells with SNP309 (G/G) have a lower 
 148 
apoptotic response in comparison to the cells with SNP309 (T/T). The higher basal 
level of MDM2 in cells with SNP309 (G/G) reduces TP53 levels and TP53-mediated 
transcription of the genes(153). Studies of MDM2 polymorphism at 309 in Li-
Fraumeni syndrome (a condition with germline TP53 mutations characterised by an 
increased risk of developing various cancers) and some other cancers showed 
correlations between SNP309 and the earlier onset of cancer but no association 
between SNP309 (G/G) and any other clinical phenotype such as tumour subtype, 
stage of tumour, or survival has been identified (156).  The higher basal level of 
MDM2 seems to be associated with lower apoptotic responses of TP53 in response to 
DNA damage. The mutation rate might be the same in SNP309 (G/G) and SNP309 
(T/T), but the fixation of mutation in clones of cells may be higher in individuals with 
SNP309 (G/G)(156).  
Considering the data regarding the association between TP53 and IM in CML cell 
lines we decided to investigate the association between TP53 polymorphism in codon 
72 and response to IM and progression free survival (PFS) in CML patients who were 
treated with IM in Hammersmith Hospital. As MDM2 is the main regulator of 
baseline level of TP53, we also investigated the effect of the MDM2 309 SNP which 
influences its transcription level to find out how variation in the level of MDM2 
affects survival and response to IM in CML patients. 
The aims of the work in this chapter were to investigate:  
1- the association between TP53 polymorphism at codon72 and response to IM and 
survival 
2- the association between MDM2 309 polymorphism and response to IM and 
survival, and 
3- the predictive value of the interaction between TP53 72 SNP and MDM2 309 SNP 
and response to IM and survival in CML patients 
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Materials and Methods 
Patients and material 
Samples from 264 CML patients receiving IM in chronic phase as either the first line 
therapy (n=223) or after failing treatment with IFNα in late chronic phase (n=41) 
were used in this study (Table 4-1). Patients were treated with IM for a median time 
of 54 months (range 3-107). Patients received IM
 
400 mg/d by mouth, and the dose 
was adjusted according to tolerance
 
and response. Genotyping was informative in 257 
and 247 samples for the TP53 and MDM2 SNPs, respectively. DNA samples from 
102 individuals with no known malignancy were used as a control population. All 
patients gave permission for the use of their anonymised samples for research 
purposes and the project was approved by the local ethics committee. DNA was 
extracted using QIAamp DNA Blood Minikit (Qiagene, Germany) as recommended 
by the manufacturer.  
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Table 4-1  Patients’ characteristics at the start of IM therapy  
 No % 
Age (median) 
Range 
 
47.2  
(15.7-83.4) 
Sex 
Male 
Female 
 
147 
117 
 
56% 
44% 
Cytogenetic Abnormality * 
Ph Chromosome 
Additional Abnormality 
 
 
250 
11 
 
95.8% 
4.2% 
Status at the start of IM 
Newly diagnosed 
IFN-α failure/Late CP  
 
223 
41 
 
 
84.4% 
15.6% 
 
Sokal Score* 
Low  
Intermediate 
High 
 
69 
109 
83 
 
26.43% 
41.76% 
31.81% 
* Unavailable data for 3 patients 
Determination of SNP genotype 
DNA fragments of 186 bp and 113 bp, containing TP53 codon72 and MDM2 codon 
309, respectively, were amplified using the forward and reverse primers detailed in 
table 4-2 under the following thermal conditions: 94
0
C for 3 minutes and then 32 
cycles of 40 seconds at 94
0
C, 40 seconds at 60
0
 C and 1 minutes at 72
0
C and at the 
end of the 32 cycles a final extension time for 10 minutes at 72
0
C. The amplified 
fragment was used as a template along with the appropriate TP53 or MDM2 Q-SNP 
primer (Table 4-2) in a pyrosequencing reaction as described in previous chapters.   
Measurement of TP53 transcript  
The level of TP53 transcript in CD34+ cells from two newly diagnosed CML patients 
was measured following 8, 16 and 24 hours treatment with 5 µM IM. Five million 
CD34+ cells were cultured with and without 5 µM IM and after 8, 16 and 24 hours 
 151 
the cells were lysed and RNA extraction and cDNA synthesis were performed as 
previously described.  The real time PCR reaction for TP53 was performed in a 
Taqman system with primer concentration of 300 nM and probe concentration of 200 
nM using the standard thermal condition (50° for 2 minutes followed by 95° for 10 
minutes and then 40 cycles of 15 seconds at 95° and 1 minute at 60°) of the ABI 7500 
platform. To normalise the data G6PD was measured for each sample using the same 
concentration of primers and probes that was used for TP53.  TP53 and G6PD were 
measured in the same plate to avoid variations and all experiments were performed in 
triplicate (Table 4-2). 
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Table 4-2 PCR Primer Sequences  
Oligo Name Sequence 
P53-F 5‘-GGTCCTCTGACTGCTCTTTTCACC-3‘ 
(Biotinylated) 
P53-R 5‘-GTACCGGTGTAGGAGCTGCTGG-3‘ 
P53-S 5‘-GGTGCAGGGGCCACG-3‘ 
MDM2-F 5‘-GGGGTGGTTCGGAGGTCT-3‘ 
MDM2-R 5‘-GTGACCCGACAGGCACCT-3‘ (Biotinylated) 
MDM2-S 5‘-GGGCTGCGGGGCCGCT-3‘ 
P53-Taq-F 5‘-GAAGAGAATCTCCGCAAGAAAGG-3‘ 
P53-Taq-R 5‘-TGGGCAGTGCTCGCTTAGT-3‘ 
P53-Taq-
Probe 
5‘-FAM-AGCCTCACCACGAGCTGCCCC-TAMRA-3‘ 
G6PD-Taq-F 5‘-GGCGATGCCTTCCATCAG-3‘ 
G6PD-Taq-R 5‘-CCAGGTCACCCGATGCA-3‘ 
G6PD-Taq-
Probe 
5‘-VIC-CGGATACACACATATTC-3‘ 
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Statistical Methods 
Probabilities of progression free survival (PFS) were calculated using the Kaplan-
Meier method. PFS was defined as survival without evidence of accelerated or blastic 
phase disease. The probabilities of cytogenetic response and cytogenetic relapse were 
calculated using the cumulative incidence procedure, where cytogenetic response or 
relapse were the events of interest and death and disease progression were the 
competitors. For PFS analysis, patients were censored at the time of stem cell 
transplant; for cytogenetic responses and emergence of KD mutation patients were 
censored at IM discontinuation. Univariate analyses to identify prognostic factors for 
PFS, cytogenetic and haematological response were carried out using the log-rank 
test. Variables found to be significant at the p<0.25 level were entered into a 
proportional hazards regression analysis; a forward stepping procedure was employed 
to find the best model.  
 
Results 
The association between age of CML onset and TP53 R72P and 
MDM2 309 polymorphism 
The range of age for the patients in this study was from 15.7 to 83.4 years old with 
the median 47.  Patients with homozygous TP53-P72 genotype had a higher chance 
(p=0.013) of developing CML at an earlier age (median 41.4) than the homozygous 
TP53-R72 patients (median: 45.2) or TP53-R72/P72 (median: 48.5). MDM2 309 
polymorphisms showed no association with the age of CML onset.  
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Frequency of TP53 Codon72 and MDM2 309 Polymorphism 
Klug et al observed that the studies investigating the association between TP53 codon 
72 polymorphism and cervical cancers where the controls were not in Hardy-
Weinberg equilibrium showed statistically significantly increased odds ratios 
compared with studies in which the controls were in Hardy Weinberg 
equilibrium(158). The distribution of genotypes for TP53 P72R and MDM2 309 SNP 
in our control population was in Hardy Weinberg equilibrium. Table 4-3 shows the 
frequencies of different alleles and genotypes for the TP53 codon 72 and MDM2 309 
polymorphisms in the CML samples and the control population. Fisher‘s exact test 
analysis did not show a significant difference between the allelic and genotypic ratios 
in the two groups for either gene.  
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Table 4-3  The frequency of TP53 R72P and MDM2 309 SNPs 
  Normal CML 
TP53 Gene Genotype at codon 72 
TP53 P72/P72  (C/C) 
TP53 R72/R72 (G/G) 
TP53 R72/P72 (G/C) 
 
13 (12.8%) 
48 (47%) 
41 (40.2%) 
 
24/256   (9.3%) 
132/256 (51.3%) 
100/256 (39.3%) 
Allele 
TP53 P72  (C) 
TP53 R72  (G) 
 
54 (38%) 
89 (62%) 
 
124 (34%) 
232 (66%) 
MDM2 Gene Genotype at 309 
MDM2 309 G/G 
MDM2 309 T/T 
MDM2 309 G/T 
 
13 (12.8%) 
40 (39.2%) 
49 (48%) 
 
38/247   (15.3%) 
103/247 (41.7%) 
106/247 (43%) 
Allele 
MDM2 309 G 
MDM2 309 T 
 
62 (41%) 
89 (59%) 
 
144 (40.7%) 
209 (59.3%) 
TP53&MDM2 
Gene 
Genotype at 309 
TP53 72/MDM2 309: CC/GG 
TP53 72/MDM2 309: CC/GT 
TP53 72/MDM2 309: CC/TT 
TP53 72/MDM2 309: GC/GG 
TP53 72/MDM2 309: GC/GT 
TP53 72/MDM2 309: GC/TT 
TP53 72/MDM2 309: GG/GG 
TP53 72/MDM2 309: GG/GT 
TP53 72/MDM2 309: GG/TT 
 
1 (0.98%) 
4 (3.92%) 
8 (7.9%) 
3 (2.9%) 
21 (20.5%) 
17 (16.8%) 
9 (8.8%) 
15 (14.7%) 
24 (23.5%) 
 
2 (0.8%) 
11(4.5%) 
10 (4.2%) 
12 (5 %) 
38 (16.4%) 
43 (18 %) 
23 (9.5 %) 
51 (21.2 %) 
49 (20.4 %) 
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TP53 polymorphism and response to IM, progression and event free 
survival 
In our cohort, 41 patients had been treated with IM in late chronic phase after IFNα 
failure. This population had a higher chance of losing complete haematological 
response (CHR) than the newly diagnosed patients treated with IM as first line 
therapy (p<0.001). Thus to avoid the effect of both resistance to therapy and the 
occurrence of additional genetic lesion appearing as a result of BCR-ABL1 
oncoprotein and to analyse a more homogenous population we carried out all tests for 
response to IM and survival in the newly diagnosed patients treated with IM as the 
front-line therapy. We found that neither TP53 P72P, nor TP53 R72R was predictive 
for loss of CHR.  
Then we investigated the predictive value of TP53 P72R polymorphism for 
progression to advanced phase.  Our results did not show any significant correlation 
between TP53 R72P and progression to advanced phase within 6 years (p=0.14). We 
also investigated the association between TP53 R72P and event free survival in this 
latter group and again TP53 R72P was not predictive of event free survival (p=0.12). 
Loss of CHR, progression to advanced phase and the possibility of events were higher 
in TP53 P72/P72 group but it did not reach to significance. This may also be 
contributed by the relative small number of patients (n=23).    
TP53 R72P and Sokal Score 
The distribution of TP53 P72R was not significantly different between low, 
intermediate and high risk Sokal score groups. 
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MDM2 309 polymorphism and response to imatinib, progression 
and event free survival 
MDM2 309 polymorphism was not associated with achievement of CCyR, loss of 
CHR, progression and event free survival in the newly diagnosed CML patients who 
were treated with IM as the first line of therapy.   
MDM2 309 polymorphism and Sokal Score 
MDM2 309 polymorphism was significantly associated with Sokal score. The 
frequency of MDM2 309 GG was significantly higher in the Sokal high risk group 
(p=0.008) (Table 4). 
Table 4-4  The association between Sokal risk groups and MDM2 309 genotypes   
 Subgroups according to the Sokal score 
Low Risk Intermediate 
Risk 
High Risk 
GG          Count 
                %within MDM2 
                %within Sokal Risk 
Group  
                 
4 
13.8% 
6.9% 
9 
31.0% 
10.3% 
16 
55.2% 
23.9% 
TT          Count 
               %within MDM2 
               %within Sokal Risk 
Group  
 
30 
31.6% 
51.7% 
43 
45.3% 
49.4% 
22 
23.2% 
32.8% 
GT          Count 
               %within MDM2 
               %within Sokal Risk 
Group  
 
35 
25.5% 
41.4% 
57 
41.6% 
40.2% 
 
45 
32.8% 
43.3% 
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The effect of interaction between TP53 and MDM2 polymorphisms 
on PFS and survival 
Since in vitro studies suggest that MDM2 309 GG reduces the basal level of TP53 
and TP53-P72 has a slower apoptotic activity, the combination of TP53 P72R and 
MDM2 309 SNP might have significant prognostic value for response and survival. 
So we investigated the prognostic values of combined genotypes in two ways. At first 
we investigated the effect of MDM2 309 polymorphism on response to IM and 
progression in each of the 3 different TP53 P72R genotype groups. MDM2 309 SNP 
was not predictive for response to IM, progression and event free survival in each 
group except TP53 P72/P72+MDM2 309 GT which was associated with higher 
chance of achieving CCyR where 100% of TP53 P72/P72+MDM2 309 TT (n=8) 
achieved CCyR. 88.9% of the TP53 P72/P72+MDM2 309 GT (n=4) achieved this 
level of response (p=0.017), but the number of patients in these two groups was too 
small for any meaningful analysis.  
We then investigated the effect of TP53 polymorphism on response to IM and 
progression in each of the 3 MDM2 309 genotype group. Of this combination, 
MDM2 309 TT+ TP53 GG was associated with lower chance of achieving CCyR 
(p=0.015) where 89% of MDM2 309 TT+ TP53 GG (n=49), 100% of the MDM2 309 
TT+ TP53 GC (n=43) and 100% of the MDM2 309 TT+ TP53 CC (n=10) achieved 
CCyR (p=0.015). Investigation of association between all possible 9 genotypes with 
response and progression free survival did not show any significant association.  
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TP53 transcript level following treatment with IM 
TP53 transcript was measured following 8, 16 and 24 hours treatment with IM. The 
level of TP53 transcript did not change significantly in the treated cells in comparison 
to the untreated control at the tested time points as shown in Figure 4-1. 
 160 
Figure 4-1  TP53 transcript level following in vitro treatment with IM in CD34+ 
CML cells 
In figure A the levels of TP53 transcripts in untreated CD34+ cells (Black) from all 
tested time points are compared with their counterpart in IM-treated CD34+ CML 
cells (Blank). In B the comparison is shown separately. There was no significant 
change in TP53 transcripts following in vitro IM therapy. 
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Discussion 
We investigated the association between TP53 polymorphism at codon 72 and 
response to IM, PFS and survival in CML patients who were treated with IM. As the 
level of TP53 protein is controlled at the transcript and protein level mainly by the 
MDM2 gene and MDM2 309 polymorphism influences its own transcript level we 
also investigated the influence of the MDM2 309 polymorphism in association with 
TP53 R72P on clinical outcome in our population of CML patients. Our study did not 
show any significant difference in the frequency of TP53 R72P alleles and genotypes 
between our CML population and the control group. This result is different from what 
was reported by Bergamaschi et al(159). The reason for this difference might be due 
to the larger number of patients in our study. The lack of difference in the frequency 
of TP53 R72P between the CML and control groups along with the result of response 
and survival analysis indicate that TP53-P72 is not associated with increased risk of 
developing CML. There is conflicting evidence from other studies about the role of 
TP53 R72P as a predisposing factor for the development of common cancers such as 
those of breast, stomach and lung (159;160). A recent pooled analysis of data from 49 
studies provided evidence that TP53 P72/P72 was not associated with cervical cancer. 
It is clearly shown that previous studies in support of this association suffered from 
unsound statistical design(158). Interestingly, however, our data demonstrated that 
TP53 P72/P72 was associated with developing CML at an earlier age. In keeping with 
this finding, an earlier median age of onset of squamous cell carcinoma of the head 
and neck, oral cancer, hereditary non-polyposis colorectal cancer and glioblastoma 
was also reported in patients with TP53 P72/P72(153;161).  
One further interpretation of our data is the evidence that genomic damage occurs 
frequently in cells over the course of a life-time and this is either repaired, or induces 
cell apoptosis if the level of damage is beyond the repairing capacity of the cell. As 
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TP53 is one of the main components of the cells response to DNA damage, its 
activity might influence the behaviour of cells when confronted with such damage. If 
the in vitro finding of the lower apoptotic activity of TP53 P72 applies to stem cells, 
the repairing mechanism will be less efficient than the same cells with TP53 R72 in 
otherwise equal conditions. If the response of the cell to damage is inefficient DNA 
repair rather than apoptosis, then the cell will give rise to a genetically mutant clone. 
Acquisition of one or more pre-cancerous mutations may increase the likelihood of 
acquiring cancerous phenotype at an earlier age, as may be supported by our findings. 
It should be noted however, that following this model, the chance of acquiring cancer 
at any age should also be increased in patients with TP53-P72; this was not observed 
in our CML population.  
Our investigation showed no clinical prognostic value for TP53-R72. Also we found 
no evidence in support of the role of TP53-P72 in predicting progression to AP/BP, 
shorter survival or in vitro studies that showed TP53-P72 has a weaker apoptotic 
activity compared to TP53-R72. However, our analysis did show that a higher 
percentage of patients with TP53-P72/P72 lost their CHR in 6 years or had less than 6 
years progression and event free survival, though these observations were not 
significant. The number of patients with this polymorphism was relatively small. 
Therefore it is possible that the relationship between TP53-P72/P72 homozygosity 
and survival may reach significance if we were to investigate a larger cohort of 
patients.  
We did not find any association between TP53 SNP at codon 72 and CCyR. One 
explanation could be that TP53 does not have a critical role in response to IM in the 
primary cells. There is no detailed study regarding the involvement and significance 
of TP53 in response to IM in primary cells and most of the available data regarding 
the role of TP53 in response to IM are from cell lines which are very different from 
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primary cells in their mechanisms of survival or apoptosis. For example in the report 
by Wendel et al(152), BCR-ABL1 transformed BaF3 cells had increased TP53 
transcript level within 6 hours following IM exposure, while we did not observe any 
change in TP53 transcript level in CML CD34+ cells following exposure to IM. 
However, the involvement of TP53 is not only via change in its transcript level, as 
this protein is activated by many post-translational changes and interaction with many 
other signalling proteins during response to apoptotic stimulants which all require 
further investigation in CML primary cells.  
The lack of difference in the frequency of MDM2 309 polymorphism between the 
CML and control populations indicates that the polymorphism at this position does 
not increase the chance of developing CML. Furthermore, we could not find an 
association between treatment failure, PFS and survival and MDM2 309 
polymorphism.  MDM2 309 GG increases the transcript basal level of MDM2, which 
in turn reduces the basal level of TP53. As TP53 is involved in apoptotic responses, 
one might expect to observe a sub-optimal response to therapy or higher chance of 
progression to AP/BP in CML patients who have MDM2 309 GG. It could also be 
expected that the patients with both MDM2 309 GG and TP53 P72/P72 would have 
less favourable outcome compared to patients who do not have this genotype. Our 
results did not show any significant association between MDM2 309 GG and 
different SNP at codon72. While the interactive effect of MDM2 and TP53 was 
associated with therapy related AML (t-AML) which is regarded as a secondary 
event(162), we could not find such any association with response to IM, survival and 
PFS in CML patients. The lack of association of MDM2 SNP309 and TP53 R72P and 
cancers such as breast and colorectal cancers has been reported(163;164). The only 
significant finding regarding MDM2 309 polymorphism in our study was the higher 
frequency of MDM2 309 GG with high Sokal risk groups. Our earlier data showed 
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that high Sokal score was associated with less favourable response to IM and a higher 
chance of developing BCR-ABL1 kinase domain mutation(99); thus increasing the 
number of patients with MDM2 309 GG in our study might show the association 
between this polymorphism and response to IM or developing BCR-ABL1 kinase 
domain mutation.  
In summary, TP53 and MDM2 polymorphisms in CML patients do not appear to 
show any clinical correlation with outcome and do not support previous findings of 
laboratory-based studies on cell lines. One possible explanation for the discrepancy 
between the in vitro observations and our results is that TP53 R72P does have a small 
influence but we did not have enough patients with TP53 P72/P72 to demonstrate it; 
in that case a larger study would be needed for better understanding of this influence. 
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Chapter 5  
Heterogeneity of CML patients at diagnosis due to 
random and non-random copy number aberrations in 
the Ph-positive clone 
 
Introduction 
Various different factors that we discussed earlier could influence the nature of the 
disease and subsequently its response to treatment. The BCR-ABL1 oncogene has 
been shown to be the main genetic cause of CML but heterogeneity of the disease 
among patients with regard to response to IM, acquisition of ABL1 kinase domain 
mutations and progression to advanced phase of the disease suggest the contribution 
of additional genetic abnormalities to the pathogenesis of the disease and its 
heterogeneous behaviour(99;142). 
To gain a more comprehensive picture of the acquired genetic lesions that may co-
operate with BCR-ABL1 in the pathogenesis of CML, a more global approach to 
genomic analysis is required. 
Current methods of gene profiling have revealed that tumour types previously thought 
to be homogenous from a histological view alone often have different underlying 
signatures. Complex mutational events seem to have a major impact on the 
expression of specific genes that contribute to the induction and progression of cancer 
and on the aggressiveness of the tumour and the clinical outcome of therapy(165). 
The assessment of tumour-cell heterogeneity has become a central focus of 
investigation in cancers including leukaemia to identify subtypes that are driven by 
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altered signalling pathways whose genetic defects correlate with prognosis and also 
offer attractive targets for molecular intervention(165). Conventional cytogenetic 
analysis was the earliest method of detecting chromosomal aberrations on a global 
scale. Complementary molecular cytogenetic techniques such as fluorescence in situ 
hybridisation (FISH) and classical comparative genomic hybridisation (CGH) were 
later developed to improve resolution and to allow analysis of tumour types for which 
analysis of metaphase cells is not possible. The principle of classical CGH is to 
identify genomic copy number changes by competitively hybridising differentially 
fluorescently labelled DNA samples against a control metaphase chromosome 
spread(166). This enabled the identification of chromosomal regions that may 
harbour genes involved in pathogenesis due to differences in copy number between 
the genomes being compared. One attempt to improve the detection of structurally 
altered genomic regions combines classic CGH with the microarray platform, 
generating the array CGH technique. Array CGH relies on competitive hybridisation 
of fragmented, labelled tumour DNA together with fragmented, but differentially 
labelled control DNA onto a matrix of genomic segments spotted in a microarray 
format (Figure 5-1)(167;168). The microarray platform facilitates higher-resolution 
mapping of genomic regions that contain copy number aberrations, such as 
amplifications and deletions.  
Development of genome-wide arrays that use unique target clones distributed evenly 
throughout the genome have increased the ability to examine cancer genomes in a 
high-throughput and high-resolution manner(169). The current spatial resolution of 
array CGH when using 60bp oligonucleotides is up to 500 times that of previous 
arrays which used segments of DNA derived from human bacterial artificial 
chromosomes (BACs) with a genomic length of approximately 200kb(170). Thus, the 
use of array CGH has enabled the detailed analysis of global copy number changes, 
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and the association of these changes with different clinico-pathological features of 
disease. Candidate genes involved in cancer pathogenesis continue to be identified 
using this approach, providing a deeper understanding of the pathogenesis of human 
malignancy.  
Recent studies have identified over 3000 loci across the human genome that vary in 
copy number between normal individuals and show no explicit effects on 
phenotype(171). These copy number variants (CNVs) may interfere with the analysis 
of array CGH studies as they are indistinguishable from inherited or acquired genetic 
copy number aberrations (CNAs) that are truly disease-associated. 
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Figure 5-1  Array-based CGH  
By convention, pathological DNA samples, for example tumour DNA, are labelled 
with a red fluorescent dye such as cyanine 5 while normal reference DNA is labelled 
with a green dye such as cyanine 3. Unlabelled human cot1 DNA is also included in 
the hybridisation mix in order to repress repetitive DNA sequences. A microarray 
scanner is used to analyse the log2
 
ratios of the different dye intensities for each spot. 
A yellow fluorescence ratio represents an even mix of green and red dye and indicates 
no copy number change. A red colour ratio indicates a copy number gain in the 
pathological sample and a ratio that shows up as green indicates a copy number loss 
in the pathological sample (167). 
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In order to exclude the effect of these ―normal‖ CNVs in the analysis of array CGH 
data, a publicly available, constantly updated database has been assembled that 
contains all known CNVs (http://projects.tcag.ca/variation). Another strategy to 
overcome this problem in cancer-related projects uses non-disease DNA from the 
same patient as a reference sample instead of pooled DNA from normal control 
individuals. By using this method, only CNAs that are acquired throughout the course 
of a disease should be identified, as the problem of picking up normal CNVs that may 
exist between individuals is eliminated. 
Different clinical outcomes for CML patients indicate heterogeneity of the disease 
which might be due to minor genetic changes in leukaemic clones. While effects of 
the genomic instability conferred by BCR-ABL1 are thought to play a major role in 
progression to blast crisis, the contribution of genomic instability to early disease 
expansion and maintenance has not been investigated. 
Therefore a high-density oligonucleotide array comparative genomic hybridisation 
(CGH) was used in this study to identify cryptic genomic lesions in presentation 
samples from 20 CML patients that were absent in the same patients‘ remission 
samples. 
 
Materials and methods 
Patients 
We studied polymorphonuclear cells (PMN) from 20 patients with newly diagnosed 
BCR-ABL1-positive CML in chronic phase prior to administration of IM by 
comparative genomic hybridisation. Their median leukocyte count was 183 x 10
9
/l. 
All 20 patients started treatment with IM 400 mg/day and had achieved CCyR in less 
than 12 months. For the reference gene for the CGH array cells were collected again 
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from all 20 patients, once complete cytogenetic response was confirmed and Q-PCR 
showed 2 to 3 log reduction in BCR-ABL1/ABL1 ratio. All patients gave informed 
consent for these studies in accordance with requirements of the Hammersmith 
Hospitals Research Ethics Committee. 
Cell separation 
PMN and CD34+ cells were separated as described in chapter 2 and 3.  
Comparative genomic hybridisation 
Patient DNA was competitively hybridised against a reference from the same patient's 
genetic material to avoid detection of constitutional polymorphic copy number 
variants (CNVs) and to limit the results to acquired leukaemia-related changes. The 
DNA from diagnostic PMN was compared against DNA of total WBC at the time of 
remission. CGH was performed with a 2.1 million oligonucleotide array (NimbleGen, 
UK; ―HD2‖ 070713_HG18_WG_CGH_HX1 design). The probes on this array were 
selected to achieve a uniform distribution throughout the genome, with approximately 
one probe every 1200 bp. Scanned array images were imported into NimbleScan 
(NimbleGen) to identify copy number aberrations (CNAs) from HD2 image and 
intensity data. Nexus 4 software (BioDiscovery Inc, CA, USA) was used to visualise 
the normalised-segmented data. In order to assess the significance of concordant 
aberrations from a set of samples, we used the Significance Testing for Aberrant 
Copy number (STAC) algorithm, which provides permutation based concordance p-
values for each location. 
Gene Expression 
Expression of the NAMPT/PBEF1 gene was measured using Hs00237184-A1 PBEF1 
(Applied Biosystem, Foster City, USA) in a 7500 ABI Real-Time PCR machine. 
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GUSB was used as the internal control gene and for normalisation of the results as 
described in chapter 3.  
Copy Number Measurement 
To confirm the copy number aberration using a second technique, TaqMan Copy 
Number Assay was used for NAMPT/PBEF1. This assay was run on Applied 
Biosystems real-time PCR systems. In a copy number quantitation reaction, purified 
genomic DNA was combined with the: 
• TaqMan® Copy Number Assay, containing two primers and a FAM™ dye labeled 
MGB probe (Hs01366191-cn) to detect the genomic DNA target sequence. 
• TaqMan® Copy Number Reference Assay, containing two primers and a VIC® and 
TAMRA™ dye-labeled probe (RNase) to detect the genomic DNA reference 
sequence. 
• TaqMan® Genotyping Master Mix, containing AmpliTaq Gold® DNA Polymerase, 
UP (Ultra Pure) and dNTPs that are required for the PCR. TaqMan® Copy Number 
Assays were run simultaneously with a TaqMan® Copy Number Reference Assay in 
a duplex, real-time PCR. Each copy number assay detects a target gene or genomic 
sequence of interest; the reference assay detects a sequence known to exist in two 
copies in a diploid genome (for example, the RNase P H1 RNA gene). After the 
reaction mix is dispensed on a plate, the reactions were run on an Applied Biosystems 
real-time PCR system using absolute quantitation settings. After amplification, the 
experiment Results Table, containing CT values for the copy number and reference 
assay for each well, was exported from the Applied Biosystems real-time PCR system 
software. The tab-delimited (.txt) file or comma-separated value (.csv) file was then 
imported into the CopyCaller™ Software for post-PCR data analysis of the copy 
number quantitation experiment. The CopyCaller™ Software performed a 
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comparative CT (ΔΔCT) relative quantitation analysis of the real-time data. The 
analysis determines the number of copies of the target sequence in each test genomic 
DNA sample. The comparative CT (ΔΔCT) method first calculated the difference 
(ΔCT) between the threshold cycles of the target and reference assay sequences. 
Then, the method compared the ΔCT values of the test samples to a calibrator sample 
that contains a known number of copies of the target sequence.  
 
Paralogue Ratio Test (PRT) & Allelic Imbalance PCR 
These two techniques were designed by a collaborating team in the University of 
Nottingham (John Armour Group) and were used to confirm the CGH array data from 
this study. The details of these two techniques are described in the appendices 
(Appendix 7 & 8). We designed an additional allelic imbalance test in our lab using 
two single nucleotide polymorphisms (SNPs) found in the region of NAMPT/PBEF1  
that was believed to be amplified based on data from CGH arrays; rs10808150 and 
rs4730153. Two sets of primers were designed to amplify genomic areas that each 
included one of the SNPs (Table 5-1). Patients heterozygous for a SNP with 
amplification present on one chromosome should show allelic imbalance due to an 
increased amount of one allele of the SNP compared to the allele that is not amplified. 
PCR reactions were carried out as described before in chapter 1. 
Bisulfite Conversion and Bisulfite PCR  
 DNA samples were converted using the Epitect® Bisulfite Kit (Qiagen, Hilden, 
Germany). 1µg of genomic PMN DNA from either CML patients or normal controls 
was used and the conversion was carried out following the manufacturer‘s standard 
protocol. The converted DNA was eluted into 20µL AL buffer (Qiagen). The bisulfite 
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PCR reactions were carried out in a volume of 25µL and contained 1µL converted 
genomic DNA, 0.5 units Platinum® Taq (Invitrogen, Carlsbad, USA), 0.2mM dNTPs 
(Bioline, London, UK), 3mM MgSO4 (Invitrogen, Carlsbad, USA) and 1µM of each 
primer (Sigma-Aldrich, Haverhill, UK)(172). Primers were designed using the online 
MethPrimer program to amplify areas rich in CpG islands (Table 5-1). CpG islands of 
the NAMPT/PBEF1  gene were identified using the web-based CpG Island Searcher 
tool(173). Thermal cycling conditions included an initial incubation step at 95°C for 
five minutes, 35 cycles of denaturation at 95°C for 30 seconds, annealing at 55°C for 
30 seconds and elongation at 72°C for 30 seconds, followed by a final elongation step 
at 72°C for five minutes. In order to check for complete conversion of the genomic 
DNA samples before running the bisulfite PCR  reactions, amplification of a part of 
the calponin promoter was carried out using the above cycling program, but with an 
annealing temperature of 63°C(172). Samples that did not show amplification of the 
usually unmethylated calponin promoter were thought to be unconverted and 
therefore not used in the bisulfite PCR reaction. PCR products were run on 2% 
agarose gels (Ultrapure™ Agarose, Invitrogen) that were stained with SYBR® Safe 
DNA gel stain (Invitrogen) to enable visualisation. 
Direct Sequencing of Bisulfite PCR Products 
The methylation status of bisulfite treated DNA can be determined by direct 
sequencing due to bisulfite conversion of exclusively unmethylated cytosine residues. 
Following PCR amplification of bisulfite treated DNA the PCR products were 
purified using the ChargeSwitch PCR clean-up kit according to the manufacturer‘s 
instructions (Invitrogen, Carlsbad, USA). 1µL of purified PCR product along with 
1µL of 10mM of each corresponding forward primer (Sigma-Aldrich) was subjected 
to Sanger‘s dideoxy chain termination reaction using a Big-Dye ABI 310 sequencer 
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(Applied Biosystems, Foster City, USA). This part of the experiment was carried out 
in the MRC Genomic Cores Laboratory, Hammersmith campus. The sequencing 
results were compared to the published NAMPT/PBEF1 sequence 
(ENSGACG00000018838) in order to deduce the methylation status of cytosines.  
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Table 5-1  The sequence of the primers 
Primer Name Sequence (5‗ to 3‗) 
PBEF1 promoter methylation F1 
 
TTAAGTAAAATTTATTTTATTTTTTTT 
 
PBEF1 promoter methylation R1 
 
ACTCCTTAACACCTAATAATTACTC 
 
PBEF1 promoter methylation F2 
 
GAGTGGGATAGGGGAATTTATTA 
 
PBEF1 promoter methylation R2 
 
CCTAAAACTAAAACCAATTAAATAAC 
 
PBEF1 promoter methylation F3 
 
GTTAGTTTTGGGAAGTTGGAGGTA 
 
PBEF1 promoter methylation R3 
 
AAAAATAAACAATAAAAAACTCCTC 
 
PBEF1 promoter methylation F4 TTGTTTTTTTTGATTTTTTTGATTTT 
 
PBEF1 promoter methylation R4 
 
CTATAAAAACTAAATTCCACCCCC 
 
PBEF1 internal CpG methylation F AGTAGAATTTAAATATTTTTTAATGA
TTAT 
 
PBEF1 internal CpG methylation R 
 
CTCCCAAATAACTAAAACTACAAAC 
 
PBEF1 promoter core methylation F 
 
TGGTTTTAGTTTTAGGTTAAGAGGT 
PBEF1 promoter core methylation R 
 
ATAAAACTCATTTTTCTCCTTCCTC 
PBEF1_rs10808150F1 
 
GGGAAACTTGAAGTGAGCAGAGA-
Biotin 
 
PBEF1_rs10808150R1 
 
GCAAGTCTGTTGGTGCTATTTTT 
 
PBEF1_rs10808150S1 
 
CCAGATAAGGCAGTGAAC 
PBEF1_rs4730153F1 
 
TAGGCAGACACTTGATCTATCCC-
Biotin 
PBEF1_rs4730153R1 
 
CCAGCTACTTCATTTGCCTTACG 
 
PBEF1_rs4730153S1 
 
AATCATATCTCATGTTTACT 
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Results  
All CML samples harboured gene copy number changes 
Comparative genomic hybridisation revealed a total of 3562 abnormalities across all 
the 20 patients who had achieved CCyR on IM. One hundred and twenty four of these 
occurred in at least three patients, of which 32 were seen in 4 patients and were 
confirmed as significant changes using the STAC algorithm (summarised in Table 5-
2). The most common aberration which was focal amplification of the 
NAMPT/PBEF1 gene on chromosome 7 was detected in 75% of patients using this 
method. In keeping with the majority of recurrent aberrations, the NAMPT/PBEF1 
amplifications were relatively small and similar in size (range 40 to 80Mb), involving 
the coding region of NAMPT/PBEF1 with only a small amount of flanking material 
(Figure 5-2). Both NAMPT and PBEF1 are the names used for the same gene. The 
enzyme NAMPT (Nicotinamide phosphoribosyltransferase) converts nicotinamide to 
nicotinamide mononucleotide (NAD
+
). This gene was also implicated in the 
maturation of B cell precursors, and hence was named PBEF1 (Pre-B-cell colony-
enhancing factor1)(174). CGH array does not allow discriminating tandem from non-
tandem duplications.  
As there were a large number of genes with genomic aberrations, we decided to focus 
on NAMPT/PBEF1 as the most commonly aberrant gene to confirm the data 
produced by CGH array. 
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Table 5-2  Summary of recurrent gene copy number aberrations detected by 
CGH in ≥ 20% of CML presentation samples  
CNA 
Location 
Gene(s) Type 
Frequency, 
% 
1 p34.1 BEST4, LK3,TCTEX1D4,LOC149478 gain 20 
1 q21.2 
HIST2H2BE,HIST2H2AC,HIST2H2AB,BOLA1 
 
gain 20 
8 p23.3 OR4F21 gain 20 
9 q12 CBWD5, CBWD3 gain 20 
9 q34.11 ASS1 loss 20 
10 q21.3 SRGN gain 20 
10 q22.1 CDH23, C10orf54 gain 20 
10 q26.2 PTPRE gain 20 
11 p11.2 PHF21A gain 20 
11 q13.1 MALAT1, SCYL1 gain 20 
17 q25.3 SLC16A3, CSNK1D gain 20 
19 p13.2 MBD3L5, MBD3L2 gain 20 
22 q11.23 CABIN1 gain 20 
5 q35.1 DUSP1 gain 25 
11 p11.2 MAPK8IP1, LOC143678, PEX16, CYLTL1B, gain 25 
2 q32.3 STK17B gain 30 
15 q24.3 PSTPIP1 gain 30 
7 q22.2 NAMPT/PBEF1 gain 75 
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Figure 5-2  CGH data of the 7q22.2 genomic region in IM responders at 
presentation 
Focus on the region of 7q22.2 containing the NAMPT/PBEF1 gene in which 
increased fluorescence ratio was observed by CGH in 15 of 20 CML presentation 
samples. The chromosome 7 ideogram below shows the location of the region of 
interest and the precise mapping position (105.6-105.7Mb). The location of the 
NAMPT/PBEF1 gene is shown in the centre. The extent of genomic gain in all 15 
patients who showed copy number aberration in this region is displayed below this, 
illustrated by the green bars of varying length. The plot above the gene illustrates the 
frequency of genomic gain across this region in the entire cohort, showing that the 
most recurrent region of gain, seen in 75% of patients, involves the majority of the 
NAMPT/PBEF1 gene. 
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Metaphase FISH 
Investigation of the physical location of the amplified NAMPT/PBEF1 gene was 
done by FISH in the cytogenetic lab in the Department of Haematology, 
Hammersmith Hospital. Metaphase FISH analysis using a BAC clone spanning the 
NAMPT/PBEF1 gene did not produce supernumerary hybridisation signals when 
applied to 3 of the patients showing NAMPT/PBEF1 amplification by CGH (data not 
shown), thus excluding insertion of the gene elsewhere in the genome. This finding 
did not exclude the possibility that the amplified segment was inserted in tandem 
with, or in close proximity to, the original sequence. 
Taqman
® 
Copy Number Assay 
TaqMan
®
 Copy Number Kit for NAMPT/PBEF1 was used to further verify the DNA 
copy number of this gene in genomic DNA extracted from PMN cells of the normal 
control and of CML patients at diagnosis and remission (Figure 5-3). Importantly, no 
CML sample was found to show a qPCR value indicating more than two copies of 
NAMPT/PBEF1. QPCR values for NAMPT/PBEF1 copy number in CML patients‘ 
remission samples were also variable but were not significantly lower than for the 
CML disease samples. The most consistent results were obtained from the DNA 
samples from normal individuals, which generally showed a copy number value of 
around two. 
 180 
Figure 5-3 NAMPT/PBEF1 Calculated Copy Number in CML, Normal and 
Remission PMN samples  
The range for normal PMN was 1.8 to 2.2 and for remission it was 1.2 to 2.1. The 
broadest copy number range was seen in CML samples with a range of 0.5 to 2.4. 
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PRT (Paralogue Ratio Test) and Allelic Imbalance Test Results 
The PRT and allelic imbalance tests were done by the Nottingham group and some of 
them were repeated in this thesis independently at the Hammersmith Hospital.  To 
confirm NAMPT/PBEF1 amplification a pseudogene on chromosome 16 was 
amplified by PCR along with the NAMPT/PBEF1 gene itself using a single primer 
pair. The genomic DNA from CGH array study (diagnosis and remission samples) 
was used for the PRT test. The average ratio for test versus reference loci was higher 
at diagnosis than at remission. The range at diagnosis went from 1.00 to 1.33 while 
the range for remission was 0.93 to 1.12. The average ratio for diagnosis was also 
higher than remission (1.20 and 1.00 respectively). The ratio for the diagnostic 
samples was significantly different from the ratio in the paired remission samples 
using the Wilcoxon signed ranks test (p=0.001). These results support the 
amplification in NAMPT/PBEF1 in CML samples. 
SNP and allelic imbalance Assay: In order to confirm a putative amplification of the 
NAMPT/PBEF1  gene, allelic imbalance tests were performed using two SNPs found 
within the region shown to be amplified by CGH (rs10808150 and 4730153) as well 
as a 3bp deletion polymorphism (rs35301913). In the case of amplification, an allelic 
imbalance in heterozygotes between alleles of these polymorphisms would be 
expected. Thus, a ratio of ≥1 would indicate amplification, whereas a ratio of one 
would indicate a lack of allelic imbalance and therefore suggest that no amplification 
was present. Germ line samples, in which no allelic imbalance was expected, were 
used as a Ph-negative control. No significant difference was observed between the 
ratios in the CML samples and the corresponding germline samples for all 
polymorphisms tested (p>0.05), indicating an absence of allelic imbalance in the 
tumour samples.  
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NAMPT/PBEF1 expression levels 
Amplification of the NAMPT/PBEF1 gene could not be confirmed using the copy 
number assay  and allelic imbalance tests. The gene expression assay was carried out 
to determine the expression level of NAMPT/PBEF1 in the PMN of the normal 
control as well as PMN of 11 CML patients who had been tested by CGH array. The 
highest level of expression was found in normal PMN samples. The normal PMN 
showed significantly higher expression than CML PMN at diagnosis (p<0.001). 
CD34+ cells from CML patients (n=4) also showed, on average, a 5-fold lower 
expression level than CD34+ cells of normal individuals (n=2). 
 
NAMPT/PBEF1 promoter and intron 6 CpG island methylation 
One alternative explanation, for the discrepancy between CGH array data and 
Taqman copy number assay might be the occurrence of differential degradation of 
NAMPT/PBEF1 in CML and control samples. Changes in chromatin architecture 
represent a mechanism by which such differential degradation could take place, since 
in theory areas of condensed chromatin would be relatively protected from the 
nuclease exposure inherent to the DNA extraction process. If chromatin condensation 
occurred in CML but not in normal samples, this could result in a relative 
overrepresentation of protected regions in the CML samples that would manifest as 
copy number changes using methods such as CGH. This model would result in no 
change in allelic ratios, assuming both alleles showed the same degree of 
condensation. In cancer research, DNA methylation has emerged as a common 
epigenetic modification seen in a variety of cancers. Hypermethylation of promoter 
regions of genes has been identified as a mechanism of chromatin remodeling, 
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namely the formation of heterochromatin, and of gene silencing(175). In keeping with 
a theory of epigenetic modification of NAMPT/PBEF1, expression of the gene was 
significantly decreased in PMN CML samples at presentation. Methylation studies of 
the NAMPT/PBEF1 promoter and intron 6 CpG island were therefore undertaken to 
pursue the theory of heterochromatin formation and subsequent silencing of 
NAMPT/PBEF1. Thus in order to investigate the mechanism of NAMPT/PBEF1 
silencing and possible heterochromatin formation in CML cells, a study of CpG 
island methylation was performed. Sequencing results that show cytosine nucleotides 
in the bisulfite-treated samples indicate the presence of methylation, as if methylation 
is present the bisulfite conversion reaction is sterically hindered and cytosines will not 
be converted to uracil but will remain as cytosines. Region one of the 
NAMPT/PBEF1 promoter showed a variable methylation pattern between samples 
within each group, but no difference between normal and CML samples. Bisulfite 
sequencing results for the NAMPT/PBEF1 promoter regions two and four, from both 
CML and normal samples showed no cytosine residues, but showed thymines in place 
of cytosines in the untreated sequence, indicating that methylation is not present in 
these regions. Region three, which contains the core promoter sequence showed 
methylation on two cytosine residues in both normal and CML samples. Interestingly, 
the intron 6 CpG Island showed methylation of 75% of CpG cytosines in CML 
samples. However, the same pattern was also found in normal samples. 
 
Discussion 
The BCR-ABL1 fusion oncoprotein interferes with signalling pathways in leukaemic 
cells and is involved in the initiation of the CML and in its progression through 
various mechanisms including genomic instability, loss of tumour suppressor function 
and differentiation arrest. However, it is clear that BCR-ABL1 alone is not entirely 
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responsible for complete transformation to CML as low levels of BCR-ABL1 are 
expressed in a large number of normal individuals(176). Some plausible explanations 
for this include that the translocation occurs in cells that are terminally differentiated 
and may undergo apoptosis or be eliminated by the immune system, or that additional 
genetic lesions are required to cause CML(3). Moreover, the presence of BCR-ABL1 
alone is not sufficient to explain the considerable clinical heterogeneity seen between 
individuals throughout the course of the disease(9). 
One method of investigating heterogeneity at the genetic level among CML patients 
is by array CGH. Classical CGH studies of CML began over a decade ago, including 
a 1997 study that used CGH to identify chromosomal imbalances in the K562 CML 
cell line and detected amplifications in chromosome arms 1q, 5p, 6p, and 16q and 
deletions in 8p, 9p, 10q, and 17p 11(177). A subsequent study used CGH to detect 
CNAs in 15 CML patients in BC, three in AP and 20 in CP, and identified 
chromosome location 1(q12–21) as a novel locus involved in CML disease 
progression(178). Microarray CGH studies in CML are to date still limited in number, 
and focus mainly on identifying CNAs involved in disease progression. A recent 
microarray CGH study carried out using an in-house 3,151 BAC clone-set with a 
resolution of approximately 1Mb identified around 75 cryptic CNAs in 26 CP and 29 
advanced phase CML patients(179). A limitation to this study is that a paired sample 
design where both CP and BC samples are taken from the same patient was not used, 
causing the detection of normal CNVs along with disease-related CNAs. A 
comparable study was performed the following year using a commercial BAC array 
platform of similar resolution which identified genomic imbalances at a significantly 
higher frequency in advanced stage patients than in CP patients (17% vs. 77%)(180). 
However, no strong candidate genes for involvement in disease progression were 
identified within these loci, and once again the study did not use a paired design, 
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meaning that polymorphic CNVs could not be excluded from the list of observed 
imbalances. Hence, although the use of CGH array in CML has allowed a more 
detailed analysis of global copy number changes when compared to classical CGH 
studies in CML, most studies have used platforms of relatively low resolution that do 
not allow detection of copy number changes less than 1Mb in size. The lack of paired 
study design in the latter reports was another limitation. As a result, there was a need 
for improved genomic characterisation of CML that focuses on specific clinical and 
biological questions. In the study described in this chapter, a 2.1 million 
oligonucleotide array was used with sensitivity much higher than previous reports. It 
revealed apparent copy number aberrations in all 20 CML-CP patients. The 
aberrations were mostly amplifications but deletions were also noted. Some of the 
aberrations appeared to have occurred randomly, but in other cases they involved 
known genes. The most common aberration was focal amplification of the 
NAMPT/PBEF1 gene on chromosome 7, detected in 75% of patients. 
Due to the large number of detected aberrations by CGH array, NAMPT/PBEF1 was 
selected for further investigation as the most common detected abnormality. Copy 
number aberration in NAMPT/PBEF1 in CML samples could not be confirmed using 
Taqman Copy Number Assay but this technique also showed variation even for the 
normal.  The collaborative team (John Armour et al) in Nottingham who had 
developed the Paralogue Ratio Test (PRT) as the method of investigating gene copy 
number changes(181), designed PRT for investigation of copy-number changes in 
NAMPT/PBEF1. PRT data were consistent with copy-number gain at 
NAMPT/PBEF1, but produced no evidence of amplification in remission samples or 
normal controls. However the allelic imbalance test and the SNP assay did not 
confirm the copy-number gain. It is possible, though unlikely, that amplification may 
have occurred on both alleles, thus maintaining the allelic ratio of the germline 
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samples. The theory of differential degradation of NAMPT/PBEF1 in CML and 
control samples mentioned above could be an explanation for the detection of 
amplification in NAMPT/PBEF1. In theory areas of condensed chromatin would be 
relatively protected from the nuclease exposure inherent to the DNA extraction 
process. If chromatin condensation occurred in CML but not in normal samples, this 
could result in a relative overrepresentation of protected regions in the CML samples. 
In cancer research, DNA methylation has emerged as a common epigenetic 
modification seen in a variety of cancers(175). Hypermethylation of promoter regions 
of genes has been identified as a mechanism of chromatin remodeling, namely the 
formation of heterochromatin, and of gene silencing(175). Methylation was not found 
in the promoter region of NAMPT/PBEF1 in selected samples which showed 
increased copy number of NAMPT/PBEF1 by CGH array, but this does not exclude 
the possibility of altered heterochromatin structure in this gene. Therefore, studies 
addressing the other means of heterochromatin condensation such as histone 
hypoacetylation and histone H3-Lys9 methylation will be necessary to confirm 
whether differential chromatin remodeling plays a role in regulating NAMPT/PBEF1  
expression and in the generation of false-positive CGH data. Lower expression of 
NAMPT/PBEF1 in diagnostic PMN and also CD34+ cells than their normal 
counterpart indirectly supports the CGH array finding in DNA aberration of 
NAMPT/PBEF1. The precise activity of NAMPT/PBEF1 is unclear, but the gene has 
a number of functions relevant to haematological malignancy including roles in 
neutrophil proliferation and in the NAD anti-apoptotic pathway(182). In vitro studies 
have shown that NAMPT/PBEF1 induced granulocyte differentiation of CD34+ 
haematopoietic progenitor cells(174). The low expression of NAMPT/PBEF1 in 
CML cells in this study indicates the involvement of this gene in pathogenesis of 
CML but the mechanism which reduces the expression of NAMPT/PBEF1 in CML is 
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not known and needs investigation. NAMPT/PBEF1 is also an essential enzyme for 
catalysing NAD+ which is needed for SIRT1 activity (Figure 5-4)(183). 
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Figure 5-4  The mechanism of NAMPT/PBEF1 effects on G-CSF-induced 
granulopoiesis 
Activation of trhe G-CSF receptor (G-CSFR) gene upon ligand binding induces 
NAMPT/PBEF1 mRNA and protein synthesis, with subsequent elevation of NAD
+
 
concentrations and NAD
+
-dependent SIRT1 activity. Increased SIRT1 activity in turn 
leads to elevated C/EBP-α and/or C/EBP-β dependent G-CSFR and G-CSF synthesis, 
with subsequent induction of granulopoiesis via an autoregulatory feedback 
loop(174).  
 
The mammalian sirtuins, SIRT1-7, are implicated in a variety of cellular functions 
ranging from gene silencing, control of the cell cycle and apoptosis(184). The study 
by Ho et al showed the transcript level of NAMPT/PBEF1 influenced activity of 
SIRT1, therefore it can be assumed that low level of NAMPT/PBEF1 transcript in 
CML cell could reduce the function of SIRT1 and subsequently change the cell cycle 
pattern or apoptosis in the leukaemic cells. The primary data obtained by a 
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collaborating colleague in the Department of Haematology in Hammersmith Hospital 
showed that transforming BCR-ABL1 positive mouse stem cells by SIRT1 reduced 
capacity of the BCR-ABL1 positive cells for proliferation and colony formation. This 
finding along with other evidence suggested that low level of NAMPT/PBEF1 in 
CML cells might result in reduced function of SIRT1 and consequently increased 
proliferation.  
The next most frequently aberrant genes in our CGH study were PSTPIP1 and 
STK17B which had genomic amplification in 30% of the patients. PSTPIP1 directs 
the PEST type protein tyrosine phosphatase to the ABL1 kinase to mediate ABL1 
dephosphorylation. STK17B is a serine-tyrosine kinase and is thought to be related to 
novel serine/threonine kinases that trigger apoptosis(185;186). Both genes are 
therefore plausible candidates for a role in CML pathogenesis. These genomic 
changes need to be confirmed using other techniques and the association between the 
transcript level and the genomic aberration should be investigated. 
While NAMPT/PBEF1 aberration detected by CGH array needs to be confirmed by 
other techniques, the primary transcript measurement showed significant reduction in 
its transcript level. This suggests that measurement of transcript levels for the other 
genomic abnormalities detected by CGH array would be a worthwhile next step. 
Further investigation of these genomic aberrations and correlating them with 
transcript and protein levels will help to understand the role of these genes on the 
pathogenesis of CML and finally their clinical implications. 
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Conclusion  
 
In this study I investigated the association between several molecular markers at the 
time of diagnosis and patients‘ response to imatinib (IM) in order to identify 
prognostic factors for achieving response to therapy and survival.  
BCR-ABL1 kinase domain mutations have been detected in many CML patients at 
the time of resistance to tyrosine kinase inhibitors (TKIs) and in vitro studies using 
cell line models have demonstrated an association between some of these mutations 
and IM resistance. The work described in chapter one was the first large study to 
investigate the prognostic value of KD in predicting progression free survival (PFS) 
and overall survival. The majority of studies concerning KD mutations had focused 
on patients with resistance to IM or after progression to advanced phase; the 
prognostic implication of KD mutations in CP patients in continuing haematological 
or cytogenetic response to IM was not established prior to the work described in this 
thesis. Similarly, it was not known whether the mutations detected were the cause of 
resistance in all cases or what impact there might be of detecting mutations at the 
time of optimal response on patients‘ subsequent outcome. The analysis of the data 
from this study showed that the presence of KD mutations and the achievement of 
CCyR were the only two independent predictors for PFS, and for the patients who 
had achieved CCyR, KD mutation was the only significant predictor for loss of 
CCyR. Importantly, KD mutations conferred an unfavourable prognosis independent 
of their kinetic pattern. The fact that mutations do not necessarily need to become the 
predominant clone in order to have an adverse effect on PFS suggests that at least in 
some cases they are not the actual cause of the progression but are a surrogate marker 
associated with the true mechanism responsible for generating resistance. Regarding 
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resistance to IM, detection of mutations which accounted for 50% or less of the BCR-
ABL1 positive clone in our study challenges the theory that these mutations are the 
cause of resistance, unless we accept that the results of the cell line studies by Liu et 
al - who showed that BCR-ABL1 mutants spread resistance to non-mutated cells 
through a paracrine mechanism - also may apply to primary CML cells in vivo(187). 
Patients with primary cytogenetic resistance to IM were more likely to develop KD 
mutations after the resistance was already identified, indicating that the mechanism of 
resistance was in operation since the beginning of therapy, which in turn suggests that 
the emergence of mutations merely reflects a higher level of ‗genomic instability‘. 
Moreover the fact that mutations were more frequent in patients in the high Sokal risk 
group supports the hypothesis that the probability of developing a mutation is related 
to the basic biology of the disease rather than being merely a random event. It has 
been proposed that the clinical variability of CML patients may itself be due to 
underlying difference between patients, particularly genomic heterogeneity.  
One of the unsolved questions regarding the BCR-ABL1 kinase domain mutations is 
the mechanism which produces them and why they emerge during tyrosine kinase 
inhibitor (TKI) therapy. The question of when kinase domain mutations arise and 
which mechanisms may predispose patients to the acquisition of mutations has 
attracted considerable interest. In some cases, identical mutations were detected at the 
time of relapse and in cells archived prior to therapy, consistent with selection of pre-
existing mutant clones in the presence of drug(188;189). Jiang et al performed 
cloning and sequencing of the BCR-ABL1 kinase domain from IM-naive diagnostic 
CML CD34+ cells and after one week culturing of the CD34+ cells with IM. Their 
data suggest that patients may possess leukaemic stem cells with BCR-ABL1 kinase 
mutations before initiation of BCR-ABL1-targeted therapies and would likely be 
predisposed to develop resistance to these agents(190). Our data concerning the 
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kinetics of the BCR-ABL1 kinase domain mutation during IM and dasatinib therapy 
showed the selection of mutations during TKI therapy and also the change in the 
pattern of mutations as a result of changing therapy. The kinetics of the T315I in two 
patients who stopped TKI showed the decline of the T315I clone without a significant 
change in BCR-ABL1 transcript level. This indicates that the dominance of the T315I 
clone was mainly due to its resistance to TKI and subsequent selection rather than to 
a higher proliferative advantage of T315I. The disappearance of the T315I and 
emergence of non-mutant BCR-ABL1 clone support the in vitro data from Griswold 
et al who reported T315I has a lower proliferative activity than the non-mutant BCR-
ABL1 positive cells. The kinetic data from this thesis showed that G250E increased 
following cessation of dasatinib and dominated the T315I BCR-ABL1 positive 
clones. The first conclusion would be that the G250E mutation has proliferative 
advantage over T315I-mutated and non-mutant BCR-ABL1 in the absence of TKI, 
but we cannot exclude the contribution of co-existing additional genetic aberrations to 
the higher proliferative rate of G250E clone. Developing techniques for separating 
different BCR-ABL1 mutant clones in order to compare their genomic content is 
needed to better understand and explain these findings. Sequencing of the BCR-
ABL1 kinase domain from 20 CML patients at blast crisis (BC) who had never been 
treated with TKI in our centre did not show any BCR-ABL1 kinase domain 
mutations(191). As the chance of detecting BCR-ABL1 kinase domain mutations 
increases at the AP or BC in patients who are treated with TKI(188), lack of detection 
of BCR-ABL1 kinase domain mutations in the 20 IM-naïve blast crisis samples 
suggests either that the mutations remain present but at low level with no proliferative 
advantage over the non-mutant BCR-ABL1 clone or that KD mutations occur as a 
result of TKI therapy. In conflict with the selection of mutation hypothesis is the 
observation reported here that in at least two CML patients the T315I mutant clone 
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appeared shortly after cessation of IM and initiation of dasatinib. If T315I is highly 
resistant to IM why were these mutant clones not selected during IM therapy? The 
emergence of T315I within just 4 months of starting dasatinib therapy in this study 
supports the theory that mutations might occur during TKI therapy. A study of B 
lymphoid blast crisis in CML linked the emergence of C>T BCR-ABL1 kinase 
domain mutations to the activity of activation-induced cytidine deaminase 
(AID)(192). The same study suggested that progression of CML-CP (chronic phase) 
to CML-LBC (lymphoid blast crisis) is characterised by aberrant expression of PAX5 
and its transcriptional target AID(192). However, as PAX5 and AID are expressed 
specifically in the lymphoid lineage, this does not explain the occurrence of mutations 
in CML CP or myeloid BC, or of alternative substitutions to C>T. By way of 
explanation, Takahashi et al(193), suggested that oscillation between myeloid and 
lymphoid phenotypes may cause the BCR-ABL1 kinase domain mutations in CP or 
alternatively, that myeloid BC originates  from mutated B lymphoid CML cells that 
have subsequently lost their B cell identity(192). One further plausible hypothesis, 
however, is that aberrant activity of an enzyme similar to AID but with specificity for 
the myeloid lineage such as APOBEC(194) (apolipoprotein B mRNA-editing enzyme 
catalytic polypeptide-like) causes the development of BCR-ABL1 kinase domain 
mutations in CP or myeloid BC CML. In addition to BCR-ABL1, IM also blocks 
ABL1, which is activated by a variety of stress signals including damaged DNA. 
According to the study by Fanata et al pharmacological inhibition of ABL1 
compromises a DNA-damage response(195), therefore it is also possible that the TKI 
therapy intended to target BCR-ABL1 might be responsible for the occurrence of 
BCR-ABL1 kinase domain mutations via inhibition of ABL1. 
In theory the patients who fail to achieve MCyR should have lower inhibition of 
BCR-ABL1 kinase activity or have aberrant activation of other signalling pathways 
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that help the leukaemic cells to survive in spite of inhibition of BCR-ABL1 onco-
protein. To investigate whether heterogeneity of response was due to differential 
activity of BCR-ABL1 kinase, I measured the in vitro inhibition of p-Crkl in 
diagnostic CD34+ cells from the patients with and without MCyR. The findings did 
not show a difference between the inhibition of p-Crkl in CD34+ cells between the 
responders and non-responders. Therefore these in vitro data are consistent with the 
notion that the level of kinase activity is not a contributing factor to the failure of 
response in the non-responders. As the dose of IM was increased in some of these 
non-responders and the optimal response was still not achieved, it seems that the 
pharmacokinetic differences do not play any major role in the failure of response. The 
p-Crkl data from this study support the idea that at least in primary cytogenetic 
failure, the cause of resistance might be due to activation of alternative pathways, 
which in itself could be due to genomic heterogeneity of the leukaemic cells. The 
findings of this study concerning the predictive value of BCR-ABL1 kinase activity at 
diagnosis seem different from reports from others who also investigated the 
predictive value of p-Crkl for response to IM(114). This discrepancy could be due to 
different methodologies including the type of the studied cells, the method of 
measuring BCR-ABL1 kinase activity and also the conditions under which BCR-
ABL1 kinase was measured (in vivo or in vitro). For example White et al measured 
the BCR-ABL1 kinase activity in MNC at 7, 14, 21 and 28 days following initiation 
of IM therapy and found a positive correlation between the levels of p-Crkl inhibition 
and achieving optimal response(114). Their study measured the in vivo inhibition of 
p-Crkl in a cell type which was different from that employed in my work. The other 
possibility to explain the positive association between inhibition of p-Crkl and 
achievement of optimal response in the study by White et al could be that after start 
of IM, the number of leukaemic cells starts to decrease and the percentage of non-
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leukaemic cells within the MNC fraction increases, which can cause reduction in p-
Crkl of the total MNC population due to the diluting effect of the normal MNCs. 
Therefore the measured p-Crkl in the latter study might not be truly representative of 
BCR-ABL1 kinase activity inhibition by IM in the CML clone. Differences in 
hOCT1 transcript level between MNC and CD34+ cell are also a potential cause for 
the discrepancy between the Adelaide data and that from this thesis. Engler et al 
reported significantly lower expression of hOCT1 in CML CD34+ cells comparing to 
more differentiated cells and also the normal counterpart(128). Furthermore, our data 
and reports from other groups showed the predictive value of hOCT1 at 
diagnosis(125;126). The hOCT1 level would be expected to influence the 
intracellular level of IM in the MNC cells from the White et al study(127), while it 
should not be a significant influencing factor in CD34+ cells from our study, since 
expression of hOCT1 is very low in this fraction(128). Therefore differential in vivo 
inhibition of BCR-ABL1 kinase could be due to different intracellular accumulation 
of IM rather than to different kinase activity of the BCR-ABL1. As the expression of 
hOCT1 is very low in CML CD34+ cells, it does not seem to influence the 
intracellular level of IM and subsequent p-Crkl inhibition. The result of the in vitro 
inhibition of BCR-ABL1 kinase in CD34+ cells from this thesis suggests that the 
failure to achieve MCyR in the patients in this investigation may be due to activation 
of alternative signalling pathways which allow the leukaemic cells to survive despite 
inhibition of BCR-ABL1 kinase, although the possibility that resistance emerges in 
cells with a higher level of maturity than CD34 cannot be completely excluded.  
The achievement of CCyR is the major objective of therapy since it is associated with 
prolonged survival(99;135;136). By 5 years approximately 50% of patients will have 
achieved a 3 log reduction in transcript levels or MMR;(99) this confers further 
clinical benefit(138) and it is often considered a more important therapeutic target 
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than CCyR(139). With continued treatment about 20-30% of patients eventually 
achieve a 4-log reduction and in 10% of patients the transcripts will become 
undetectable (complete molecular response or CMR)(99). In some cases CMR may 
be the equivalent of ―cure‖ as it is possible to discontinue the IM in some of these 
patients without subsequent relapse(140;141). The reasons underlying the different 
responses in different patients are unclear but they may be attributed to the intrinsic 
heterogeneity of CML(35;142). In chapter 3 I demonstrated that measurement of 
hOCT1 transcript levels at diagnosis among the patients who had achieved CCyR 
could predict the achievement of MMR, 4-log transcript reduction and CMR and this 
difference in hOCT1 expression among patients again supports the concept of 
heterogeneity and its influence on response to treatment. The hOCT1 transcript 
measurement showed up to one log difference in transcript levels among the normal 
volunteers in this thesis. The genetic differences which cause the variation in the 
baseline expression of hOCT1 might be an interesting topic for future investigation.  
The study of hOCT1 in this thesis also showed significant variation in the transcript 
level of hOCT1 among subpopulations of CML cells. The expression of hOCT1 was 
significantly lower in diagnostic CD34+ cells compared to PMN. This indicates the 
importance of hOCT1 for intracellular level of IM in the more differentiated cells, 
mainly myeloid cells, and also the type of the cells which should be studied for 
prognostic investigations. 
In the search of other prognostic factors for response to IM, I considered TP53 as it 
was reported to play a major role in response to IM in BCR-ABL1 positive BaF3 cell 
lines. As TP53 polymorphism at codon 72 influences the apoptotic activity of TP53, I 
investigated the association between this polymorphism and response to IM. The 
result of this investigation showed that the TP53 P72/P72 was associated with earlier 
age of onset in CML. The genomic damage occurs frequently to cells over the course 
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of a life-time and this is either repaired, or induces cell apoptosis if the level of 
damage is beyond the repairing capacity of the cell. As TP53 is one of the main 
components of the cells response to DNA damage, its activity might influence the 
behaviour of cells when confronted with such damage. If the in vitro finding on the 
lower apoptotic activity of TP53 P72 applies to the stem cells, the repair mechanism 
will be less efficient than the same cells with TP53 R72 in otherwise equal 
conditions. If the response of the cell to damage is inefficient DNA repair rather than 
apoptosis, then the cell will give rise to a genetically mutant clone. Acquisition of one 
or more pre-cancerous mutations may increase the likelihood of acquiring cancerous 
phenotype at an earlier age, as may be supported by our findings. Although patients 
with TP53 P72/P72 showed a lower level of response to IM and higher risk of 
progressing to advanced phase, this difference did not reach conventional levels of 
significance; this could be due to the relatively small number of patients with this 
polymorphism in this study. The investigation of MDM2 309 SNP which controls the 
basal level of TP53 did not show any association with response or survival but 
MDM2 309 G/G was associated with higher Sokal score and a high score is 
associated with a higher rate of IM failure. Thus MDM2 309 G/G could be a predictor 
of response if the number of cases with this SNP increased in a larger study. In a 
study by Ellis et al the MDM2 SNP309 and the TP53 codon 72 polymorphism 
interacted to modulate responses to genotoxic therapy and were determinants of risk 
for therapy related-AML(162). We did not see any association between interaction of 
MDM2 309 and TP53 72 SNP interaction and response to IM in the CML population. 
This could be due to the difference in the nature of therapy which is inhibition of 
ABL kinase domain by IM in CML patients rather than damaging DNA by alkylator 
chemotherapy which was used in the AML study(162). 
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Different factors that were discussed earlier could influence the nature of the disease 
and subsequently its response to treatment. Referring to the earlier discussions about 
the variations in response to IM and different mechanism of IM resistance it was 
needed to explore the genes and their variations in a global scale in CML cells rather 
than screening them individually. The investigation of the whole genome in the 
leukaemic clones of CML patients was attempted using a 2.1 million oligonucleotide 
array which had a sensitivity much higher than earlier studies to make it possible to 
find aberrations which were not detected previously(178-180). The high resolution 
approach revealed copy number aberrations in all CML-CP patients. The aberrations 
were mostly amplifications but deletions were also noted. Some of the aberrations 
appeared to have occurred randomly, but in other cases they involved known genes. 
The most common aberration was focal amplification of the NAMPT/PBEF1 gene on 
chromosome 7, detected in 75% of patients. These primary data showed the variation 
in the genomic content of the BCR-ABL1 positive clones among CML patients. 
Confirmation of array CGH findings is challenging, as currently there is no 
established standard molecular method to quantify copy number of small genomic 
regions. Since there were a large number of detected CNAs by CGH analysis, 
NAMPT/PBEF1 was selected for further investigation as it was the most commonly 
detected abnormality. The investigation of copy-number changes in NAMPT/PBEF1 
using PRT showed evidence in support of amplification similar to the data produced 
by CGH array, but Taqman Copy Number Assay, allelic imbalance test and SNP 
assay failed to confirm the copy number changes in NAMPT/PBEF1.  
Differential degradation of NAMPT/PBEF1 in CML and control samples could be an 
explanation for the detection of apparent over-representation of NAMPT/PBEF1 
sequences by CGH. If chromatin condensation at specific loci occurred in CML but 
not in normal samples, this could result in a relative overrepresentation of DNA 
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regions in the CML samples via protection from mild enzymatic degradation during 
the extraction process. Hypermethylation of promoter regions of genes has been 
identified as a mechanism of chromatin remodeling, namely the formation of 
heterochromatin, and of gene silencing(175). Methylation was not found in the 
promoter region of NAMPT/PBEF1 in selected samples but this does not exclude the 
possibility of altered heterochromatin structure in this gene as other means of 
heterochromatin condensation such as histone hypoacetylation and histone H3-Lys9 
methylation exist, and should be investigated to confirm whether differential 
chromatin remodeling plays a role in regulating NAMPT/PBEF1 expression and in 
the generation of false-positive CGH data. The precise activity of NAMPT/PBEF1 is 
unclear, but the gene has a number of functions relevant to haematological 
malignancy including roles in neutrophil proliferation and in the NAD anti-apoptotic 
pathway(182). In vitro studies showed that NAMPT/PBEF1 induced granulocyte 
differentiation of CD34+ haematopoietic progenitor cells(174). The study by Ho et al 
showed the transcript level of NAMPT/PBEF1 influenced activity of SIRT1. The 
mammalian sirtuins, SIRT1-7, are implicated in a variety of cellular functions ranging 
from gene silencing, control of the cell cycle and apoptosis(184). It can therefore be 
assumed that low level of NAMPT/PBEF1 transcript in CML cells could reduce the 
function of SIRT1 and subsequently change the cell cycle pattern or apoptosis in the 
leukaemic cells. Primary data from ongoing work showed that forced expression of 
SIRT1 in BCR-ABL1 positive mouse stem cells reduced the proliferation and colony 
forming capacity of the BCR-ABL1 positive cells. All the evidence from this thesis 
and the collaborative research so far suggest that low level of NAMPT/PBEF1 in 
CML cells might result in reduced function of SIRT1 and consequently increased 
proliferation.  
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The functional role of NAMPT/PBEF1 with respect to myeloid differentiation and 
apoptosis, together with the significantly lower expression of NAMPT/PBEF1 in 
CML cells shown in this study, support the involvement of this gene in the 
pathogenesis of CML. 
Exploring the prognostic factors at diagnosis or the mechanism of resistance to TKI 
needs to be performed on a larger scale and to focus on the entire genome rather than 
on BCR-ABL1 gene alone. Further investigation of these genomic aberrations and 
correlating them with transcript and protein levels will help to understand the role of 
these genes in the pathogenesis of CML and finally their clinical implications. The 
CGH array is currently used in our lab to study the genomic changes of the diagnostic 
CML samples from the patients who failed to achieve MCyR and comparing these 
changes to the ones from the patients who achieved CCyR. The result of this study 
might give a better idea about the genes whose aberrations contribute to primary 
resistance to IM. The same approach can be used to identify the genes which are 
involved in secondary resistance. 
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Possible future avenues for further research 
The results reported in this thesis raise new issues which could well be addressed in 
future work. While my first chapter and many other published papers have focused on 
the clinical significance of kinase domain mutations and their prognostic value, much 
less effort has thus far been devoted towards exploring the mechanisms which 
produce these mutations. It is commonly believed that most or all of these BCR-
ABL1 KD mutations exist at low level before the start of imatinib therapy and that 
the affected clone then derives a selective growth advantage, but to my knowledge no 
research group has yet tried to characterise the range and frequency of these 
mutations at diagnosis using modern techniques such as ultra deep sequencing. An 
attractive avenue for continuing my work could therefore be to study the evolution of 
specific mutations identified at diagnosis and to relate the expansion of individual 
sub-clones to their in vitro sensitivity to the different TKIs.  
While the BCR-ABL1 kinase mutations are responsible for some cases of acquired 
resistance to TKIs, in most patients the mechanisms underlying this secondary 
resistance are still completely unknown. One approach would be to investigate other 
pathways downstream of BCR-ABL1 signalling which might be activated 
independently of BCR-ABL1, since such BCR-ABL1-independent pathways could be 
involved in the progression to the advanced phases of CML.  
The primary array CGH data described here showed that specific genetic sequences 
or groups of genes had aberrant genomic patterns in diagnostic CML samples when 
compared to non-leukaemic samples from the same patients. The NAMPT/PBEF1 
gene was the most commonly identified aberration and was associated with 
significantly reduced transcript levels in CML granulocytes. The recent report that 
NAMPT/PBEF1 is involved in myeloid differentiation together with the data in this 
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thesis lead to the conclusion that this gene might play a still undefined causal role in 
CML. Thus understanding the molecular changes in NAMPT/PBEF1 in CML cells 
which result in amplification pattern detected by array CGH and also reduced 
transcript levels, along with functional study of this gene in association with BCR-
ABL1, should justify further research. I would also like to use array CGH to 
investigate possible genomic aberrations at diagnosis in patients who fail to achieve 
primary haematological or cytogenetic responses to TKI to identify other genes which 
might contribute to pathogenesis of CML and to define genomic patterns which can 
be used as prognostic factors at diagnosis. 
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Appendices 
Appendix 1: Reagents used for cDNA synthesis: 
5mg/ml random hexamer primers: Reconstitute 50U pdN6 (Pharmacia) with 539µl of 
sterile water. Then add 21µl 0.5mol/L KCl. 
5X RT Buffer (usually supplied) with M-MLV reverse transcriptase (RT): 
0.25mol/L Tris-HCl, pH 8.3, 0.375mmol/l KCl, 15mmol/l MgCl2.  
25 mM dNTP stock: Mix an equal volume of ultrapure 100mmol/L dATP, dCTP, dGTP 
and dTTP 
0.1M dithiothreitol (DTT) usually supplied with M-MLV RT. 
cDNA mix: to 428 µl of 5X RT-buffer add the following, 21.5 µl of DTT, 85.5 µl of 25 
mmol/l dNTPs, 45 µl of 5mg/ml random hexamers and make up to 1000µl with sterile 
water. 
 
Appendix 2: Nested PCR 
The first step: To amplify across the BCR-ABL1 
First round PCR-mix without Taq polymerase 
 Total volume- 10ml 
 10Xbuffer (–MgCl2): 1ml 
 dNTP: 0.25mM 
 MgCl2: 1.8 mM 
 Primer (Forward) B2A: 600nM 
 Primer (Reverse) JAMR: 600nM 
 Water: add to total volume of 10ml 
Make aliquots of 200ul and store at –70 C 
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First round PCR to amplify BCR-ABL1 transcript 
 Add 1 l of Taq polymerase (5unit/l) to 200l of the PCR mix. 
 For each reaction, take 20l of PCR mix; add 5l of cDNA. 
 Put the tubes in the PCR machine and Run the PCR under Nick 60 (Appendix 
3) 
 Store the PCR products at 4C till the second round PCR is run. 
The second step: To amplify the ABL1 kinase domain from the first round PCR 
products (so as to exclude normal ABL1-kinase) 
Second round PCR mix to amplify the ABL1- kinase domain 
 Total volume- 10ml 
 10Xbuffer (–MgCl2): 1ml 
 dNTP: 0.25mM 
 MgCl2: 1.8 mM 
 Primer (Forward) NTPb+: 600nM 
 Primer (Reverse) NTPE-: 600nM 
 Water: add to total volume of 10ml 
 Make aliquots of 500l and store at –70 
Second round PCR to amplify ABL1-kinase domain  
 To 500l of the PCR mix add 2l Taq polymerase 
 For each reaction, take 50l of the mix and add 1l of the first step PCR 
product (amplified BCR-ABL transcript). 
 Run on Nick-60 protocol (Same as first round PCR). 
 Store the PCR products at 4C. 
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Appendix 3: Nick 60 program 
95o 3 min 
94o 40 sec 
61o 40 sec 
72o 1 min 
72o 10 min 
4o  
Appendix 4: Buffer and mixtures for pyrosequencing 
Binding mixtutre: (for each sample) 
 38 μL Binding Buffer (Qiagen) 
 2  μL Cepharose beads 
 20 μL water 
 20 μL PCR product 
Annealing Buffer: (for each sample) 
 24.2 μL Annealing Buffer 
 0.8 μL sequencing primer 10 μM 
 
Appendix 5: Calculation of hOCT1 plasmid quantity 
hOCT1 plasmid: 4007 bp 
The molecular weight of the hOCT1 plasmid; 4007 x 660=2644620 Dalton 
2644620 Dalton =4.3914978237e-18 gram 
The amount of plasmid: 40.7 ng/µL 
The number of plasmids in each µL: 40.7 ÷ 4.3914978237e-12= 9267908498178 
32 Cycles 
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In order to have 10-folds dilutions of this plasmid starting with 10
6
 copy per 2.5 µL 
the stock plasmid was diluted tRNA buffer in a way to produce 10
6
 copy per 2.5 µL 
and then subsequently serial dilutions of 10
6
 was prepared. 
 
Appendix 6: Preparation of tRNA buffer 
Reagents: tRNA (5.2mg per 1000 unit vial), EDTA: 0.5M, Tris-HCl: 1M 
The final concentration: 1mM Tris-HCl, 0.1mM EDTA, 50µg/ml tRNA 
Add 10 ml water to the lyophilised tRNA to dissolve it. 
For preparation of 100 ml tRNA buffer mix 100 µL Tris-HCl, 20 µL EDTA, 9.6 ml 
dissolved tRNA and 90.28 ml DNAse and RNAse free water. 
 
Appendix 7: Paralogue Ratio Test 
The paralogue ratio test (PRT) first described by Armour et al was carried out as an 
alternative means of substantiating the overrepresentation of NAMPT/PBEF1  
identified by CGH by simultaneously amplifying a region within NAMPT/PBEF1  
and a control pseudogene elsewhere in the genome.  The primers were designed to 
amplify the NAMPT/PBEF1  gene itself (chromosome 7) to give a product of 225bp, 
and the chromosome 16 pseudogene, to give a product of 235bp. NAMPT/PBEF1  
copy number can be assayed by separating these products using capillary 
electrophoresis and measuring the chromosome 7 to chromosome 16 ratio. The PCR 
reaction was carried out in a volume of 10µL using 1µL 10x LD mix, 0.5µL of 
genomic DNA, 1µM of each primer (Sigma-Aldrich)  and 0.1 units of Taq DNA 
polymerase (Invitrogen). Cycling conditions included an initial denaturation step at 
95ºC for 2 minutes, 28 cycles of denaturation at 95ºC for 30 seconds, annealing at 
55ºC for 30 seconds and elongation at 68ºC for one minute, followed by a final 
elongation step at 72ºC for 20 minutes. 1µL of PCR reaction was mixed with 10µL of 
 236 
HiDi/ROX500 solution and run in duplicate on the ABI PRISM
®
 3100 Genetic 
Analyzer capillary electrophoresis instrument (Applied Biosystems). Results were 
recorded and analysed using the GeneMapper
® 
version 4.0 software (Applied 
Biosystems). This part of the work was designed by John Armour group in 
Nottingham University. 
 
Appendix 8: Allelic Imbalance PCR 
In order to confirm a putative amplification of the NAMPT/PBEF1 gene, a PCR 
reaction for differentiation of NAMPT/PBEF1 alleles based on the rs35301913 
insertion/deletion (―indel‖) was performed. This polymorphism presents itself as a 
3bp deletion (ACC) from 105707115 to 105707117 on chromosome 7. In the event of 
amplification of one chromosome 7 homologue, one would expect to see an allelic 
imbalance in individuals heterozygous for the polymorphism. Primers were designed 
to amplify an area of NAMPT/PBEF1 containing this polymorphism, resulting in a 
product of either 156 or 153bp in length, depending on whether the deletion was 
present or not. PCR reactions were carried out in a volume of 10µL, using 10ng of 
genomic DNA, 1µM of each primer (Sigma-Aldrich, Haverhill, UK)  and 0.05 units 
of Taq DNA polymerase (Invitrogen, Carlsbad, USA). Cycling conditions included 
an initial denaturation step at 95ºC for two minutes, 24 cycles of denaturation at 95ºC, 
annealing at 60ºC and elongation at 70ºC (all for 30 seconds) and a final elongation 
step at 72ºC for 20 minutes. In order to distinguish and quantify the alleles by their 
difference in length, 1µL of PCR reaction was mixed with 10µL of HiDi/ROX500 
solution and run in duplicate on the ABI PRISM
®
 3100 Genetic Analyzer capillary 
electrophoresis instrument (Applied Biosystems, Warrington, UK). Results were 
recorded and analysed using the GeneMapper
® 
version 4.0 software (Applied 
Biosystems). A ratio that did not differ significantly from one indicated a lack of copy 
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number aberration, while a ratio that was significantly different to one implied that an 
allelic imbalance was present due to a copy number change in the PCR-amplified 
region. 
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